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QUILL ON SCALPEL
Intramedullary Rod Fixation of Femoral
Shaft Fractures:
J.P. Waddell, MD, FRCSC
Member, Editorial Board. Canadian Journal o f  Si 
Hospital, University o f  Toronto, Toronto, Ont.
I n this issue of the Journal (pages 286 to 290) McLaren and associ­
ates have demonstrated through 
analysis of a small group of patients 
treated at their institution that 
closed intramedullary nailing of dia­
physeal fractures of the femur gives 
results that are preferable to those 
of similar fractures treated by the 
open technique. Presumably both 
groups of patients were managed by 
the same surgeons, since, as the au­
thors state, the better results were 
achieved even while the operators 
were learning the closed technique.
Comment
’. Chief, Orthopedic Surgery, St. Michael's
The controversy of open versus 
closed nailing will always be with 
us. Although there is an increasing 
movement toward closed nailing as 
the treatment of choice, there re­
main circumstances when open nail­
ing appears to be preferable, such 
as in cases of multiple fractures in 
the same extremity, severe open 
fractures, inability to obtain a satis­
factory closed reduction or to pass 
a guide wire, or equipment failure.
Through an analysis of their 
problems McLaren and associates 
have documented the pitfalls com­
mon to both types of nailing and 
have suggested methods by which 
these may be avoided.
I concur with their conclusion 
that closed nailing offers a superior 
outcome, but I would caution that a 
well-done open nailing is infinitely 
preferable to a poorly done closed 
nailing. Therefore, surgeons who 
set out to perform closed nailing 
and find themselves in difficulty 
should not hesitate to open the 
extremity at the fracture site and 
proceed with a properly done open 
nailing. ■
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Iatrogenic Injuries to Popliteal Vessels
J.E. Mullens, MD, MS, FACS, FRCSC
Assistant Secretary-Treasurer, The Canadian Medical Protective Association, Toronto, Ont.
I n this issue o f the Journal (pages 294 to 297), Rubens and col­
leagues report their experience o f 
two iatrogenic injuries to the popli­
teal artery that occurred during 
high tibial osteotomy.
During any operation in or near 
the knee the popliteal vessels are at 
risk. In the last 5 years the Canadi­
an Medical Protective Association 
(C M PA ) has opened five files on 
iatrogenic injuries to these vessels; 
two injuries occurred during osteot­
omy o f the tibia and three during 
arthroscopic surgery. Iatrogenic in­
juries to vessels can occur during 
elective or emergency operations in 
any discipline of surgery and, al­
though the CMPA hears o f some o f 
them, it is likely that there are 
others that are not reported. Every 
surgeon is trained to operate safely 
near vital structures, but even the 
most skilled can injure a normal 
structure accidentally while operat­
ing competently and carefully. Such 
misadventures are inherent risks o f 
operations.
It is well established in Canadian 
law that the risks o f each operation 
must be discussed with the patient 
as part o f informed consent. Injury 
to the popliteal vessels, although 
rare, may have devastating effects 
on the patient. Hence, here, if the 
patient has not been warned o f such 
possibilities, the surgeon may be 
found negligent should damage to 
these structures occur. In obtaining
the patient’s consent for operation, 
the surgeon must be satisfied that 
the risk is, or is not, one that would 
be regarded by a reasonable patient 
in similar circumstances as being 
substantial. That means asking spe­
cifically about professional and rec­
reational activities. For example, a 
professional dancer should be made 
aware that an operation on the knee 
presents special risks if the nerves 
or vessels adjacent to the knee are 
injured. Every conceivable risk need 
not be discussed. In addition, each 
surgeon must take personal experi­
ence into consideration; the risk o f 
the procedure in the individual sur­
geon ’s hands may be higher or 
lower than that generally reported 
in the literature. It is important for 
the surgeon to record that such a 
discussion has taken place.
Surgeons are sometimes loathe 
to admit, even to themselves, that 
they have caused a complication, 
and this often exacerbates an al­
ready serious situation which can 
be repaired easily if dealt with im­
mediately. All surgeons must learn 
early to acknowledge when a seri­
ous complication has occurred and 
be prepared to accept the most 
likely explanation even if it is the 
worst possible one. This requires 
the honesty and humility to discuss 
the problem with the patient and 
return the patient to the operating 
room with dispatch if necessary. 
When in doubt, the surgeon should
not hesitate to seek the advice and 
assistance o f an experienced col­
league. Although it is by no means 
easy, surgeons must bring to their 
own professional work the objectivi­
ty and decisiveness that they would 
expect to find in the work o f others. 
It is delay and denial that some­
times make legal defence difficult.
What o f the legal defensibility o f 
iatrogenic injuries? Does iatrogenic 
injury automatically signify negli­
gence or carelessness? N ot neces­
sarily. The answer in each case will 
depend upon the opinion o f expert 
consultants asked to consider the 
question o f whether such an event 
could occur in the hands o f a 
reasonably competent practitioner 
o f like skill and experience. The 
matters open to detailed review in­
clude the training and expertise o f 
the surgeon, the indications for and 
choice o f operation, the manner o f 
its performance and the attentive­
ness and quality o f the postopera­
tive care.
When the surgeon is faced with 
an iatrogenic complication, he 
should be honest with the patient 
and next o f kin, while not admitting 
fault. The operative notes should be 
clear and explicit, and the progress 
notes should be timely and precise 
because they will be important to 
the defence if a law suit results. A 
telephone call to the CM PA for ad­
vice at this time also makes good 
sense. ■
256 CJS, VOL. 33, NO. 4, A U G U S T  1990
QUILL ON SCALPEL
Management of Inguinal Sarcomas
W.J. Temple, MD, FACS, FRCSC
Member. Editorial Board, Canadian Journal o f  Surgery. Director o f  Surgery, Tom Baker Cancer 
Centre, Calgary, Alta.
I n this issue (pages 309 to 312) Bell and colleagues present an 
interesting and valuable report on 
inguinal sarcomas as a distinct enti­
ty. They highlight the important 
issues, which are similar for most 
histologic types of sarcoma in this 
area — obtaining local control, pri­
mary wound healing and the team 
approach for the management of 
sarcomas.
Curing a local sarcoma in the 
inguinal region while maintaining a 
functional extremity is often diffi­
cult because the vascular and neu­
ral supplies to the leg are located 
within a few millimetres of the 
tumour. The management principle 
in these patients includes preopera­
tive treatment to sterilize the tu­
mour margins so that a marginal 
resection is sufficient. In general, 
the only consistent, useful tech­
nique is preoperative radiotherapy 
of 5000 to 6000 cGy. Alternatively, 
our experience1 with preoperative 
treatment indicates that a modified 
Eilber regimen of intra-arterial ad­
ministration of Adriamycin, 30
mg/d continuous perfusion for 3 
days and 300 cGy/d of radiothera­
py for 10 days is highly effective in 
multiple sites, including the ingui­
nal area. If the vessels and nerves 
are still involved after preoperative 
treatment, one must still resect 
them and carry out arterial recon­
struction. Similarly, if en bloc resec­
tion requires sacrifice of the femoral 
nerve, one may expect a reasonably 
functioning leg, so that a young 
patient may be able to walk without 
a brace or other device. In our 
experience1 at the Tom Baker Can­
cer Centre in four patients who 
had inguinal sarcoma, neoadjuvant 
local treatment also resulted in 
long-term control at 3 to 5 years’ 
follow-up.
The second challenge in manag­
ing inguinal sarcomas is to provide 
primary wound healing. This ana­
tomical area is known for its poor 
wound healing in surgery of similar 
magnitude, even when there has 
been no preoperative radiotherapy. 
The consequence of wound break­
down and infection when vascular
reconstruction is required is often 
amputation. The use of non- 
irradiated tissue flaps, such as the 
rectus myocutaneous or tensor fas­
cia lata-myocutaneous flaps, pro­
vides safe and dependable cover. A 
wide defect can also be closed safely 
and dependably with prosthetic 
mesh covered by omentum and a 
skin graft.
Finally, Bell and colleagues illus­
trate that a key component in han­
dling a sarcoma successfully is the 
team approach. In their series an 
experienced oncologic surgeon, a 
medical oncologist, a radiation on­
cologist, a vascular surgeon and a 
plastic surgeon were all involved. 
This not only minimizes major po­
tential morbidity but maximizes the 
chances of local and regional con­
trol.
Reference
1. T emple WJ, Russell JA, A rthur K, et al: 
Neoadjuvant treatment in conservative 
surgery of peripheral sarcomas. Can J  
Surg 1989; 32: 361-365
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HOW I DO IT
Intraoperative Angiography: a Simplified 
Technique
Carlos Del Campo, MD, FRCSC
I ntraoperative angiography is a valuable technique when a preop­
erative percutaneous approach is 
not adequate or desirable and when 
the technical aspects of the proce­
dure are to be visualized.
Traditionally, intraoperative angi­
ography has been performed by 
needle stick into the artery or the 
graft itself.12 Mavor, Walker and 
Dhall3 have recommended the use 
of a Portex nylon intravenous can­
nula, and embolectomy catheters 
with a second lumen have been 
marketed for this purpose.
The technique I describe is inex­
pensive, uses materials readily avail­
able in all operating rooms and has 
several advantages over other tech­
niques.
Most peripheral vascular inter­
ventions involve the lower extremi­
ty. Emergency embolectomies must 
often be done with insufficient angi­
ographic information. Although the 
technique described applies to the 
lower extremity, it is also applicable 
to the upper extremity and other 
sites.
Technique
The femoral vessels are exposed 
through a standard groin incision. 
The patient is systemically hepari­
nized, and the common femoral, 
superficial femoral and deep femoral 
arteries are clamped. A longitudinal 
arteriotomy is made in the common 
femoral artery extending into the 
superficial femoral artery. Proximal 
flow is checked by momentarily 
releasing the proximal clamp. Prox­
imal and distal clots are removed 
with a balloon embolectomy cathe­
ter of the appropriate size.
The arteriotomy is closed primar­
ily or patched with a segment of an 
adjacent superficial vein or fabric as 
indicated. A continuous 5-0 mono­
filament stitch is used. Both ends of 
the suture are left untied. The plas­
tic cannula of a no. 14 Jelco intra­
venous catheter (Critikon Canada 
Inc., Markham, Ont.) is cut from its 
hub. Both suture ends are threaded 
into the cannula using a straight 
needle, and a rubber shod clamp is 
used to tighten it as a tourniquet 
(Fig. 1). A pediatric feeding tube of 
the preferred size is selected. The 
guide wire of the previously used 
embolectomy catheter is utilized to 
stent the pediatric feeding tube so it 
can be manipulated proximally and 
distally. This step provides enough 
rigidity to allow easy retrograde 
advancement of the feeding tube to 
the aortic bifurcation. Blood is not 
lost because the tourniquet is easily 
snugged around the feeding tube.
The guide wire also allows easy 
visualization of the catheter under 
fluoroscopic control if desired. The 
guide wire is removed, and angiog­
raphy is carried out using a 60-ml 
syringe containing the perferred 
contrast medium.
A radiographic plate is placed 
inside a sterile bag and centred 
under the area to be visualized. The 
contrast is injected as fast as possi­
ble, the speed depending on the size 
of the pediatric feeding tube used. 
When the distal run-off is to be 
visualized, a better-quality picture 
can be obtained by directing the 
feeding tube downstream and
FIG. I. Diagram showing final stage of 
intraoperative angiogram. Note proxi­
mal location of pediatric feeding tube 
with guide wire in its lumen. Rubber 
shod clamp prevents fracture of mono­
filament suture.
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clamping the common femoral ar­
tery or applying digital pressure at 
the time of injection. This step 
allows a higher concentration of 
dye and prevents the washout ef­
fect. The feeding tube is then re­
moved and the two sutures are tied 
together.
Discussion
Intraoperative angiography in 
vascular surgery is or may be indi­
cated in the following situations:
•  When limb ischemia, due to 
an embolus, has been present for 
several hours and surgical interven­
tion must not be delayed.
•  In patients with poor run-off, 
which is not clearly visualized pre- 
operatively in spite of added digital 
subtraction techniques, due to poor 
flow.
•  When postoperative flow is 
poor after arterioplasty (i.e., intimal 
flap, distal embolization) and endar­
terectomy.
•  When there is unexpected 
poor inflow (i.e., proximal stenosis).
In cases of thrombosis of the 
vascular repair in the immediate 
postoperative period, angiography 
is rarely indicated. Intraoperative 
angiography saves time and pro­
vides information that cannot be 
obtained when the graft is occlud­
ed.
All materials required are inex­
pensive and readily available in the 
operating room. A single-lumen em- 
bolectomy catheter sells for $32.97 
versus $47.00 for the double-lumen 
catheter. The no. 5 pediatric feed­
ing tube costs only $1.01. Thus, 
embolectomy and angiography per­
formed by the above method will 
save $13.02 per patient. If embolec­
tomy is not needed, the cost can be 
reduced to $1.01. In centres per­
forming several hundred operations 
a year the saving could be substan­
tial. A portable x-ray machine usu­
ally suffices. Fluoroscopy with an 
image intensifier may be desirable 
in some cases but is not indispensa­
ble.
The pediatric feeding tube has a 
soft, rounded tip, so vessel damage 
is unlikely; it provides better dye 
flow than a double-lumen embolec­
tomy catheter because of its larger 
lumen and multiple side holes. 
Stenting of the pediatric feeding 
tube with the guide wire from the 
embolectomy catheter provides 
more rigidity for manipulation 
against flow and is accomplished at 
no extra cost.
The small size of the Jelco cathe­
ter for tourniquet control makes all 
subsequent steps easier.
Patch angioplasty is recommend­
ed in most cases. In patients who 
have a large artery, this procedure 
can be done directly through the
suture line of a direct closure if 
desired.
This technique of angiography 
offers two important advantages: 
the iliac vessels proximal to the 
graft can be visualized and direct 
puncture of the patch or graft, 
which may lead to increased turbu­
lence and stricture when closing the 
needle hole, is avoided.
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SESAP VI Question
Item 130
Which of the following statements about carcinoid syndrome is TRUE?
(A) It is more frequently seen in association with tumors originat­
ing in the hindgut than in the foregut
(B) It is rarely associated with diarrhea as a major complaint
(C) It is manifest by cutaneous flushing, which is directly related to 
the effect of serotonin
(D) Symptoms may be reproduced by the pentagastrin provocative 
test, especially in patients whose tumors originate in the 
midgut
(E) Symptoms are rarely improved by less-than-total resection of 
hepatic metastases
For the answer to and critique of Item 130 see page 270.
(Reproduced by permission from SESAP VI Syllabus; Surgical Educa­
tion and Self-Assessment Program No. 6. For enrolment in the Surgical 
Education and Self-Assessment No. 6, please apply to the American 
College of Surgeons, 55 East Erie St., Chicago, IL 60611.)
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P alliative Treatment of Advanced 
Colorectal Carcinoma With the YAG Laser
A.G. Nagy, MD, FRCSC
The Nd-YAG laser was used to provide palliative treatment for eight patients (two 
women and six men), ranging in age from 53 to 76 years, who had locally advanced 
colorectal cancer. The main indications for treatment were obstruction, bleeding and 
copious rectal mucus discharge. Only one complication, a Staphylococcus aureus 
infection, followed the treatment; the infection was easily controlled. The laser 
treatment was considered to ease the symptoms in five patients, but survival was not 
influenced by the treatment. This form of palliation must be evaluated in larger 
numbers of patients to assess its real value in advanced colorectal cancer.
Le laser Nd-YAG a ete utilise comme traitement palliatif d’un cancer colorectal 
localement avance chez huit patients (deux femmes et six hommes) dont l’age variait 
de 53 a 76 ans. Les indications principales du traitement furent l’obstruction, les 
saignements ou un ecoulement muqueux abondant. On a enregistre une seule 
complication au traitement, soit une infection a Staphylococcus aureus qui fut 
facilement maitrisee. On a juge que le traitement au laser avait ameliore les 
symptomes de cinq patients mais il n’eut aucune influence sur la survie. Cette forme 
de traitement palliatif doit etre evaluee chez un plus grand nombre de malades afin 
d'etablir son interet reel dans les cancers colorectaux avances.
S urgical resection is the treat­ment of choice for both cure 
and palliation of colorectal carcino­
ma. However, resection is associat­
ed with substantial morbidity and 
mortality in cases of locally ad­
vanced or metastatic disease. Proxi­
mal diverting colostomy does not 
always control symptoms such as 
bleeding or excessive mucus dis­
charge. Some patients are simply 
too ill medically to undergo surgery 
or refuse surgery. For them, treat­
ment options include radiotherapy, 
chemotherapy, electrocoagulation 
or cryotherapy. If radiotherapy fails 
to control local disease it cannot be 
repeated, so other treatments must 
be considered. Successful applica­
tion of laser therapy in obstructing
carcinoma of the esophagus led to 
attempts to apply the same therapy 
for palliation in patients with ad­
vanced colorectal cancer.
The application of Nd:YAG laser 
treatment in eight patients who had 
advanced colorectal carcinoma is 
reported in this paper.
Patients and Methods
Patients
Eight patients (six men, two 
women) with advanced or recurrent 
rectal adenocarcinoma were referred 
for palliative endoscopic laser 
coagulation by the gastrointestinal 
follow-up clinic of the Cancer Con­
trol Agency of British Columbia.
Seven patients had documented, 
advanced, recurrent, local pelvic 
disease or metastases. They had 
received previous pelvic irradiation 
and prolonged courses of chemo­
therapy with 5-fluorouracil. The re­
maining patient initially refused 
conventional surgical treatment for 
an obstructing carcinoma of the 
rectosigmoid and received Nd:YAG 
laser treatment as primary therapy.
The patients ranged in age from 
53 to 76 years (mean 65 years). 
Preoperative preparation included 
saline enemas and irrigations.
The patients were subjected to a 
maximum of three treatment ses­
sions (total of 14 sessions for all 
patients). Treatment was carried out 
under general anesthesia (three ses­
sions), spinal anesthesia (six) or 
intravenous sedation (five). As expe­
rience with the technique improved, 
only intravenous sedation was used.
Equipment and Technique
The procedure was carried out 
through a flexible colonoscope 
(Olympus CF Type 20M; Carsen 
Medical & Scientific Co. Ltd., Mark­
ham, Ont.) with the patient in the 
lithotomy position. A Medi-Las 
2YAG model 621 laser source (Uni­
tec Medical Lasers Inc., Oakville, 
Ont.) was employed. Safety goggles 
were worn throughout the proce­
dure. The flexible laser fibre was 
introduced through the biopsy 
channel of the colonoscope. A coax­
ial flow of carbon dioxide was used 
to cool the laser tip. Following 
passage of the delivering fibre the 
tip was held approximately 1 cm 
distal to the target tissue and the 
laser beam was directed with the
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red aiming beam. Laser coagulation 
was directed at the most accessible 
and protruding tumour or the most 
obvious bleeding site on the surface 
of the tumour. Each laser shot was 
limited to 1 second duration and the 
power ranged from 30 to 90 W. 
Treatment was terminated when a 
whitish grey coagulum covered the 
tumour surface. As experience was 
gained more total energy (joules) 
was applied at each session.
Selection, Criteria and Treatment 
Policy
Patients were selected for this 
treatment approach when, in the 
oncologists’ opinion, there was no 
further adjuvant therapy to offer. 
One patient steadfastly refused con­
ventional primary surgical treat­
ment but accepted laser treatment 
to his obstructing rectosigmoid car­
cinoma. Strangely, following im­
provement of his symptoms he con­
sented to conventional surgical re­
section.
In all cases, patients were in­
formed before the treatment that no 
definite benefit could be guaranteed 
from this experimental approach. 
However, it was gratifying to note 
that after symptomatic improve­
ment some patients sought further 
treatment when symptoms im­
proved. Others refused further at­
tempts at laser treatment and no 
undue pressure was brought upon 
them to continue with this form of 
palliation.
Results
The details of treatment with the 
YAG laser in these eight patients 
are summarized in Table I. Treat­
ment failed in two patients. In one 
the rectal lumen could not be dis­
tended, so the laser beam could not 
be focused at the tumor. In the 
second patient treatment had to be 
abandoned when copious semiliq­
uid feces entered the rectal segment 
following distension with carbon di­
oxide and after only 500 J had been 
applied. Feces interfere with visual­
ization and the delivery fibre tip 
cannot be adequately cleaned.
In one woman who had extensive 
pelvic disease and pelvic discomfort, 
only the invading intraluminal tu­
mour mound was vaporized, leaving 
a posterior rectal ulcer, and her 
symptoms did not improve much. 
Her surgeon elected to cauterize 
the tumour invading her rectum 
with electrocautery from time to 
time.
In the remaining five patients the 
goals of treatment were achieved, 
thus the results of treatment were 
considered satisfactory.
Severe bloody mucus discharge 
was satisfactorily treated in two 
patients for the remainder of their 
lives. One of these patients required 
three treatment sessions — two 
several days apart and a third 
session at 6 months after the first. 
Six months later he died of the 
disease but remained free of mas­
sive mucopurulent discharge. The 
other patient also had satisfactory 
palliation though he refused further 
treatment sessions offered to him to 
try to debulk his rectal mass. In a 
third patient, bloody diarrhea (more 
than 10 movements daily) was suc­
cessfully controlled with two treat­
ments, 3 months apart.
In two other patients, initial ob­
struction was relieved, allowing an 
antegrade bowel preparation; one 
refused conventional surgical treat­
ment for his rectosigmoid carcino­
ma, diagnosed 18 months earlier. 
He had bloody diarrhea, every 30 
minutes, with crampy abdominal 
pain and abdominal distension when 
he consented to laser treatment. His 
symptoms were markedly improved 
(four to six bowel movements daily) 
and he elected to undergo rectosig­
moid resection, in one stage, follow­
ing adequate bowel preparation. He
remains well at 18 months. The last 
patient had his obstruction relieved 
by laser treatment and then under­
went laparotomy aimed at resecting 
the suture line recurrence of his 
cancer. At laparotomy, however, he 
was found to have extensive meta­
static disease with peritoneal im­
plants and he was treated by proxi­
mal colostomy only. He died of his 
disease 5 weeks after the initial 
laser treatment. No complication of 
laser treatment was noted at lapa­
rotomy.
Complications
Only one complication was en­
countered — a Staphylococcus au­
reus septicemia which occurred im­
mediately after laser treatment. This 
episode of sepsis was quickly con­
trolled with intravenously adminis­
tered antibiotics. The patient under­
went further laser treatment with 
no undesirable side effects.
Discussion
In this preliminary report of laser 
coagulation of advanced rectosig­
moid adenocarcinoma eight patients 
were so treated between January 
1987 and July 1988. During this 
same period numerous reports of a 
similar treatment protocol have ap­
peared in the literature.’"‘Although 
Fleischer5 described laser treatment 
of gastrointestinal neoplasms with 
good results as early as 1984, prog­
ress in the application of this mode 
of therapy has been slow. Over the 
last 4 or 5 years it has become 
apparent that this modality of palli­
ation for advanced colorectal malig­
nancy is feasible and desirable in 
selected patients.
Radiotherapy has been found ef­
fective in local control of small 
rectal tumours and in preventing 
local recurrence after surgery for 
rectal carcinoma.6 However, in 
cases of advanced local disease,
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YAG LASER AND COLORECTAL CANCER
T a b le  1. Patient Data and Results of Treatment
P atien t Age, 
no. yr
Tum our  
location, 
S ex cm
Extent of 
d isease
N o. ot
M a in  P rev ious  la s er  
sym ptom s tre a tm e n t sessions
To ta l
la s er
energ y , J C o m m ents
P o s t-tre a t­
m e n t
course
70
65
12
10
75
59 12
5 53 M
6 53 M
7 76 M
8 66 M
Advanced
pelvic
disease,
liver
metastases
Ascites, 
widespread 
metastases, 
suture line 
recurrence
Pelvic
recurrence,
invading
rectum
Liver/lung
metastases,
pelvic
recurrence
5 Extensive 
pelvic 
disease
16
15
Suture line 
recurrence
Extensive
pelvic
disease
Locally
advanced
disease
Mucus,
bleeding
Incomplete
obstruction
Anterior resection, 
divided proximal 
colostomy, pelvic 
irradiation with 
5-FU
Rectosigmoid 
resection. 5-FU
Constipation, Transverse
pelvic 
discomfort
Bloody
diarrhea
(10/d),
tenesmus
colostomy, 
resection of 
rectosigmoid, 
closure of 
colostomy, pelvic 
irradiation with 
5-FU
Resection of 
rectosigmoid, 
pelvic irradiation 
with 5-FU
Mucus +  +  + 
Blood +  +  
Pain +
Obstruction, 
crampy 
abdominal 
pain and 
distension
Mucopurulent 
discharge (8 
diapers/d)
Bloody 
diarrhea 
(every 
30-60 min) 
(incomplete 
obstruction)
Colostomy for 
unresectable 
cancer, pelvic 
irradiation with 
5-FU
Sigmoid resection. 
5-FU
Palliative Flartmann 
resection, pelvic 
irradiation with 
5-FU
None
1 attempt 0 Rectal stump
encased with 
tumour, not 
distensible. 
Technical 
failure
1 500 Inadequate
luminal 
preparation. 
Technical 
failure.
Refused
further
treatment
1 1380 No measurable
relief of
symptoms,
but invading
tumour
vaporized,
leaving rectal
ulcer
2 2292 3 bowel
movements/d 
after 1st 
treatment. 
Recurrent 
symptoms 
after 3 mo. 
Improved on 
further 
treatment
2 3965 Mucus and
blood loss 
improved but 
pt refused 
more 
treatment
2 2860 Obstruction
relieved, 
bowel prep, 
reoperation. 
Extensive 
disease found. 
Colostomy 
only. No com­
plication of 
laser therapy
3 9600 Minimal
discharge post 
treatment. 
Septicemia 
after 2nd 
session
3 22 834 Obstruction
relieved (4-6  
bowel
movements/d)
Finally
consented to
anterior
resection
Alive 21 mo
Died 7 mo
Alive 2 yr. 
Further 
conventional 
cauterization 
of rectal 
tumour
Died 9 mo
Died 11 mo
Died 4 wk 
post-op (5 
wk after 
laser
treatment)
Died 10 mo 
after last 
treatment. 
Renal failure
Well 18 mo.
No evidence 
of disease
5-FU =  5-fluorouracil.
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bleeding and mucus discharge often 
persist despite completion of adju­
vant radiotherapy. In these patients, 
therapy with the YAG laser may 
provide palliation for obstruction, 
troublesome discharge of mucus 
and bleeding.7
The Nd:YAG laser is ideally suit­
ed for application in general sur­
gery. At low powers (10 to 15 W) 
and comparatively long exposure (2 
seconds) it can shrink and coagu­
late tissue, and at high powers (90 
to 100 W) and shorter exposure 
(0.5 to 1 second) it can vaporize 
tissue. The YAG wavelength of 
1064 nm is absorbed best by the 
colour black.
When carbonization of the tissue 
has taken place the beam of the 
YAG laser will act as a cutting and 
vaporizing instrument. With the 
non-contact quartz fibres used in 
the present series, there are disad­
vantages. The quartz tip, for in­
stance, may be damaged should it 
come in contact with blood, feces or 
tissue, and this was a problem. The 
introduction of contact sapphire 
probes may improve our ability to 
vaporize endoscopically or cut tu­
mours more efficiently, that is, at 
lower energy levels and more pre­
cise delivery to the offending tu­
mour.8
There are no series at present to 
compare the applications of YAG 
laser therapy, radiotherapy and 
electrocautery. Often, YAG laser 
therapy is applied only after radia- 
totherapy has been tried and trou­
blesome local symptoms persist. 
Electrocautery is applicable only in 
low lesions, whereas YAG laser en­
ergy can be delivered at high loca­
tions through the colonoscope. As 
with electrocautery, YAG laser ther­
apy is usually applied during several 
treatment sessions and the total 
amount of energy applied should be 
dictated by the extent of local dis­
ease being treated. The ameliora­
tion of the patients’ symptoms will
dictate how often laser coagulation 
should be employed. At repeat en­
doscopic evaluation, previously 
treated areas appear as whitish, 
fibrotic, avascular areas with areas 
of necrotic coagulum visible, de­
pending on the time elapsed since 
previous treatment.
In this series there was only one 
case in which a resected specimen 
was available for pathological exam­
ination. The pathologist reviewing 
the slides commented: “ ...the sur­
face tumour was basically in the 
muscle, implying that the mucosa 
and submucosa had been lost. 
Whether this loss was due to tu­
mour or to laser is unknowable.” It 
is evident from clinical reports, 
however, that the endoluminal ob­
structing tumour mound seems per­
manently destroyed and luminal 
patency is maintained on long-term 
follow-up.8 One can only speculate 
that the necrosis of the mucosal 
lesion and the subsequently noted 
whitish fibrous avascular luminal 
surface prevents endoluminal re­
growth of the tumour. It is clear 
that tumour continues to grow lat­
erally, however, and progression of 
the disease is not halted by laser 
treatment in these advanced lesions.
Our patients experienced sub­
stantial improvement after laser 
therapy for troublesome bloody di­
arrhea and discharge of mucus. 
Survival was likely not influenced, 
but palliation of these annoying 
symptoms was gratifying. In addi­
tion, obstruction was relieved by 
recanalization of the lesion in two 
patients. The implication of recanal­
ization is that a one-stage proce­
dure may become possible after the 
recanalization and antegrade bowel 
preparation. It is not clear how 
many laser treatments or laser 
“shots” should be applied in indi­
vidual patients. These answers will 
only become clearer following ex­
tensive applications of laser cauteri­
zation in larger numbers of pa­
tients. Palliative laser coagulation 
of advanced colorectal cancer is 
here to stay and should be em­
ployed in larger centres associated 
with regional cancer agencies. Fur­
ther developments in this form of 
therapy may occur with the advent 
of sapphire-tipped laser probes, 
which will allow application of the 
laser energy through direct contact 
with the tumour. Any gastrointesti­
nal surgeon trained in endoscopy 
and familiar with the use of the 
laser can use this modality. Laser 
training courses are widely available 
in the United States and should 
soon become more accessible in 
Canada.
I thank the oncologists at the Cancer 
Control Agency of British Columbia 
who referred their patients for this 
modality of treatment. I also gratefully 
acknowledge the assistance of Dr. R. 
Miller, who kindly reviewed and com­
mented on the pathological material of 
one of the patients in this series.
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Preoperative Radiotherapy for 
Adenocarcinoma of the Rectum
E.M. Webber, MD; J.K. MacFarlane, MD, FRCSC, FACS
Curative surgery remains the principal treatment for rectal carcinoma.
Unfortunately failure following surgery, particularly through local recurrence, is an 
all too common event. Among the potential adjuvant therapies, preoperative 
radiotherapy holds clear promise. A review of the clinical trials evaluating this 
treatment modality shows that it can decrease the rate of local recurrence and may 
even improve the overall 5-year survival. Preoperative radiotherapy is consistently 
well tolerated up to doses as high as 60 Gy; it does not complicate the surgical 
resection or increase the perioperative morbidity and mortality. Preoperative 
radiotherapy warrants further investigation to select those patients who are most 
likely to benefit from it.
La chirurgie a visees curatives demeure le principal traitement du cancer du rectum. 
Malheureusement, les echecs de chirurgie, particulierement dus a des recidives 
locales, sont frequents. Parmi les therapies adjuvantes possibles, la radiotherapie 
preoperatoire est nettement prometteuse. Une revue des essais cliniques qui ont 
evalue cette modalite therapeutique, montre qu’elle peut reduire le taux des 
recidives locales et ameliorer la survie a 5 ans. La radiotherapie preoperatoire est 
regulierement bien supportee jusqu’a concurrence d’une dose de 60 Gy; elle ne 
complique pas la resection chirurgicale et elle n’augmente pas la morbidity et la 
mortality peroperatoires. La radiotherapie preoperatoire vaut d’etre davantage 
etudiee afin de choisir les patients les plus susceptibles d’en beneficier.
The results of surgical treatment of rectal carcinoma have 
changed little over the past 25 
years despite efforts to increase 
early detection of the disease. The 
overall 5-year survival is 30% and is 
50% for those who undergo cura­
tive resection.12 Between 25% and 
50% of failures after surgery are 
attributed to local recurrence,
which occurs in up to 65% of 
patients with Dukes’ stage C dis­
ease.3
When performing surgery for 
rectal carcinoma the surgeon en­
counters problems not seen in sur­
gery of other colonic carcinomas. 
The rectum is confined within a 
small bony cavity, adjacent to im­
portant genitourinary structures; it
possesses no peritoneal covering or 
mesentery. These factors prevent 
the establishment of wide excision 
margins and increase the risk of 
tumour spillage at surgery. Because 
of the survival and recurrence sta­
tistics, other therapeutic modalities, 
including combinations of radio­
therapy and chemotherapy, are 
being investigated. The role of adju­
vant radiotherapy in improving the 
outcome of the disease has attract­
ed considerable interest.
History
The preoperative use of radio­
therapy dates back 75 years, with 
more intensive work being done 
during the past 30 years. In 1914 
Symonds4 described the case of a 
73-year-old man who was found to 
have an annular rectal carcinoma 
3.75 cm above the anus. Radium 
bromide (100 mg) was applied to 
the tumour for 6 hours on each of 
5 consecutive days. One week after 
completion of this treatment no 
tumour was visible or palpable. Be­
cause of local stricturing 3 months 
later a diverting colostomy was cre­
ated. Two months after that the 
tumour site was excised and the 
bowel ends were reanastomosed by 
a transperineal route. The postoper­
ative course was uncomplicated; the 
colostomy was closed 1 month lat­
er.
During the 1930s radiation treat­
ment alone was attempted using 
high voltage x-rays or interstitial
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radium; results were not favoura­
ble.5 The first major report of pre­
operative radiotherapy was that by 
Stearns, Deddish and Quan6 at the 
Memorial Center for Cancer in New 
York who presented a retrospective 
analysis of 1786 patients with carci­
noma of the rectum and rectosig­
moid colon seen between 1939 and 
1951. Of these, 1276 underwent 
surgical exploration; the tumour 
was resected in 971. Of the 1276 
patients, 727 had received preoper­
ative radiotherapy (an average of 
less than 20 Gy). The group receiv­
ing preoperative radiotherapy had a 
higher resectability rate than the 
control group (86% versus 69%). 
The only groups showing a differ­
ence in survival were those who had 
Dukes’ stage C tumours: the 5-year 
survival rate was 37% in the irradi­
ated group compared with 23% in 
the controls. Local recurrence was 
not analysed. Despite the inherent 
limitations of this type of study it 
spurred further investigations.
Clinical Trials
The group at Memorial Hospital 
then embarked on a prospective 
randomized control trial comparing 
surgery alone to radiotherapy (20 
Gy over 2 weeks) followed by sur­
gery7 (Table I). This trial ran from 
1960 to 1967 and involved 347 
patients. A further 443 patients 
treated (nonrandomly) between 
1957 and 1959 were included in the 
study. Of the total number, 376 
patients received radiotherapy fol­
lowed by surgery and 414 under­
went surgery alone (controls). The 
5-year survival was 65% in the 
radiation group compared with 67% 
in the control group. There was no 
difference in the rate of local recur­
rence when local lymph nodes were 
tumour-free at the time of surgery. 
When tumour had spread to region­
al lymph nodes, however, there was
a reduced incidence of local recur­
rence in the irradiated group. At the 
same time the Veterans Administra­
tion Surgical Adjuvant Group (VA- 
SAG)8 initiated a prospective ran­
domized trial in 700 patients with 
biopsy-proven rectal carcinoma, 
comparing surgery alone to radio­
therapy (20 to 25 Gy over 2 weeks) 
followed by surgery (Table I); 353 
had surgery alone and 347 had 
radiotherapy followed by surgery. 
The incidence of Dukes’ stage C 
disease was lower in the irradiated 
group (24%) than in the control 
group (38%). Preoperative radio­
therapy was found to be beneficial 
only in patients who had ab­
dominoperineal resection; the 
5-year survival in those who had 
received preoperative irradiation 
was 40.8% compared with 28.4% in 
the controls, and the local recur­
rence rate was 29% and 40% respec­
tively. No difference between the 
two groups was found in patients 
who underwent other surgical pro­
cedures (Hartmann procedure, sub­
total colectomy, anterior resection). 
In these patients the 5-year survival 
was 38.5% in the irradiated group
versus 39.8% in the controls, and 
the local recurrence rates were 29% 
and 26% respectively. A second pro­
spective randomized control trial by 
the Veterans group9 compared sur­
gery alone to 31.5 Gy of radiothera­
py followed by surgery (Table I). A 
total of 361 patients were entered 
into the study; 180 received surgery 
alone and 181 had radiotherapy 
followed by surgery. Abdominoperi­
neal resection was performed in 
94% of cases. The 5-year survival 
was 50% in both groups; there was 
no comment about the respective 
rates of local recurrence.
Kligerman and associates10 de­
scribed the Yale University experi­
ence. There, 31 patients were ran­
domized to receive preoperative ra­
diotherapy (45 Gy) followed by sur­
gery or to receive surgery alone. 
The number of patients in the study 
was too small to make statistical 
comparisons of 5-year survival. Ra­
diotherapy did not increase the 
morbidity. Dukes’ stage C disease 
was less common in the irradiated 
group (23%) than in the control 
group (69%).
Between 1960 and 1972 at the
Table 1. Results of Preoperative Radiation for Carcinoma of the Rectum
Local 5-year 
Patients recurrence survival
Trial Dose, Gy No RT RT No RT RT No RT RT
Retrospective
Memorial, 19747 20 414 376 23 13* 65 671
Virginia, 198615 40-60 106 60 40 16 48 52
Springfield, 198814 
Prospective
40-50 109 40 51 19 57 85
VASAG I, 19758 20-25 353 347 36 13$ 32 40$
Toronto, 197712
40 29§ 28 41 §
5 65 55 - 35 35$
17 35*
MRC, 198413 5 275 277 57 55 38 42
20 272 53 40
E0RTC I, 198416 34.5 - 121 __ 59 _ 15
34.5 +  5-FU _ 126 _ 46 _ 15
VASAG II, 1986® 31.5 180 181 _ _ 50 50
E0RTC II, 1988’8 34.5 175 166 30 15 59 69
RT =  radiotherapy, 5-FU =  intravenous 5-fluorouracil. 
‘ Patients with Dukes’ stage C disease. 
fOverall survival.
$AII patients included.
§Patients having abdominoperineal resection.
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University of Oregon patients with 
carcinoma of the rectosigmoid were 
treated preoperatively with high- 
dose (50 to 60 Gy) radiotherapy.11 
Before initiating the radiotherapy 
57 patients were deemed to have 
resectable tumours (i.e., the tumour 
was mobile). Forty of these patients 
underwent potentially curative re­
section and 38 (72%) were tumour- 
free at 5 years. Eight of the 57 died 
with a pelvic tumour; of these 1 had 
refused surgery, 1 had liver metas- 
tases at the time of surgery, 3 had 
unresectable tumours and 3 had 
tumour in the resection margin at 
surgery. Of the 40 patients who 
had curative resections, none suf­
fered a pelvic recurrence. Most pa­
tients suffered from transient diar­
rhea; 16 had complications and 1 of 
them died. This complication rate 
compared favourably with that seen 
in a historical control group not 
receiving radiotherapy.
Rider and colleagues,12 in Toron­
to, described their experience with 
preoperative low-dose radiotherapy 
(5 Gy in a single dose just before 
surgery) (Table I): 125 patients 
were randomized to either this 
treatment or surgery alone. The 
overall 5-year survival was about 
40%, with no significant difference 
between treatment groups. In pa­
tients who had Dukes’ stage C 
rectal carcinoma, however, the 
5-year survival was over 35% in the 
irradiated group but less than 20% 
in the group who had surgery 
alone. No complications were attri­
buted to the radiotherapy; no analy­
sis of local recurrence was reported.
A multicentre study in Britain13 
compared three groups: one group 
(275 patients) had surgery alone, a 
second group (277 patients) re­
ceived a single dose of 5 Gy fol­
lowed by surgery and a third group 
(272 patients) received 20 Gy in 10 
fractions followed by surgery (Table 
I). In all, 824 patients with rectal 
carcinoma were randomly assigned
to one of these treatment groups. 
There was no difference in 5-year 
survival (about 50%) or in the 
5-year local disease-free rate (about 
55%) among the three groups. 
There was no increase in technical 
difficulties or postoperative compli­
cations associated with either radio­
therapy group.
In Springfield, Massachusetts 
Reed and collaborators14 reviewed 
149 patients with rectal carcinoma 
(Table I). Forty patients had re­
ceived between 40 and 50 Gy of 
radiotherapy preoperatively, fol­
lowed by surgery, and 109 patients 
underwent surgical resection alone 
(controls). The 5-year survival was 
better in the irradiated group than 
in the controls (85% versus 57%), 
as was local recurrence (19% versus 
51%). One irradiated patient and 
four control patients had an anasto­
motic leak. Thirteen irradiated pa­
tients had bowel fibrosis attributed 
to the treatment; 1 required steroid 
enemas to control rectal bleeding 
and another required a diverting 
colostomy. There was no increased 
risk of a second primary tumour 
(colonic or extracolonic) postopera- 
tively during the follow-up period 
(15% versus 10% in the control 
group).
Fortier and associates15 described 
the experience at the University of 
Virginia between 1972 and 1983 
with high-dose preoperative radio­
therapy for patients having rectal 
carcinoma (Table I). Sixty patients 
received between 40 and 60 Gy 
before surgery. Fifty-six of these 
showed no metastases at the time of 
surgery and underwent resection. 
They were followed up for a mean 
of 43 months. When they were 
compared with 106 patients who 
had undergone resection alone, no 
significant difference in the 5-year 
survival was noted (52% versus 
48%). Of the group receiving radio­
therapy 16% had local recurrence 
compared with 40% in the controls.
No difference was observed in the 
rates of major complications requir­
ing hospitalization (5% in each).
Between 1972 and 1976 the Eu­
ropean Organization on Research 
and Treatment of Cancer (EORTC) 
conducted a prospective random­
ized trial of treatment of rectal 
carcinoma, comparing 34.5 Gy of 
radiotherapy followed by surgery to 
34.5 Gy of radiotherapy plus 10 
m g/kg of intravenous 5-fluoro- 
uracil (5-FU) followed by surgery 
(5-FU sensitizes cancer cells to 
the lethal effects of radiation)1617 
(Table I). There were 247 patients 
in the trial, and they were fol­
lowed up for a mean of 5.2 years. 
Lymph-node involvement was seen 
in 29% of patients receiving radio­
therapy and surgery compared with 
38% in patients receiving radiother­
apy, 5-FU and surgery; the differ­
ence was of marginal statistical sig­
nificance. Local recurrence was 
found in 15% of both groups at 5 
years, but liver metastases were less 
frequent in the group receiving 
5-FU.
In 1976 the EORTC initiated a 
second prospective randomized tri­
al, this time comparing surgery 
alone to 34.5 Gy of irradiation 
followed by surgery for treatment of 
rectal carcinoma18 (Table I). Of the 
466 patients entered into the trial, 
341 underwent curative resection. 
Of these, 175 underwent surgery 
alone and 166 received radiotherapy 
before surgery. In those who had 
curative surgery, the 5-year survival 
was 69% in the radiotherapy group 
compared with 59% in the control 
group (p = 0.08). Local recurrence 
at 5 years was 15% in the radiother­
apy group compared with 30% in 
the control group (p =  0.003). 
When all patients (including those 
not having curative surgery) were 
considered, local recurrence at 5 
years was still significantly less fre­
quent in the group receiving preop­
erative radiotherapy.
CJS, VOL. 33, NO. 4, AUGUST 1990 267
WEBBER & MACFARLANE
Discussion
There are two distinct uses of 
preoperative radiotherapy. One is to 
shrink large tumours, making re­
section easier or even possible in 
tumours previously deemed un- 
resectable. Pilepech and col­
leagues19 described 44 patients con­
sidered to have unresectable rectal 
carcinomas. After irradiation with 
40 to 50 Gy, 27 patients underwent 
complete resection. Twenty-two of 
these patients remained disease-free 
for a median of 27 months postop- 
eratively (up to 48 months). Kliger- 
man20 reviewed 15 patients with 
unresectable rectal carcinomas. 
After receiving between 35 and 58 
Gy, nine patients underwent suc­
cessful resection, and three re­
mained disease-free after 21 to 85 
months. Stevens, Allen and Fletch­
er11 described 40 patients consid­
ered to have unresectable rectal 
tumours (i.e., the tumour was fixed) 
before receiving radiotherapy. Fol­
lowing irradiation 22 tumours were 
considered resectable and 20 resec­
tions were performed. Three of 
these patients were alive and tu­
mour-free at 3.5, 7 and 7 years; two 
others died without evidence of can­
cer. Of patients who did not under­
go resection, one was alive and 
tumour-free at 7 years and two 
others died without evidence of tu­
mour. In the whole group of 40 
patients, 30 died with tumour; 25 
of them had pelvic disease at the 
time of death. Complications from 
tumour and irradiation were consid­
erable in these patients.
The second use of preoperative 
irradiation is to facilitate complete 
elimination of the tumour at the 
primary site. In this regard the 
actions of surgery and radiotherapy 
are complementary. Although sur­
gery effectively removes the bulk of 
tumour, microdeposits of cancer are 
often left behind; radiation can elim­
inate these.21 In this respect preop­
erative radiotherapy offers no ad­
vantage over postoperative radio­
therapy. However, preoperative ra­
diotherapy does possess some in­
herent advantages. First, it avoids 
the risk of irradiating small bowel, 
which may become lodged in the 
pelvis after surgery.22 Romsdahl 
and Withers23 described 62 patients 
who received 50 Gy 3 to 8 weeks 
after surgery. Seven patients had 
adverse symptoms attributed to the 
radiation. One patient died of com­
plications, two patients suffered 
chronic radiation enteritis and eight 
further surgical procedures were 
required by these patients because 
of adhesions, fistulas, strictures and 
intestinal necrosis. However, in the 
experience of Hoskins and associ­
ates24 from the Massachusetts Gen­
eral Hospital where 97 patients re­
ceived 50 Gy of radiotherapy after 
surgical resection of carcinoma of 
the rectum and rectosigmoid, there 
was no increase in the complication 
rate (4%) when compared to a 
group that had surgery only. Sec­
ond, preoperative radiotherapy de­
creases the number and viability of 
cancer cells spilled into the local 
tissues or circulation at the time of 
surgery.25 Finally, tumour radiosen­
sitivity is dependent on tissue oxy­
genation, which is likely to be di­
minished postoperatively.2126
There are several arguments 
against the routine preoperative use 
of radiotherapy. Some people have 
thought that adenocarcinoma of the 
rectum is insensitive to radiation; 
however, the studies described 
above and the personal experience 
of one of the authors (JKM) refute 
this notion. Others believe that 
postoperative radiotherapy offers 
several advantages over preopera­
tive radiotherapy. First, it avoids 
the delay of 1 month or more before 
surgery that preoperative radiother­
apy imposes. But although preoper­
ative radiotherapy delays surgery it 
does not delay the initiation of
treatment. Second, by waiting until 
after surgery to decide whether ra­
diotherapy should be offered, the 
stage and the grade of the tumour 
are accurately known (preoperative 
staging by computed tomography 
and endorectal ultrasonography is 
an imperfect process).27 Since sur­
gery alone is curative in more than 
30% of cases it would be helpful to 
be able to select patients with no 
risk of local recurrence so that they 
could be spared the deleterious ef­
fects of radiation.
Unfortunately, this is not possi­
ble. In the second EORTC study,18 
three of the six patients with 
Dukes’ stage A disease treated by 
surgery alone suffered local recur­
rence. In a series at the Massachu­
setts General Hospital 8% of pa­
tients with Dukes’ stage A tumours 
had local recurrence.28 Several fac­
tors are known to correlate with an 
increased risk of local recurrence; 
these include tumour stage, tumour 
grade, the number of involved 
lymph nodes and the presence of 
blood vessel invasion. In an il­
luminating study, Moosa29 at the 
University of Chicago gathered data 
on 152 patients who had previously 
undergone abdominoperineal resec­
tion for carcinoma of the rectum 
and whose 5-year postoperative 
courses were known. All of the 
information available about each pa­
tient at the end of the postoperative 
period (barium enema, operative re­
sult and pathology report) was col­
lected. This information was pre­
sented to a panel of six independent 
observers (two surgeons, two pa­
thologists, one gastroenterologist 
and one radiotherapist) who were 
asked to predict which patients 
would have local recurrence. In this 
series local recurrence was found in 
31 patients (20%). The six panelists 
predicted local recurrence correctly 
in 34% to 68% of cases. Nobody 
predicted recurrence correctly at a 
rate better than by chance alone.
a  r
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Hence, even after surgery it is ex­
tremely difficult to predict which 
patients will or will not suffer local 
recurrence.
Third, there is concern about 
anastomosing bowel which has 
been subjected to radiation, particu­
larly in high doses. Schrock, De- 
veney and Dunphy30 reviewed all 
1703 colonic anastomoses per­
formed at the University of San 
Francisco between 1951 and 1970. 
They found anastomotic leakage in 
4.5% of cases overall but in 14% of 
patients who had previously re­
ceived abdominal radiation. Howev­
er, it is not clear that the irradiated 
patients were comparable to the 
group as a whole. Stevens’ group at 
the University of Oregon31 com­
pared 79 patients who underwent 
anterior resection and primary 
bowel anastomosis to 13 patients 
who had anterior resection and pri­
mary anastomosis after receiving 50 
Gy of irradiation. Four patients had 
protective colostomies; no complica­
tions were seen in them. Of the nine 
without colostomiy, two had small- 
bowel obstruction secondary to ad­
hesions, two had anastomotic ab­
scesses and one had a wound dehis­
cence. Stevens, Fletcher and Allen31 
concluded that the primary anasto­
mosis was safe following irradia­
tion, provided that the proximal 
bowel was outside the radiation 
field; they recommended colostomy 
in all cases.
Friedmann and his group32 re­
viewed the outcome of 133 patients 
who had anterior resections for rec­
tal carcinoma. Forty patients had 
received 45 Gy preoperatively (65% 
had protective colostomy) and the 
other 93 patients had no preopera­
tive radiotherapy (42% had protec­
tive colostomy). The overall compli­
cation rate was 25% in those having 
radiotherapy and 27% in the control 
group. Anastomotic leak rates were 
10% in the radiotherapy group and 
7% in the controls. The anastomotic
leak rate was much higher in pa­
tients with colostomy (14%) than in 
those without (1%). This difference 
was attributed to an inherent differ­
ence in the two groups; a colostomy 
was more likely to be used when 
the anastomosis was less than ideal. 
Finally, in Daytona Beach, Florida, 
Robertson and associates33 reviewed 
40 patients with rectal carcinoma 
who had received 45 Gy over a 
5-week period followed by anterior 
resection of the rectosigmoid colon 
1 to 3 weeks later. One patient had 
severe diarrhea pre- and postopera- 
tively, which responded to antidiarr- 
heal medication. There were no se­
vere complications or anastomotic 
leaks in this group.
Conclusions
There is no ideal systemic adju­
vant treatment for rectal carcinoma 
currently available to greatly im­
prove the prognosis over that pro­
vided by surgery alone. The studies 
to date of preoperative radiotherapy 
have failed to show conclusively an 
improvement in survival, let alone 
the optimal dose required to achieve 
it. Despite the lack of proof that 
survival is increased, it is clear that 
preoperative radiotherapy may de­
crease the rate of local recurrence, 
probably in a dose-related fashion. 
If this were its only benefit preoper­
ative radiotherapy could be consid­
ered a success, as local recurrence 
is a devastating complication, pro­
gressing to a miserable death.
As for the optimal dosage, high, 
tumoricidal dose irradiation (50 Gy 
or more) seems the most appealing. 
Concern about the possible deleteri­
ous effects of such treatment have 
not been borne out. The greatest 
decrease in local recurrence and the 
greatest potential for complete cure 
reside with this form of therapy. 
Chemotherapy and postoperative 
radiotherapy will likely play a role
in the treatment of those patients 
for whom preoperative radiotherapy 
and surgery are less than satisfacto­
ry.
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SESAP VI Critique
Item 130
The carcinoid syndrome is seen only in patients with hepatic metastases and is clinically manifested by cutaneous 
flushing, hyperperistalsis and diarrhea, asthma, and hemodynamic alterations that may result in vasomotor 
collapse. The syndrome was initially believed to be due to excessive amounts of circulating serotonin. 
Subsequent observations testify to the inadequacy of this simple hypothesis, and the biochemical aspects of the 
malignant syndrome are much more complex.
Etiology of the flushing in these patients remains unknown. Infusion of somatostatin abolished the flushing, 
which suggests that is humorally mediated.
The tumor originates from the embryologic midgut in patients with the classic carcinoid syndrome. Patients 
with metastatic disease generally have elevated levels of serotonin and substance P in the peripheral blood. 
Several agents have been used to provoke the carcinoid symptoms, including alcohol and catecholamines, 
calcium, and most recently pentagastrin. In a recent series of 17 patients with known midgut carcinoids, 16 of 
whom had hepatic metastases, pentagastrin caused flushing in all. It induced gastrointestinal symptoms in all 
but one and universally elevated circulating serotonin levels. The pentagastrin test with measurements of 
setononin levels in the peripheral blood seems to be superior to infusion of calcium as a provocative test to 
document the diagnosis of carcinoid syndrome. Partial resection of hepatic metastases may ameliorate some of 
the symptoms of carcinoid syndrome. m
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Preoperative Chest X-ray Films in 
Elective Surgery: a Valid Screening Tool
M. Gagner, MD, CSPQ;* A. Chiasson, MD, CSPQ
The authors reviewed retrospectively 1000 patients who had a preoperative chest 
x-ray film made and who underwent elective surgery. Results showed that 5.8% of 
women and 10.5% of men (7.4% of all patients) had an abnormal preoperative chest 
x-ray film. These abnormalities were much more frequent (30%) in patients over 50 
years of age than in younger patients (3%). Of the 74 patients whose films revealed 
abnormalities, 68 (92%) had a history or symptoms of cardiorespiratory disease. Of 
the six patients with x-ray film abnormalities but without symptoms or a pertinent 
history, none had a change in clinical outcome because of radiography. Guidelines 
are recommended for selectively ordering preoperative chest x-rays in surgical 
patients.
Les auteurs ont etudie retrospectivement 1000 patients avec radiographie pulmonai- 
re preoperatoire ayant eu une chirurgie elective. Les resultats demontrent que 5.8% 
des femmes et 10.5% des hommes (7.4% du total) ont une radiographie pulmonaire 
preoperatoire anormale. Ces anormalitees sont plus frequentes (30%) chez les 
patients ages de plus de 50 ans, compare a les patients moins de 50 ans (3%). Sur 
les 74 cas d’anormalitees, 68 (92%) ont une histoire positive ou ont des symptomes 
ou histoire cardiorespiratoires. Les six cas d’anormalitees sans symptomes ou 
histoire pertinente, n’ont influence le resultat clinique. Des recommendations sont 
proposees pour l’ordonnance de radiographie pulmonaire preoperatoire chez les 
patients ayant a subir une chirurgie elective.
A history, physical examination and work-up form the basis for 
excellent preoperative care. Chest 
radiography is often ordered rou­
tinely and accounts for more than 
50% of all diagnostic radiologic 
procedures. That surely represents 
a major health care expenditure, 
and for the patients significant ex­
posure to ionizing radiation.1 There 
is controversy over the use of this 
investigative procedure, and wheth­
er it should be considered a valid 
screening tool or should be reserved 
for selected patients who stand to 
benefit most from it.2 This retro­
spective study was undertaken to 
evaluate the role and the impor­
tance of preoperative chest x-ray 
films in elective surgery, in the 
setting of a small community hospi­
tal.
Patients and Methods
We retrospectively studied pa­
tients who had been admitted to our 
hospital for elective surgery, minor 
and major, during a 45-month peri­
od (Sept. 1, 1981 to May 31, 1985). 
Patients were included when a pre­
operative chest x-ray film had been 
made within the 3 months preced­
ing the operation. The charts of 
1000 such patients were reviewed, 
and the sex, age, pertinent history, 
physical findings and radiologists’ 
reports were recorded.
Findings
There were 657 females and 343 
males. The proportion of chest 
x-ray films showing an abnormality 
is presented by age group in Fig. 1. 
Overall, 7.4% of the patients — 
5.8% of females and 10.5% of males 
— had an abnormal chest x-ray 
film. There was a progressive in­
crease in the rate of abnormalities 
above the age of 29 years. The 
lowest was 1%, in the 20 to 29-year 
age group, and the highest was 
56%, in patients more than 70 years 
old. Children had a slightly higher 
proportion of abnormalities (3% for
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those 0 to 9 years old and 2% for 
those 10 to 19 years old) than 
young adults (1%).
A marked elevation in the fre­
quency of abnormalities was noted 
in patients over 50 years of age 
(Table I); 30% had a abnormal chest 
x-ray film, compared with 3% in 
patients under this age. In women, 
23% over the age of 50 years had 
abnormalities compared with 2.7% 
for those younger than 50 years. 
The difference was even more pro­
nounced among men above and 
below the age of 50 years, 41% 
versus 3.6% (Table I).
The clinical records of the 74 
patients who had an abnormal chest 
x-ray film revealed that 68 (92%) of 
them had had an associated illness, 
pertinent medical history or symp­
toms that explained the radiologic 
findings (Table II). The majority of
patients with an associated illness 
had had either pulmonary or pleural 
fibrosis, or chronic obstructive pul­
monary disease. Others had had a 
cardiovascular disease, a recent or 
prior respiratory infection, asthma, 
sarcoidosis, recent chest trauma or 
previous cardiothoracic surgery. 
Cough, hemoptysis and dyspnea 
were the relevant symptoms.
Of the six patients with an abnor­
mal chest x-ray film, but no perti­
nent clinical history or signs, two 
had apical pulmonary calcifications, 
one had early lobar pneumonia as­
sociated with early peritonitis, one 
had granulomatous lesions of the 
left hilum, one had a small focus of 
atelectasis and one had cardiomeg- 
aly associated with signs of chronic 
obstructive pulmonary disease. 
None of these radiologic findings 
had clinical implications, except in
the patient with an early lobar 
pneumonia, who also needed an 
appendectomy, and who was treated 
with antibiotics for both conditions 
concomitantly.
Comments
For decades a basic preoperative 
work-up has been routine because 
surgeons heed that most important 
surgical aphorism: “avoid sur­
prises”. Consequently unnecessary 
examinations have been performed 
on a large number of patients. In 
recognition of this, guidelines have 
been issued for the selection of 
patients. Theoretically, preoperative 
chest x-ray films can serve as a 
screening tool or as a baseline for 
comparison if a postoperative x-ray 
film becomes necessary.
Ten years ago, one multicentre 
study (10 619 patients) in the Unit­
ed Kingdom showed that no ratio­
nal guidelines were in use for pre­
operative chest radiography.3 It also 
showed that preoperative x-ray 
films did not influence the decision 
to operate or the management of 
anesthesia, and that they did not 
provide baseline values. Following 
that study, norms were established 
for ordering preoperative x-ray
Table II. Associated Illnesses or Symptoms 
in 74 Patients With an Abnormality on the 
Preoperative Chest X-ray Film
Associated Illness/Symptoms No.
Pulmonary or pleural fibrosis 25
Chronic obstructive pulmonary 
disease 22
Cardiovascular disease 5
Recent respiratory infection (or 
prior pneumonia) 3
Asthma 3
Sarcoidosis 2
Recent chest trauma 2
Previous cardiothoracic surgery 1
Other (hereditary metabolic disease) 1 
Cough 2
Hemoptysis 1
Dyspnea 1
No important associated illness or 
symptoms 6
FIG . 1. F requency of abnorm al ch est x-ray film s by age g roup .
Table 1. Incidence of Abnormalities on Chest X-ray Films in Patients Younger or Older than 50
Years
No. abnormal/total (%)
Age, yr Female Male All
< 50 
> 50
15/557 (2.7) 
23/100 (23.0)
10/280 (3.6) 
26/63 (41.2)
25/837 (3.0) 
49/163 (30.1)
Totals 38/657 (5.8) 36/343 (10.5) 74/1000 (7.4)
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films. Radiologists subsequently 
noted a decline in the number of 
such films requested.4 The use of 
the Royal College of Radiologists’ 
(England) guidelines (Table III) has 
since been studied in four English 
hospitals.4 Seventy-five percent of 
the patients so examined had indi­
cations for chest radiography, and 
it was concluded that these guide­
lines were suitable for wider imple­
mentation in the National Health 
Service. These recommendations 
are similar to those of the World 
Health Organization scientific 
group on the indications and limita­
tions of major x-ray diagnostic in­
vestigations.1
According to Mendelson and col­
leagues,5 the properative chest ra­
diograph could still be valuable as a 
baseline examination. Their data 
showed that in 65 of 369 consecu­
tive general surgical patients, sur­
geons had postoperative chest x-ray 
films made. They stated that a 
preoperative baseline radiograph 
was essential in making an accurate 
interpretation in 33 (51%). But if 
one reviews the data carefully, it 
can be seen that 27 of these 33 
patients had radiographic changes 
compatible with postoperative ate­
lectasis, and in most cases this 
followed cholecystectomy or bowel 
surgery. The presence of abnormali­
ties on chest x-ray films after ab­
dominal surgery is well known, and 
these changes are often minor and
Table III. Guidelines for Preoperative Chest
Radiography Among Patients Admitted for 
Elective Noncardiopulmonary Surgery, 
Recommended by the Royal College of 
Radiologists (England)
1. Those with acute respiratory symptoms
2. Those with possible metastases
3. Those with suspected or established 
cardiorespiratory disease who have not 
undergone chest radiography in the 
previous 12 mo
4. Recent immigrants from countries 
where tuberculosis is still endemic, who 
have not had chest radiography within 
the previous 12 mo
without signs or symptoms.6 Still, 
some technical aspects of preopera­
tive baseline chest x-ray films may 
be important. Harris7 suggested 
that if these films are indicated, 
they should be made with the pa­
tient supine or sitting in bed, to 
make comparison with a postopera­
tive chest x-ray more accurate.
In another study,8 the records of 
318 eligible patients out of 341 
admitted to a vascular service ward 
were studied to examine the value 
of preoperative chest x-ray films 
with regard to postoperative chest 
complications. Of those whose 
chest films had shown a major 
abnormality, 40% had a postopera­
tive complication compared with 9% 
in those whose preoperative film 
had been normal. In only 3% of all 
the patients did the findings lead to 
changes in management, and no 
operation was cancelled for that 
reason. The authors concluded that 
the making of routine preoperative 
chest x-ray films did not improve 
the outcome and that they should 
be ordered only in selected cases. 
Similarly, if a routine chest x-ray 
film was made during an emergency 
admission, no improvement of care 
resulted.9
A protocol for selectively order­
ing preoperative chest x-ray films 
was assessed by Charpak and col­
leagues.10 The indications for pre­
operative chest x-ray films after full 
clinical history and physical exami­
nation were: any lung disease, 
major surgical emergencies (e.g., 
peritonitis, multiple trauma), a cur­
rent history of smoking in patients 
older than 50 years, immunosup­
pression (including that caused by 
malnutrition, steroid therapy or 
chemotherapy) and lack of a prior 
health examination in immigrants. 
Preoperative chest x-ray examina­
tions were done in 1101 of 3866 
available patients (28%). In 52% of 
these, chest x-ray films were abnor­
mal. In only 5% of the 1101 pa­
tients did chest x-ray lead to modifi­
cation of management or treatment. 
No deaths or pulmonary complica­
tions could be linked to the lack of 
preoperative chest x-ray films.
In a prospective study on the 
value of preoperative investigations, 
McKee and Scott11 showed that 
16% of 400 preoperative radio- 
graphic investigations revealed an 
abnormality, but only 0.013% 
changed the management of the 
patient. They recommended that 
chest x-ray films be made in pa­
tients over the age of 60 years. 
There is certainly a rational basis 
for ordering chest x-ray films after 
a certain age, because abnormalities 
are more frequent. However, this is 
mainly because the frequency of 
cardiopulmonary disease is higher 
and because the effect of tobacco 
use becomes tangible. In our study, 
men over the age of 70 years had 
two-and-a-half times as many abnor­
malities as women in the same age 
group, presumably because the pro­
longed use of tobacco is much more 
common in men.
With regard to chest x-ray exami­
nations in children, Sane and asso­
ciates12 reported that in 3.8% the 
results changed the management of 
the anesthesia or the operative 
treatment. But Wood and Hoekel- 
man,13 in a more recent study also 
done in children, found clinically 
significant changes in only 1.2%; 
0.4% of operations were cancelled. 
This last study is more in accor­
dance with our findings, where 2% 
to 3% of children’s chest x-ray films 
had an abnormality and no opera­
tions were cancelled.
In an effort to resolve the issue 
of whether strict guidelines should 
be implemented, or, instead, a wide 
screening be practised, some au­
thors have proposed a controlled 
prospective and randomized trial 
with clinical outcome as the end 
point.1415 One could question the 
feasibility of such a study on the
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grounds that it would require a 
large group of patients if death was 
the end point, and that it could be 
unethical.
Our study, in a small community 
hospital, demonstrated that abnor­
malities are present on preoperative 
chest x-ray films in only 7.4% of 
patients and that such abnormali­
ties are 10 times more frequent in 
patients over the age of 50 years 
than under. If preoperative chest 
x-ray films had been made only in 
cases in which there were clinical 
symptoms or a pertinent cardiore­
spiratory history, 92% of these ab­
normalities would have been no­
ticed. Of the 8% that would have 
been missed (0.6% of all patients), 
none of these patients would have 
suffered from a clinical prejudice or 
would have had their operation can­
celled.
We believe it is reasonable to 
order a preoperative chest x-ray 
film when there is a cardiorespirato­
ry disease or when the surgeon 
suspects such a disease after a 
thorough clinical history and physi­
cal examination. Preoperative chest 
x-ray films should not be routine in 
all patients in any age group. We 
highly recommend application of 
the guidelines of Charpak and asso­
ciates,10 the Royal College of Radi­
ologists of England3 or the World 
Health Organization.1
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THERAPEUTIC CLASSIFICATION
Antibiotic
ACTION
Cefotetan Disodium is a semisynthetic, beta-lactamase resistant (refer to 
STABILITY TO BETA-LACTAMASES), cephalosporin (cephamycin) antibiotic. 
In vitro studies indicate that the bactericidal action of cefotetan results from 
an interference of bacterial cell wall synthesis by inhibiting the cross-linking 
of peptidoglycan. Studies with 14C-labelled cefotetan have shown that on 
reaching the target penicillin-binding proteins (PBPs) in the inner membrane, 
the radiolabelled antibiotic binds principally to PBP 3 followed by PBP 1A 
and 1B. Cefotetan, like other cephamycins, does not bind to PBP 2.
The plasma elimination half-life of cefotetan is 3 to 4.6 hours after either 
intravenous or intramuscular administration. In normal patients, from 51 % to 
81 % of the administered dose is excreted unchanged by the kidney in 24 
hours. The biliary tract is the other major route of elimination.
INDICATIONS AND CLINICAL USE
CEFOTAN (Cefotetan Disodium) is indicated for the treatment of the following 
infections when caused by susceptible strains of the designated organisms:
Urinary tract infections caused by E. coli and Klebsiella species (including 
K. pneumoniae), Proteus mirabilis and indole-positive Proteus.
Lower respiratory tract infections caused by Streptococcus pneumoniae 
(formerly D. pneumoniae), Staphylococcus aureus (penicillinase and non­
penicillinase-producing), Haemophilus influenzae (including ampicillin- 
resistant strains), Klebsiella species (including K. pneumoniae) and E. coli.
Skin and skin structure infections caused by Staphylococcus aureus (penicil­
linase and non-penicillinase-producing), Staphylococcus epidermidis, Strep­
tococcus pyogenes, Streptococcus species (excluding Enterococci) and 
E. coli.
Gynecologic infections caused by Staphylococcus aureus (penicillinase and 
non-penicillinase-producing), Staphylococcus epidermidis, Streptococcus 
species (excluding Enterococci), E. coli, Proteus mirabilis, Neisseria gonor- 
rhoeae, anaerobic gram-positive cocci and gram-negative bacilli, Bacteroides 
species (excluding B. distasonis, B. ovatus and B. thetaiotaomicron).
Intra-abdominal infections caused byE. coli, anaerobic gram-negative bacilli, 
Bacteroides species (excluding B. distasonis, B. ovatus and B. thetaiotao­
micron).
Bone and joint infections caused by Staphylococcus aureus.
Specimens for bacteriological examination should be obtained prior to therapy 
in order to isolate and identify causative organisms and to determine their 
susceptibilities to CEFOTAN. Therapy may be instituted before results of 
susceptibility studies are known. However, once these results become avail­
able, the antibiotic treatment should be adjusted accordingly.
CONTRAINDICATION
CEFOTAN (Cefotetan Disodium) is contraindicated in patients with Type 1 
hypersensitivity reactions (ie, hives, angioedema, bronchospasm or ana­
phylactic shock) to the cephalosporin group of antibiotics.
WARNINGS
BEFORE THERAPY WITH CEFOTAN (Cefotetan Disodium) IS INSTITUTED, 
CAREFUL INQUIRY SHOULD BE MADE TO DETERMINE WHETHER THE 
PATIENT HAS HAD PREVIOUS HYPERSENSITIVITY REACTIONS TO 
CEFOTETAN DISODIUM, CEPHALOSPORINS, PENICILLINS OR OTHER 
DRUGS. CEFOTAN SHOULD BE GIVEN CAUTIOUSLY TO PENICILLIN- 
SENSITIVE PATIENTS. ANTIBIOTICS, INCLUDING CEFOTAN, SHOULD BE 
ADMINISTERED WITH CAUTION TO ANY PATIENT WHO HAS DEMON­
STRATED SOME FORM OF ALLERGY, PARTICULARLYTO DRUGS. IF AN 
ALLERGIC REACTION TO CEFOTAN OCCURS, ADMINISTRATION OF 
CEFOTAN SHOULD BE DISCONTINUED. SERIOUS ACUTE HYPERSEN­
SITIVITY REACTIONS MAY REQUIRE EPINEPHRINE AND OTHER 
EMERGENCY MEASURES.
PSEUDOMEMBRANOUS COLITIS HAS BEEN REPORTED WITH THE USE 
OF CEPHALOSPORINS, INCLUDING CEFOTAN, (AND OTHER BROAD- 
SPECTRUM ANTIBIOTICS); THEREFORE, IT IS IMPORTANTTO CONSIDER 
THIS DIAGNOSIS IN PATIENTS WHO DEVELOP DIARRHEA IN ASSOCIATION 
WITH ANTIBIOTIC USE.
Treatment with broad-spectrum antibiotics may alter normal flora of the colon 
and may permit overgrowth of Clostridia. Studies indicate a toxin produced 
by Clostridium difficile is one primary cause of antibiotic-associated colitis.
Mild cases of colitis may respond to drug discontinuance alone.
Moderate to severe cases should be managed with fluid, electrolyte and 
protein supplementation as indicated. When the colitis is not relieved by drug 
discontinuance or when it is severe, consideration should be given to the 
administration of oral vancomycin for antibiotic-associated pseudomembranous 
colitis produced by C. difficile. Other causes should also be considered.
PRECAUTIONS
General: Prolonged use of CEFOTAN (Cefotetan Disodium) may result in 
overgrowth of non-susceptible organisms and organisms initially sensitive to 
the drug. Careful observation of the patients is essential. If superinfection 
does occur during therapy, appropriate measures should be taken.
CEFOTAN may be associated with a fall in prothrombin activity. Those at risk 
include patients with renal or hepatic impairment, poor nutritional state, the 
elderly, and patients with cancer. Prothrombin times should be monitored in 
patients at risk and exogenous Vitamin K administered as indicated.
CEFOTAN should be used with caution in individuals with a history of gastro­
intestinal disease, particularly colitis.
A disulfiram-like reaction characterized by flushing, sweating, headache and 
tachycardia may occur when alcohol (beer, wine, etc.) is ingested within 72 
hours after CEFOTAN administration. Patients should be cautioned about the 
ingestion of alcoholic beverages following the administration of CEFOTAN.
Patients with impaired renal function; ie, creatinine clearance of 30 ml/min or 
less, should be placed on a special dosage schedule for CEFOTAN recom­
mended under DOSAGE AND ADMINISTRATION.
Drug Interactions
Renal function should be carefully monitored, especially if high dosages of 
the aminoglycosides are to be administered or if therapy is prolonged, because 
of the potential nephrotoxicity and ototoxicity of aminoglycosidic antibiotics. 
Although, to date, this has not been noted when CEFOTAN was given alone, 
increased nephrotoxicity has been reported following concomitant adminis­
tration of cephalosporins and aminoglycoside antibiotics. However, at the 
recommended doses, enhancement of nephrotoxicity is unlikely to be a 
problem with CEFOTAN.
Drug/Laboratory Test Interactions
A false positive reaction for glucose in urine may occur with Benedict’s or 
Fehling’s solution.
High concentrations of cefotetan may interfere with measurement of serum 
and urine creatinine levels by Jaffe reaction and produce false increases in 
the levels of creatinine reported.
Use in Pregnancy
The safety of CEFOTAN in the treatment of infection during pregnancy has 
not been established. The use of CEFOTAN in pregnant women requires that 
the likely benefit from the drug be weighed against the possible risks to the 
mother and fetus. Reproduction studies have been performed in rats and 
monkeys at doses up to 20 times the human dose and have revealed no 
evidence of impaired fertility or harm to the fetus due to cefotetan. There are, 
however, no adequate and well-controlled studies in pregnant women. Because 
animal reproductive studies are not always predictive of human response, 
CEFOTAN should be used during pregnancy only if clearly needed.
Use in Nursing Mothers
Cefotetan is excreted in human milk in very low concentrations. Caution 
should be exercised when CEFOTAN is administered to a nursing woman.
Pediatric Use
Safety and effectiveness in children have not been established.
ADVERSE REACTIONS
In clinical studies, the following adverse effects were considered related to 
CEFOTAN (Cefotetan Disodium) therapy.
Gastrointestinal: Gastrointestinal symptoms occurred in 1.5% of patients, 
the most frequent were diarrhea (1 in 80) and nausea (1 in 700).
Hematologic: Hematologic laboratory abnormalities occurred in 1.4% of 
patients and included eosinophilia (1 in 200), positive direct Coombs' test 
(1 in 250) and thrombocytosis (1 in 300). Transient thrombocytopenia and 
leucopenia have been reported.
Hepatic: Hepatic enzyme elevations occurred in 1.2% of patients and in­
cluded a rise in SGPT (1 in 150), SGOT (1 in 300), alkaline phosphatase 
(1 in 700) and LDH (1 in 700).
Hypersensitivity: Hypersensitivity reactions were reported in 1.2% of 
patients and included rash (1 in 150) and itching (1 in 700). During post­
marketing experience with CEFOTAN, anaphylactic reactions have been 
reported.
Local Effects: Local effects were reported in less than 1% of patients 
and included phlebitis at the site of injection (1 in 300) and discomfort 
(1 in 500).
SYMPTOMS AND TREATMENT OF OVERDOSAGE
To date, there have been no documented cases of overdosage with 
CEFOTAN (Cefotetan Disodium). If overdosage should occur, it should be 
treated symptomatically. CEFOTAN may be removed by dialysis.
DOSAGE AND ADMINISTRATION
DOSAGE: Adults: The usual adult dosage is 1 or 2 g of CEFOTAN (Cefotetan 
Disodium) administered intravenously or intramuscularly every 12 hours for 
5 to 10days. Proper dosage and route of administration should be determined 
by the condition of the patient, severity of the infection and susceptibility of the 
causative organism. Therapy may be started while awaiting the results of 
susceptibility testing.
PHARMACEUTICAL INFORMATION 
Chemistry
Trade Name: CEFOTAN +
Proper Name: Sterile Cefotetan Disodium U.S.P.
Chemical Name: CEFOTAN is the disodium salt of [6R-(6(*, 7«)]-7-[[[4-
(2-amino-1 -carboxy-2-oxoethylidene)-1,3-dithietan-2- 
yljcarbonyl] amino]-7-methoxy-3-[[(1 -methyl-1 H- 
tetrazol-5-yl)thio]methyl]-8-oxo-5-thia-1-azabicyclo 
[4.2.0]oct-2-ene-2-carboxylic acid.
The intravenous route is preferable for patients with bacteremia, bacterial 
septicemia, or other severe or life-threatening infections, or for patients who 
may be at risk particularly if shock is present or impending.
GENERAL GUIDELINES FOR CEFOTAN DOSAGE
Type of Infection Daily Dose Frequency and Route
Urinary T ract 1 - 4 g 500 mg every 12 hours IV or IM 
1 or 2 g every 24 hours IV or IM 
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(mg/ml)
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2 g 10 - 20 11 - 21 182 - 95
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ORIGINAL ARTICLES
Simultaneous Liver and Whole Pancreas 
Harvesting in the Multiorgan Cadaveric 
Donor
Jacques Corman, MD, FRCSC; Pierre Daloze, MD, FRCSC; Christian Smeesters, MD, FRCSC; 
Maroun Aboujaoude, MD; Stephan Busque, MD; Gilles St-Louis, MD, FRCPC;
Hugues Beauregard, MD, FRCPC
Simultaneous harvesting of the liver and whole pancreas is usually not performed 
because it is believed that the shared vascular supply of both organs is incompatible 
with safe grafting. A careful review of the vascular anatomy, however, shows that 
simultaneous removal of the two organs is feasible, and a technique is described by 
which the liver is revascularized in the recipient through the celiac axis or the 
common hepatic artery and the pancreas is revascularized through the superior 
mesenteric and splenic arteries. When the vascular supply is abnormal, 
reconstruction of the vascular tree of one or both organs may be needed. The results 
of this technique used on 10 recipients are analysed.
Le prelevement simultane, pour fin de greffe, du foie et du pancreas entier n’est 
habituellement pas pratique parce qu’on croit que le partage du lit vasculaire des 
deux organes est incompatible avec la securite de la greffe. Une etude approfondie 
de l’anatomie vasculaire montre toutefois que le prelevement des deux organes est 
possible et on decrit une technique permettant la revascularisation du foie chez le 
receveur a partir du tronc coeliaque ou de l’artere hepatique commune, et la 
revascularisation du pancreas, a partir des arteres mesenterique superieure et 
splenique. Quand l’apport vasculaire est anormal, il peut etre necessaire de 
reconstruire l’arbre vasculaire d’un, ou meme des deux organes. On analyse les 
resultats obtenus a l’aide de cette technique chez 10 receveurs.
The need for organ transplanta­tion far exceeds the availability 
of cadaveric donor organs. There­
fore, optimal use of a donor’s or­
gans is mandatory, and multiorgan 
harvesting has become common in 
most transplant centres.
Simultaneous removal of the liver 
and the whole pancreas is seldom 
performed because the partially
shared vascular supply of the two 
organs is considered incompatible 
with safe grafting in the recipi­
ents.1'2 Thus, in those conditions 
one of the organs is wasted for 
transplantation.
Careful review of the vascular 
anatomy of the liver and pancreas 
suggested to us that, in most in­
stances, both organs can be simul­
taneously harvested and successful­
ly transplanted.3
Vascular Anatomy
The most common (approximate­
ly 60% of cases4'6) disposition of the 
liver and the duodenopancreatic ar­
teries is described in Fig. 1. The 
three main arterial supplies of the 
pancreas (gastroduodenal, superior 
mesenteric and splenic arteries) 
communicate with one another by 
anastomosis within the gland, ei­
ther by pancreaticoduodenal ar­
cades or by branches of the splenic 
or the inferior pancreatic arteries.7'8 
Thus, a whole duodenopancreas 
can be safely revascularized 
through the superior mesenteric 
and the splenic arteries in the recip­
ient.
However, considerable anatomic 
variation may be encountered, espe­
cially at the level of the liver where 
the main hepatic artery may arise 
directly from the aorta instead of 
the celiac axis or the left and right 
hepatic arteries may originate from 
a variety of sites (Fig. 2).
The vascular anatomy of the pan­
creas is more constant, and most of 
the variations are found within the 
gland, downstream of the three 
main vessels, except for the posteri­
or branch of the superior pan­
creaticoduodenal artery, which orig-
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inates from the hepatic artery in 
2.7% of the cases, the anterior and 
posterior branches of the inferior 
pancreaticoduodenal artery, which 
arises from the first jejunal artery 
in 7.4%, and the dorsal pancreatic 
artery, which finds its origin on the 
celiac axis or the common hepatic 
artery in 33% of cases.7'8 Whatever 
the origin of these vessels, they 
usually communicate within the 
pancreas. With respect to the ve­
nous circulation, the portal vein 
usually supplies the liver through a 
common trunk, and its pancreatic 
branches are located in the gland 
(Fig. 3).
Thus, harvesting of the whole 
pancreas and the first, second and 
third parts of the duodenum with 
intrapancreatic segments of the su­
perior mesenteric, inferior mesen­
teric, splenic and portal veins 
should not jeopardize venous re­
turn.
Harvesting Technique
Of the different approaches used 
for multiorgan harvesting, the most 
common technique, described by 
Starzl and colleagues1 consists of a 
step-by-step dissection and skele­
tonization of the organs to be re­
moved in the heart-beating donor 
with in situ flush cooling at or near 
the end of the dissection. A recent 
variation is that of rapid cooling in 
situ and en bloc removal of all the 
splanchnic organs followed by fur­
ther bloodless ex vivo dissection.9
We use Starzl’s method for the 
hemodynamically stable donor. In 
the unstable donor we use an inter­
mediate method: rapid, flush cool­
ing in situ removal of the heart or 
lungs, or both, and progressive in 
vivo dissection of the abdominal 
organs in a bloodless field under 
cold perfusion.
FIG. 2. Variation of hepatic arterial 
supply. Common hepatic (CHA) or 
right hepatic artery (RHA) arises from 
superior mesenteric artery (SMA), and 
left hepatic artery (LHA) originates 
from left gastric artery (LGA). PV =  
portal vein, GDA =  gastroduodenal 
artery, SA =  splenic artery, DPA =  
dorsal pancreatic artery.
FIG. 3. Venous anatomy of pancreas. 
PV = portal vein, LG =  left gastric 
vein, SPD =  superior pancreaticoduo­
denal vein, SV =  splenic vein, IPD =  
inferior pancreaticoduodenal vein, SM 
= superior mesenteric vein, IM =  
inferior mesenteric vein, LGE =  left 
gastroepiploic vein.
FIG. 1. Normal arterial supply of liver and pancreas. RHA =  right hepatic artery, 
LHA = left hepatic artery, CA = cystic artery, PHA = proper hepatic artery, PV =  
portal vein, RGA =  right gastric artery, CBD = common bile duct, CHA = common 
hepatic artery, LGA =  left gastric artery, DPA = dorsal pancreatic artery, SA =  
splenic artery, GDA = gastroduodenal artery, PSPDA = posterior superior 
pancreaticoduodenal artery, ASPDA =  anterior superior pancreatiocoduodenal 
artery, PDA =  pancreaticoduodenal arcades, PIPDA = posterior inferior pan­
creaticoduodenal artery, AIPDA =  anterior inferior pancreaticoduodenal artery, 
GPA =  great pancreatic artery, IPA = inferior pancreatic artery, FJA =  first jejunal 
artery, SMA = superior mesenteric artery, SMV = superior mesenteric vein, IMV =  
inferior mesenteric vein.
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A generous midline incision is 
made from the suprasternal notch 
to the pubis, with sternotomy and 
transverse extensions laterally to 
both sides of the abdomen. The 
pericardium is opened, and heart 
function is assessed. The Toldt fas­
cia is opened, and the left colon is 
retracted medially. The aortoiliac 
carrefour is dissected free, and the 
inferior abdominal aorta is can- 
nulated with a no. 16 French cathe­
ter through the left common iliac 
artery. A no. 24 French cannula is 
inserted into the inferior vena cava 
to permit venous decompression 
and drainage when hypothermic 
flush perfusion has started. The 
infradiaphragmatic aorta is ap­
proached through the diaphragmat­
ic crura and encircled with an um­
bilical tape. The superior mesenteric 
vein is isolated and prepared for 
further precooling of the liver. 
Those first maneuvers take only a 
few minutes and allow rapid cold 
perfusion of the abdominal organs 
and quick harvesting of the heart 
when the donor is unstable.
In normal situations or after 
rapid cooling the aorta is progres­
sively skeletonized from the aor­
toiliac carrefour up to the celiac 
axis with section-ligatures of the 
inferior mesenteric and lumber ar­
teries. The left renal and adrenal 
veins are isolated, as are the renal 
and superior mesenteric arteries and 
the celiac axis. The left adrenal vein 
is transected between ligatures, and 
the renal arteries are located in 
order to protect them from the 
clamp that will be placed later on 
the aorta, just below the superior 
mesenteric artery.
After a Kocher maneuver has 
been performed the hepatic pedicle 
is carefully examined for anomalous 
arterial vascularization. The various 
elements are dissected as far as 
possible from the hilum. The com­
mon duct is ligated at the level of 
its entrance in the head of the
pancreas and transected. The gall­
bladder is opened and washed free 
of bile. The common hepatic artery 
is dissected toward the celiac axis, 
with isolation of the gastroduode­
nal, splenic and left gastric arteries. 
A search is made for a left hepatic 
artery originating from the left 
gastric artery; if not present, the 
left gastric artery is ligated and 
transected at the level of the celiac 
axis.
The portal vein is then isolated 
down to the confluence of its two 
tributaries, the superior mesenteric 
and splenic veins. Small accessory 
pancreatic and left gastric veins are 
transected between ligatures. The 
gastrocolic ligament is divided, and 
the first portion of the duodenum 
isolated. The right gastric artery 
and the short gastric vessels are 
ligated and divided, and the spleen 
is mobilized upward and medially 
together with the tail and body of 
the pancreas. Superior and inferior 
edges of the gland are progressively 
freed of areolar tissues. The inferior 
mesenteric vein is severed between 
ligatures. The dissection is extend­
ed to include the aortic origin of the 
celiac axis and superior mesenteric 
artery.
The uncinate process is then 
freed from the retroperitoneal struc­
tures. The first portion of the duo­
denum is divided as close as possi­
ble from the pylorus. The fourth 
portion of the duodenum is mobi­
lized and staple closed. The superi­
or mesenteric artery is transected 
distal to the first jejunal branch, 
and the superior mesenteric vein is 
cannulated. Liver pediculization is 
completed later, after the organs 
have been satisfactorily cooled, by 
dividing the ligaments and isolating 
the supra- and infrahepatic vena 
cavae.
When the abdominal dissection 
has been completed, 70 U /kg of 
heparin is given intravenously and 
dissection of the heart is begun.
During this time precooling of the 
liver is performed through the supe­
rior mesenteric vein with cold (4°C) 
Ringer’s lactate solution. As soon 
as the cardioplegia solution is start­
ed and effective circulation has 
ceased, the infradiaphragmatic 
aorta is cross-clamped, and the a 
cold intracellular preservation flush 
is started through the cannulated 
left iliac artery. Ringer’s lactate 
portal perfusion is replaced by the 
preservation fluid.
The venous effluent is drained 
initially through the cannulated in­
ferior vena cava; when the heart has 
been removed, the effluent is aspi­
rated from the transected inferior 
vena cava in the pericardial cavity.
When the abdominal organs are 
uniformly perfused and satisfactori­
ly cooled, they are detached one by 
one from their aortic and venous 
connections. Both kidneys are har­
vested with a patch of aorta and 
vena cava. The gastroduodenal ar­
tery is transected between ligatures, 
as close as possible to its origin. 
The arterial supply of the liver 
along with a patch of aorta is 
detached from the aorta at the level 
of the celiac axis. The splenic artery 
is also divided close to its origin, 
and the distal stump is left open 
(Fig. 4). The portal vein is transect­
ed at the level of the superior edge 
of the pancreas (Fig. 4), and the 
suprahepatic and infrahepatic vena 
cavae are transected. The re- 
trohepatic vena cava is freed, the 
right adrenal vein is ligated and 
divided, and the liver is removed.
The duodenopancreas is har­
vested with an aortic patch at the 
level of the superior mesenteric ar­
tery, and the spleen is detached 
from the gland after the splenic 
vessels are ligated. Figure 5 shows 
both organs detached from their 
normal vascular supply. Harvesting 
is terminated with removal of lymph 
nodes, for immunologic studies, and 
both common iliac arteries and their
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external and internal branches, for 
further arterial reconstruction if 
needed.
If a right or common hepatic 
artery arises from the superior mes­
enteric artery, the surgeon must 
determine whether the liver and the 
whole pancreas can be harvested 
simultaneously. This decision de­
pends on the calibre of the aberrant 
vessel. When its diameter is 4 mm 
or more, both organs can be har­
vested and the liver will be revas­
cularized in the recipient through 
an arterial reconstruction performed 
later. If the diameter is satisfactory, 
the aberrant artery is cut at the 
level of the superior edge of the 
head of the pancreas, and the distal 
part is ligated while the left arterial 
supply is provided by the celiac 
axis. If the arterial diameter is too 
small for safe reconstruction, the 
liver is removed with an aortic 
patch, including both the celiac and 
superior mesenteric arteries. The 
head of the pancreas and the duode­
num are sacrificed, and a segmental 
pancreas is harvested on the splenic 
arterial and venous vessels.
Discussion
Current techniques of multiorgan 
harvesting stem from Starzl’s pio­
neer work in transplantation.910 
However, most transplantation 
teams avoid simultaneous harvest­
ing of the liver and the whole 
pancreas, because the technique is 
considered incompatible with safe 
grafting in the recipient1'2 unless a 
segmental graft is chosen for pan­
creatic replacement. In this situa­
tion, one of the organs is wasted for 
transplantation; however, the pauci­
ty of the donor pool commands 
optimal use of all donated organs.
The experience of our unit with 
pancreas transplantation has been 
described previously.1112 We prefer 
to use whole duodenopancreatic
graft instead of the more fragile 
segmental graft. Careful review of 
the vascular anatomy of the liver 
and pancreas suggested to us that 
in most instances both organs can 
be simultaneously harvested and 
successfully transplanted.3
During harvesting it is important 
to be familiar with the vascular 
anatomy in order to trace aberrant 
or accessory vascular supplies 
which, if not respected, preclude 
successful grafting. This vascular 
anatomical “map” can be well dem­
onstrated on arteriograms, but arte­
riography complicates donor sur-
FIG. 4. Level of section of vascular 
supply for simultaneous harvesting of 
liver and pancreas. (Top) Arterial lev­
els: CHA =  common hepatic artery, 
GDA =  gastroduodenal artery, SA =  
splenic artery, DPA =  dorsal pancreat­
ic artery, SMA =  superior mesenteric 
artery. (Bottom) Venous levels: PV =  
portal vein, SV = splenic vein, SMV =  
superior mesenteric vein, IMV = in­
ferior mesenteric vein.
veillance and may jeopardize the 
delicate hemodynamic equilibrium 
of the brain-dead donor. Thus, we 
prefer to rely on a careful and 
precise dissection of the vascular 
tree. This important step-by-step 
dissection is best done by an experi­
enced surgical team that harvests 
all abdominal and, if possible, tho­
racic organs, thus avoiding the un­
coordinated and troublesome efforts 
of several teams.
Because the three main arterial 
supplies of the pancreas (gas­
troduodenal, superior mesenteric 
and splenic arteries) communicate 
one way or another, the whole 
duodenopancreatic graft can be 
safely revascularized by anastomos­
ing the superior mesenteric and 
splenic arteries in the recipient, pre­
serving the normal arterial supply 
for the hepatic homograft. The only
FIG. 5. Separation of vascular supply 
of both liver and duodenopancreas. 
Gastroduodenal and splenic arteries 
have been transected as close as possi­
ble to vessel of origin to preserve 
pancreatic vascularization through su­
perior pancreaticoduodenal and dorsal 
pancreatic arteries. Both grafts are 
harvested on Carrel patch of aorta at 
level of celiac trunk and superior mes­
enteric artery. GDA =  gastroduodenal 
artery, RGA =  right gastric artery, 
LGA =  left gastric artery, SA =  sple­
nic artery, CHA =  common hepatic 
artery, PV =  portal vein, DPA =  
dorsal pancreatic artery, SMV = supe­
rior mesenteric vein, SMA =  superior 
mesenteric artery, FJA =  first jejunal 
artery, IMV =  inferior mesenteric vein.
4-
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exception would be a dorsal pancre­
atic artery arising directly from the 
donor celiac axis or aorta. In such 
cases, the duodenopancreatic homo­
graft can be revascularized on a 
double patch of celiac and mesen­
teric vessels, providing there is one 
common hepatic artery and its ca­
libre is sufficient to permit an end- 
to-end anastomosis with the recipi­
ent’s common hepatic artery.
Abnormal origin of the right or 
the common hepatic artery from the 
donor superior mesenteric artery 
does not contraindicate simulta­
neous removal of both hepatic and 
whole-pancreatic grafts, if the ca­
libre of this aberrant vessel permits 
a safe arterial reconstruction. If 
necessary, an interposed Y-shaped 
arterial iliac carrefour from the 
donor can provide easier revascular­
ization of the liver through a large 
single vessel.13-17
We have performed five simulta­
neous liver and whole-duodenopan- 
creas harvestings. Subsequent 
transplantation of the liver and the 
whole pancreas have been realized 
in 10 different recipients. Four 
duodenopancreatic homografts have 
been revascularized by anastomos­
ing the superior mesenteric Carrel 
patch onto the recipient common 
iliac artery, and the splenic artery 
onto the recipient internal iliac ves­
sel, without an interposed arterial 
graft. The corresponding livers 
have been revascularized either 
through the recipient common he­
patic artery or directly through the 
recipient aorta, using the donor 
celiac Carrel patch. None of those 
grafts suffered vascular stenosis or 
thrombosis and all of them achieved 
good function in the postoperative 
period.
One duodenopancreas has been 
anastomosed to the recipient com­
mon iliac artery through the donor 
aortic patch comprising the celiac
trunk and the superior mesenteric 
artery. The patient’s recovery was 
uncomplicated and long-term func­
tion of the graft adequate. However, 
the corresponding liver, which had 
been revascularized by anastomos­
ing the donor proper hepatic artery 
to the recipient common hepatic 
artery, sustained an arterial throm­
bosis 5 days postoperatively. The 
problem has been related to a 
marked discrepancy between the 
donor and the recipient hepatic ar­
teries. Retrospectively, it would 
have been advantageous to inter­
pose an arterial segment of the 
donor iliac carrefour between both 
vessels. The recipient has since un­
dergone a successful retransplanta­
tion.
Other transplant teams have also 
performed simultaneous liver and 
whole pancreas harvesting and have 
recently reported success.16'18
Conclusions
Contrary to general belief we 
think that the rich and intricate 
vascular supply of the pancreas, 
once it is carefully outlined, allows 
simultaneous harvesting of both 
liver and whole pancreas in most 
instances. This permits optimal use 
of all donated organs, at a time 
when recipients desperately await 
life-saving transplants.
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Volvulus of the Gallbladder: a Case 
Report
P.H. Macdonald, BSc, MD, FRCSC; R.F. Pace, MD, FRCSC
Torsion of the gallbladder is a surgical emergency that occurs predominantly in the 
elderly and whose presentation is indistinguishable from acute cholecystitis. If 
patients being treated conservatively for acute cholecystitis fail to improve promptly, 
laparotomy is indicated, because the diagnosis of gallbladder torsion cannot be 
excluded. Cholecystectomy before the onset of gangrene and rupture of the 
gallbladder is curative.
La torsion de la vesicule biliaire constitue une urgence chirurgicale. Elle survient 
surtout chez des personnes agees et son tableau clinique est indifferenciable de celui 
d’une cholecystite aigue. Quand un patient traite de fa?on conservatrice pour 
cholecystite aigue n’arrive pas a s’ameliorer promptement, il y a lieu de proceder a 
une laparotomie car le diagnostic de torsion de la vesicule biliaire ne peut etre exclu. 
La cholecystectomie est curative lorsqu’elle est pratiquee avant qu’il n’y ait 
gangrene et rupture de la vesicule biliaire.
V olvulus of the gallbladder is a rare condition, indistinguish­
able from acute cholecystitis at the 
time of presentation. Clinical and 
radiologic findings are not defini­
tive. Although the diagnosis can 
only be made by laparotomy, chole­
cystectomy is curative, and surgery 
is facilitated by the lax peritoneal 
attachments that predispose to the 
condition. A recent case highlights 
the clinical features.
Case Report
A 74-year-old man presented with 
a 3-day history of cramping mid­
abdominal pain, with increasing dis­
comfort localized to the right upper 
quadrant. He was anorexic and nau­
seated, but had not vomited. He had 
a known aortic aneurysm, chronic 
obstructive pulmonary disease and 
early senile dementia.
He appeared extremely frail and 
in moderate distress. His vital signs 
were within normal limits, and ex­
amination of the abdomen disclosed 
the presence of moderate abdominal 
distension, with tenderness and full­
ness in the right upper quadrant. A 
nontender abdominal aortic aneu­
rysm was easily palpated to the left 
of the midline.
The leukocyte count was 12.8 X 
109/L , and computed tomography 
showed the presence of the abdomi­
nal aortic aneurysm (6.3 cm in 
diameter) but no evidence of a leak. 
The gallbladder was distended, with 
a thickened wall, suggestive of
acute cholecystitis. Abdominal ul­
trasonography showed the addition­
al presence of gallstones within the 
gallbladder.
Initial management consisted of 
intravenous administration of fluids 
and broad-spectrum antibiotics, but 
over the next 3 days the patient 
experienced increasing tenderness 
with a palpable mass in the right 
upper quadrant. At surgery, the 
gallbladder was found to be grossly 
distended with extensive gangrene 
of the gallbladder wall. Further, the 
gallbladder was suspended from the 
liver by a long mesentery and had 
undergone torsion about the level 
of the cystic duct (Fig. 1). Detor­
sion was easily performed. A chole­
cystectomy was then carried out. 
The patient’s recovery was uncom­
plicated and he was discharged 
home 7 days after the operation. 
Pathological examination confirmed 
the presence of gallstones and gan­
grene of the gallbladder wall.
Discussion
Sporadic reports of gallbladder 
torsion have followed the initial 
case reported by Wendel in 18981 
of a floating gallbladder. Although 
the entity has been described in 
young patients, the majority of 
cases involve the elderly.
In order for the gallbladder to 
undergo torsion it must be suspend­
ed by a long mesentery. True con­
genital mesenteries of the gallblad­
der occur in less than 5% of the
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VOLVULUS OF GALLBLADDER
population,2 but since this is pre­
dominantly a disease of the aged, it 
is likely that some additional ac­
quired features are necessary.34 The 
loss of visceral fat and elasticity 
with aging may serve to elongate 
the mesentery, and spinal deformi­
ty, such as kyphosis, may place the 
gallbladder in a more dependent 
position and increase its susceptibil­
ity to torsion.
In predisposed persons, torsion 
may be initiated by any of three 
factors: vigorous peristalsis of adja­
cent viscera, cholelithiasis with 
acute dilatation of the gallbladder, 
and atherosclerosis of the cystic 
artery, which then acts as a rigid 
fulcrum for torsion.4-6 In our pa­
tient, gallstones may have increased 
the predisposition to volvulus and 
precipitated the acute event. An 
analogous situation occurs in the 
colon where chronic constipation 
leads to lengthening of the sigmoid 
and its mesentery; acute torsion 
may follow a sudden rise in intrasig- 
moid pressure because of retained 
stool.3
The clinical presentation of acute 
gallbladder torsion (right upper 
quadrant abdominal pain and a ten­
der mass) is indistinguishable from 
acute cholecystitis. If left untreated, 
it will lead to rupture of the gall­
bladder, peritonitis and sepsis. Un­
fortunately, there are no diagnostic 
tests or features which can distin­
guish the condition with certainty. 
Ultrasonography or computed to­
mography may disclose gallstones 
or show evidence of gallbladder 
inflammation by virtue of thicken­
ing of the gallbladder wall or by the 
presence of pericholecystic fluid. 
Hydroxyiminodiacetic acid (HIDA) 
scanning will only demonstrate oc­
clusion of the cystic duct, although 
a “bull’s-eye” image that may be 
characteristic of this condition has 
been described.7
Although torsion of the gallblad­
der is a rare condition, the diagno­
sis should be considered in elderly 
patients who present with signs and 
symptoms of acute cholecystitis. In 
patients without gallstones, scan­
ning evidence of gallbladder inflam­
FIG. 1. Operative findings of acute torsion of gallbladder, with necrosis of 
gallbladder wall and twisting at level of cystic duct.
mation or cystic duct obstruction 
should suggest the possibility of 
either acalculous cholecystitis or 
gallbladder torsion, both of which 
are best managed by cholecystecto­
my. In patients who are operated on 
early for acute gallstone cholecysti­
tis, the diagnosis of torsion will be 
made at the time of laparotomy, and 
cholecystectomy will be facilitated 
by the lax peritoneal attachments 
and will be curative.3 If patients 
being treated conservatively for 
acute gallstone cholecystitis fail to 
improve promptly, then laparotomy 
is indicated, as the diagnosis of 
torsion cannot be excluded and 
delay in treatment may lead to 
gallbladder rupture.
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Cefizox"
sterile ceftizoxime sodium
THERAPEUTIC CLASSIFICATION
Antibiotic
ACTION
In vitro studies indicate that the bactericidal action of ceftizoxime results from inhibition of 
cell-wall synthesis in aerobic and anaerobic gram-positive and gram-negative organisms. In 
vitro, ceftizoxime shows a strong affinity for penicillin-binding proteins la, lbs and 3 of E. coli.
INDICATIONS AND CLINICAL USES
CefizoxTM (sterile ceftizoxime sodium) may be indicated in the treatment of the infections 
listed below when caused by susceptible strains of the designated microorganisms:
LOWER RESPIRATORY TRACT INFECTIONS caused by Streptococcus sp. (including S. 
pneumoniae but excluding enterococci); Klebsiella sp.; Proteus mirabilis; Escherichia coli; 
Haemophilus influenzae (including ampicillin-resistant strains); Staphylococcus aureus 
(including penicillinase-producing but excluding methicillin-resistant strains); Serratia sp.; 
and Enterobacter sp.
URINARY TRACT INFECTIONS caused by Escherichia coli; Staphylococcus epidermidis; 
Pseudomonas aeruginosa; Proteus mirabilis; Klebsiella sp.; Serratia marcescens; and 
Enterobacter sp.
Due to the nature of the underlying conditions which usually predispose patients to Pseudo­
monas infections of the urinary tract, a good clinical response accompanied by bacterial 
eradication may not be achieved despite evidence of in vitro sensitivity.
INTRA-ABDOMINAL INFECTIONS caused by Escherichia coli; Staphylococcus epidermidis; 
Streptococcus sp. (excluding enterococci); Klebsiella sp.; Bacteroides sp. (including 8. 
fragilis)', Peptococcus sp.; and Peptostreptococcus sp.
SEPTICEMIA caused by Streptococcus sp. (excluding enterococci but including S. pneu- 
moniaeY, Staphylococcus aureus (excluding methicillin-resistant strains); Escherichia coli; 
Bacteroides sp. (including 8. fragilis); Klebsiella sp.; and Serratia marcescens.
SKIN STRUCTURE INFECTIONS caused by Staphylococcus aureus (excluding methicillin- 
resistant strains); Staphylococcus epidermidis; Escherichia coli; Klebsiella sp., (including K. 
pneumoniae); Streptococcus sp. (excluding enterococci but including Group A B-hemolytic 
Streptococcus pyogenes); Proteus mirabilis; Serratia sp.; Enterobacter sp.; Bacteroides sp. 
(including 8. fragilis); Peptococcus sp., and Peptostreptococcus sp.
BONE AND JOINT INFECTIONS caused by Staphylococcus aureus (excluding methicillin- 
resistant strains); Proteus mirabilis; Peptococcus sp.; and Peptostreptococcus sp.
Specimens for bacteriologic culture should be obtained prior to therapy in order to identify 
the causative organisms and to determine their susceptibilities to ceftizoxime. Therapy with 
CefizoxTM may be initiated before results of the susceptibility studies are known. However, 
modification of the treatment may be required once these results become available.
CONTRAINDICATIONS
CefizoxTM (sterile ceftizoxime sodium), is contraindicated in persons who have shown 
hypersensitivity to ceftizoxime or other members of the cephalosporin group of antibiotics.
WARNINGS
Before therapy with CefizoxTM (sterile ceftizoxime sodium) is instituted, careful inquiry 
should be made to determine whether the patient has had previous hypersensitivity 
reactions to cephalosporins, penicillins, or other drugs. CefizoxTM should be given 
cautiously to penicillin-sensitive patients. Antibiotics, including CefizoxTM, should be 
administered with caution to any patient who has demonstrated some form of allergy, 
particularly to drugs. If an allergic reaction to CefizoxTM occurs, its administration should 
be discontinued. Serious acute hypersensitivity reactions may require epinephrine and other 
emergency measures.
Pseudomembranous colitis has been reported with the use of CefizoxTM (and other anti­
biotics). Therefore, it is important to consider this diagnosis in patients administered 
CefizoxTM who develop diarrhea.
Treatment with broad-spectrum antibiotics alters normal flora of the colon and may permit 
overgrowth of Clostridia. Studies indicate a toxin produced by Clostridium difficile is one 
primary cause of antibiotic-associated colitis.
Mild cases of colitis may respond to drug discontinuance alone. Moderate to severe cases 
should be managed with fluid, electrolyte and protein supplementation as indicated. When 
the colitis is not relieved by drug discontinuance or when it is severe, consideration may be 
given to the administration of oral vancomycin or other suitable therapy. Other possible 
causes of colitis should also be considered.
PRECAUTIONS
General: Transient elevations of BUN and serum creatinine have been observed in clinical 
studies. However, there is no other evidence that CefizoxTM (sterile ceftizoxime sodium) has 
produced alterations in renal function. Renal status should be periodically evaluated, 
especially in seriously ill patients.
Prolonged use of CefizoxTM may result in the overgrowth of nonsusceptible organisms 
including species originally sensitive to the drug. Careful observation of the patient is 
essential. If superinfection occurs during therapy, appropriate measures should be taken. 
CefizoxTM should be administered with caution to individuals with a history of gastro­
intestinal disease, particularly colitis.
Impaired Renal Function: Since ceftizoxime is excreted primarily in the urine, patients with 
impaired renal function (i.e., creatinine clearance 5il.32 mL/s or £  79 mL/min) should be 
placed on a special dosage schedule recommended under DOSAGE AND ADMINISTRATION. 
Normal dosages in these individuals are likely to produce excessive serum concentrations 
of ceftizoxime.
Drug Interactions: The concomitant administration of some cephalosporins and amino­
glycosides has caused nephrotoxicity. The effect of administering CefizoxTM concomitantly 
with aminoglycosides is not known.
Pregnancy: The safety of CefizoxTM jn pregnancy has not been established. The use of 
CefizoxTM jn pregnant women requires that the likely benefit from the drug be weighed 
against the possible risk to the mother and fetus. The pharmacokinetics of CefizoxTM jn 
pregnant patients has not been investigated. Reproduction studies performed in rats and 
rabbits have revealed no evidence of imoaired fertility or harm to the fetus caused by cefti­
zoxime. Animal reproduction studies, however, are not always predictive of human 
response.
Labour and Delivery: The safety and efficacy of CefizoxTM Use during labour and delivery 
has not been investigated.
Nursing Mothers: Ceftizoxime is excreted in human milk in low concentrations (less than 
4% of serum concentrations at 1 hour after dosing). The clinical significance of this is 
unknown; therefore caution should be exercised if CefizoxTM is to be administered to a 
nursing woman.
Infants and Children: The safety of CefizoxTM jn infants less than 6 months of age has not 
been established. In children six months of age and older, treatment with CefizoxTM has 
been associated with transient elevated levels of eosinophils, SGOT, SGPT and CPK 
(creatine phosphokinase). The CPK elevation may be related to intramuscular 
administration.
Elderly Patients: The elimination of ceftizoxime may be reduced due to an age-dependent 
reduction in renal function.
ADVERSE REACTIONS
CefizoxTM (sterile ceftizoxime sodium) is generally well tolerated.
Adverse Incidence Incidence
Reaction <  1 % >1 % but <5%
Hypersensitivity: Rash A
Pruritus
Fever
Liver: Transient elevation of SGOT, 
SGPT and alkaline phosphatase
Blood: Neutropenia
Leukopenia
Thrombocytopenia
Transient eosinophilia j l  
Thrombocytosis
Positive direct Coombs’ test 1
Renal: Transient elevation 
of BUN and creatinine
Local: Injection site: burning, cellulitis, 
phlebitis (with IV administration), 
pain, induration, tenderness, 
parasthesia
Genitourinary: Vaginitis
Gastro­
intestinal:
Diarrhea, Nausea, Vomiting, Pseudomembranous colitis
No disulfiram-like reactions have been reported with CefizoxTM 
TREATMENT OF OVERDOSAGE
No case of acute overdosage has been reported to date; consequently there is no specific 
information available on symptoms or treatment. In cases of suspected overdosage, 
supportive therapy should be instituted according to symptoms. Serum ceftizoxime levels 
can be reduced by hemodialysis.
DOSAGE AND ADMINISTRATION
CefizoxTM (sterile ceftizoxime sodium) may be administered either intramuscularly or intra­
venously after reconstitution.
Dosage and route of administration should be determined by the condition of the patient, 
severity of the infection and susceptibility of the causative organism(s). The intravenous 
route may be preferable for patients with bacterial septicemia, or other severe or life 
threatening infections.
The usual course of treatment should be 7-14 days, and should normally continue at least 48 
hours after evidence of bacterial eradication has been obtained. For B-hemolytic strepto­
coccal infections, a minimum of 10 days of treatment is recommended.
DOSAGE
Adults: The recommended daily dosage of CefizoxTM is 1 to 12 grams administered in ^  
equally divided doses every 8 or 12 hours (see Table 1 below).
Type of Infection Daily Dose 
(Grams)
Frequency and Route
Uncomplicated 
Urinary Tract
1 500 mg q12h, IV or IM
Other Sites 2-3 1 g q8h or q12h, IV or IM
Severe or 3-6 1 g q8h, IV or IM, to
Refractory 2g q8h orq12h, IVor IM*
Life-Threatening 9-12 3or4g q8h IV
‘ When administering 2 g intramuscularly, the dose should be divided and injected into 
different large muscle masses.
Because of the serious nature of urinary tract infections due to Pseudomonas aeruginosa 
and because many strains are only moderately susceptible to CefizoxTM, higher dosage 
may be appropriate when urinary tract infections are caused by these organisms. Other . 
therapy should be instituted if the response is not prompt.
Adults with Impaired Renal Function: In patients in whom the creatinine clearance is 
1.32 mL/s (79 mL/min) or less, the dosage of CefizoxTM must be reduced. Following an initial 
loading dose of 500 mg to 1.0 g IM or IV, the maintenance dosing schedule presented in 
Table 2 should be followed in patients with reduced renal function.
4
TABLE 2 Reconstitution Table for Standard Vials - I.M. Injection
Renal
Function
Creatinine 
Clearance 
mUs mUmin
Less Severe 
Infections
Life-Threatening
Infections
Mild
Impairment
0.83-1.32 50-79 500 mg 
q8h
750 mg to 1.5 g 
q8h
Moderate to severe 
impairment
0.08-0.82 5-49 250 or 500 mg 
q12h
500 mg to 1.0 g 
q12h
Hemodialysis
patients*
0-0.07 0-4 500 mg q48h or 
250 mg q24h
500 mg to 1.0g 
q48h or 500 mg 
q24h
*ln patients undergoing hemodialysis no additional supplemental dosing is required. 
DOSING, HOWEVER, SHOULD BE SCHEDULED SO THAT THE PATIENT RECEIVES THE 
DOSE AT THE END OF THE DIALYSIS. When started 24 hours after administration of 1 g of 
CefizoxTM, hemodialysis has been shown to reduce serum levels by 50%.
hen only the serum creatinine level is available, creatinine clearance may be calculated 
om the following formulae (for patients 18 years and over only). The serum creatinine level 
ould represent renal function at the steady state.
ies:
atinine Clearance 
(mUmin)
eatinine Clearance 
(mL/s)
Weight (kg) x (140 • age)
72 x serum creatinine (mg/100 mL)
Weight (kg) x (140 • age)
49 x serum creatinine ( /imol/L) 
Females: 0.85 of the above values
Infants and Children: The following dosage schedule is recommended:
TABLE 3
Age Group Unit Dosage Frequency and Route
Infants (6 mo-2 yrs.), 
and 50 mg/kg IV or IM q6h or q8h, IV or IM
Children (2-12 yrs.)
The pediatric dosage should not exceed the maximum adult dosage for serious infections. 
ADMINISTRATION
Intramuscular The reconstituted solution of CefizoxTM should be injected well within the 
body of a relatively large muscle, such as the gluteus. When administering 2 g IM doses, the 
dose should be divided equally and then injected into different large muscle masses.
Intravenous: Injection (bolus): The reconstituted solution of CefizoxTM should be injected 
slowly over 3 to 5 minutes, directly or through the tubing system by which the patient is 
receiving another compatible intravenous solution. During administration of the solution 
containing CefizoxTM, jt js desirable to temporarily discontinue administration of the other 
solution.
Intermittent or continuous infusion: The further diluted reconstituted solution of CefizoxTM 
should be administered over a 20 to 30 minute period.
NOTE: CefizoxTM solutions should not be physically mixed with any other drug. There is a 
known incompatibility with aminoglycoside antibiotics. Therefore, they should not be 
physically mixed with CefizoxTM solutions nor administered at the same site.
PHARMACEUTICAL INFORMATION
CHEMISTRY
Trade Name: CEFIZOXTM 
Proper Name: Ceftizoxime Sodium
Chemical Name: Sodium [6R-(6<*, 7B(Z)]]-7-[[(2,3-dihydro-2-imino-4-thiazolyl) 
(methoxyimino)acetyl]amino]-8-oxo-5-thia-1-azabilcyclo(4.2.0] oct-2 -ene-2- 
carboxylate
Structural Formula:
JXJ -C-CONH— J------^  J
Molecular Formula: C i3H i2N50sS2Na 
Molecular Weight: 405.38
Description: Ceftizoxime Sodium is a white to pale yellow crystalline powder.
Composition: CefizoxTM vials contain ceftizoxime sodium (expressed in terms of free 
acid). The sodium content of each gram of CefizoxTM jS approximately 60 mg (2.6 mEq 
sodium ion).
Solutions of CefizoxTM range from colourless to pale yellow, depending upon the diluent 
and volume used. The solution should be discarded if it becomes cloudy. The pH of 
freshly reconstituted solutions usually ranges from 6.0 to 8.0.
A solution of 1 g CefizoxTM in 13 mL Sterile Water for Injection is isotonic.
RECONSTITUTION
STANDARD VIALS (1 GRAM and 2 GRAMS)
For Intramuscular Injection: Reconstitute with Sterile Water for Injection or Bacteriosta­
tic Water for Injection.
Vial Diluent to be
Approximate
Available
Approximate
Average
Size Added to Vial Volume Concentration
1 9 3.0 mL 3.7 mL 270 mg/mL
2g 6.0 mL 7.4 mL 270 mg/mL
Shake well until dissolved.
For Intravenous Injection: Reconstitute only with Sterile Water for Injection.
Reconstitution Table for Standard Vials - I.V. Injection
Vial Diluent to be
Approximate
Available
Approximate
Average
Size Added to Vial Volume Concentration
1 g 10 mL 10.7 mL 95 mg/mL
2 g 20 mL 21.4 mL 95 mg/mL
Shake well until dissolved.
For Intravenous Infusion: Reconstitute as for intravenous injection. Further dilute the 
reconstituted solution to 50 to 100 mL with one of the “ Solutions for Intravenous 
Infusion" (see below).
TABLE 4: Solutions for Intravenous Infusion
Sodium Chloride Injection 
5% or 10% Dextrose Injection
5% Dextrose and 0.9%, 0.45% or 0.2% Sodium Chloride Injection
Ringer’s Injection
Lactated Ringer's Injection
10% Invert Sugar in Sterile Water for Injection
5% Sodium Bicarbonate in Sterile Water for Injection
5% Dextrose in Lactated Ringer’s Injection ONLY when reconstituted with 4% Sodium 
Bicarbonate Injection.
STABILITY OF SOLUTIONS
Storage: All reconstituted solutions and those further diluted should be used within 24 
hours if stored at room temperature or within 48 hours if refrigerated. These storage limits 
are from the time of the initial reconstitution.
Incompatibility: CefizoxTM should not be added to blood products, protein hydrolysates 
or amino acids. CefizoxTM should not be mixed together with an aminoglycoside.
DOSAGE FORMS
Availability: CefizoxTM jS available as a sterile powder in Standard Vials of 1 gram or 
2 grams, containing ceftizoxime as sodium salt.
Storage: CefizoxTM powder for injection should be stored at room temperature (15°-30°C).
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Intramedullary Rod Fixation of Femoral 
Shaft Fractures: Comparison of Open and 
Closed Insertion Techniques
A.C. McLaren, MD, FRCSC; J.H. Roth, MD, FRCSC; C. Wright, MD
Meta-analysis of published series of intramedullary rod fixation in fractured femurs 
revealed significantly higher union rates, lower deep infection rates and a better 
range of knee motion when closed rather than open techniques of insertion were 
used. A separate retrospective review of 58 femoral fractures at one hospital showed 
outcomes consistent with those reported in the literature; these results were 
obtained during a 6-year period when staff were learning closed techniques. 
Technical failures of the closed technique can be avoided by paying attention to 
well-established operative details. A system for grading outcomes was developed to 
compare objectively the results of treatment of fracture patients. The literature and 
the authors’ experience support the adoption of closed techniques for intramedullary 
rod insertion in femoral shaft fractures.
Une meta-analyse des series publiees sur l’osteosynthese des fractures femorales par 
tige intramedullaire, revele un taux significativement plus eleve de fusion, un taux 
moins eleve d’infection profonde et une meilleure amplitude des mouvements 
lorsque des techniques d’insertion fermee sont utilisees plutot que des techniques 
ouvertes. Une etude retrospective independante de 58 fractures femorales reduites 
dans un hopital montre des resultats compatibles avec ceux de la litterature; ces 
resultats ont ete obtenus sur une periode 6 ans, alors que le personnel se 
familiarisait avec les techniques d’osteosynthese fermees. Les echecs techniques de 
la methode fermee peuvent etre evitees en portant une attention particuliere a des 
details operatoires bien etablis. Une echelle devaluation des resultats a ete mise au 
point afin d’objectiver la comparaison des resultats therapeutiques chez les patients 
victimes de fractures. La litterature, de meme que l’experience des auteurs, 
favorisent l’adoption des techniques fermees pour l’insertion de tiges intramedullai- 
res lors des fractures du corps du femur.
I ntramedullary fixation of frac­tures o f the femoral shaft has 
become established as the optimal 
means o f fixation for diaphyseal 
fractures o f the femur. 1-11 Recently, 
this was extended to many meta­
physeal fractures, using locked in­
tramedullary rods.2-5-6'12-13 However, 
the closed insertion technique advo­
cated by Kuntscher14 was initially 
replaced by open techniques to en­
sure anatomical reduction and add 
supplemental fixation.415-19 There 
have been many reports, generally 
retrospective,8-9-15-17-20-21 on both ap­
proaches. Modern closed techniques 
and implants achieve stable fixation 
in good position and have higher
union rates and a lower frequency 
of infection.3-6-8-10-12-15-18-20-39
In spite of a consensus in favour 
of the closed technique, the techni­
cal demands and specialized equip­
ment required are a continuing con­
cern.'-5-7-40
Our purposes in this investiga­
tion were to analyse the pooled 
results from the literature (meta­
analysis) and to review our institu­
tion’s experience with respect to 
open and closed intramedullary rod 
fixation of femoral shaft fractures 
during the period when our hospi­
tal’s staff was learning the closed 
technique. Two questions were ad­
dressed. First, can the results re­
ported in the literature be achieved 
during the learning period, and sec­
ond, is the effort o f learning the 
closed technique justified by im­
proved outcome?
Methods
To obtain an overview of out­
com es,41 data published up to 1987 
were subjected to nonparametric 
analysis using the x 2 test. The 
comparable outcome criteria were 
delayed union, nonunion and ma- 
lunion, infection and range of knee 
motion. The raw data for series 
with consistent definitions of each 
criterion were pooled and analy-
sed.3"6-8-10-12- 15- 18.20-39
The clinical charts and x-ray 
films of all patients aged 16 years
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or older who had been treated at 
our hospital between January 1981 
and December 1986 with in­
tramedullary rod fixation of a femo­
ral shaft were reviewed. This was 
the period when closed intramedul­
lary fixation techniques were being 
learned by our consulting staff. 
Pathologic fractures were excluded.
Fractures were classified as prox­
imal, mid-shaft or distal shaft. Com­
minution was graded from 1 to 4, 
according to the method of Win- 
quist and Hansen.42 Open fractures 
were graded as I, II or Ilia, Illb, 
IIIc, after Gustilo and Anderson.43 
Bridging callus was defined radio- 
logically as continuous mineralized 
callus between the most distal and 
the most proximal fragments across 
the fracture site. Union was defined 
as the ability of the patients to bear 
their weight without pain, with cal­
lus bridging the fracture (the frac­
ture line was generally obscured but 
still visible). Removal of the in­
tramedullary rod was usually car­
ried out when sufficient remodelling 
had taken place to obliterate the 
fracture line. Delayed union was 
defined as progressive but incom­
plete healing at 6 months. Nonun­
ion was defined as failed union after 
more than 6 months, with no pro­
gression of fracture healing for 
more than 3 months; bridging cal­
lus would be lacking, and additional 
treatment would be required to 
stimulate healing of the fracture.
We developed a scoring system to 
quantify the end result, with points
being assigned to complications. 
These included one point for prob­
lems without functional implica­
tions, two points were assigned for 
problems with short-term functional 
implications, three points for prob­
lems with long-term functional im­
plications, five points for failure of 
operative treatment. A cumulative 
score of 0 was an excellent result, 1 
to 2 was considered a good result, 3 
to 4 fair and 5 or more poor.
Results
Meta-analysis of published series 
was used to compare outcomes in 
2529 fractures treated by the closed 
technique with outcomes in 714 
fractures treated using the open 
technique. Not all criteria could be 
consistently applied to every case, 
so the denominators varied (Table 
I). The pooled results showed that 
the closed technique had signifi­
cantly (p < 0.001) better results 
with respect to nonunion, delayed 
union and knee range of motion. 
There were fewer deep wound infec­
tions with the closed technique (p < 
0.01). Rotation and shortening, 
however, were better when the open 
technique had been used (shorten­
ing p < 0.001, rotation p < 0.01). 
There was no difference between 
open and closed techniques with 
respect to superficial wound infec­
tion and angulatory deformity.
In the series from our hospital 
there were 61 patients. Six were
lost to follow-up, leaving 55 pa­
tients with 58 fractures available for 
analysis. Thirty-eight fractures had 
been treated with open techniques 
and 20 with closed techniques. The 
characteristics of the patient groups 
are outlined in Table II. A majority 
in both groups were young men. All 
injuries resulted from high energy 
impacts, motor vehicle accidents 
being most common. A high pro­
portion of patients had multiple 
injuries; three had bilateral femoral 
fractures. The details of the injuries 
are presented in Table III. Open 
fractures in the closed treatment 
group were generally debrided on 
the first day and the patient was 
returned for closed rod insertion, 
concurrent with wound closure, 
after 4 days of traction. Open frac­
tures in the open treatment group 
were treated by immediate fixation 
in multiply injured patients, includ­
ing grades I, II and Ilia fractures, 
or by delayed open rod insertion for 
isolated injuries.
Table II. Characteristics of Patients and
Their Injuries
Open Closed
Features (n =  35)* (n =  20 )t
Mean age, yr
(range) 24 ( 1 7 - 59) 27.6 (15 -  72)
Sex, M/F 
Cause 
Motor 
vehicle
26/11 19/5
accident 34 21
Fall 2 1
Industrial 
No. with 
multiple
1 2
injuries 
Other injuries 
Lower
30 21
limbs
Upper
18 11
limbs 11 7
Head 16 6
Face 11 5
Spine 2 0
Chest 7 5
Abdomen 1 1
Pelvis 0 2
*Two patients were lost to follow-up. 
tFour patients were lost to follow-up.
Table I. Pooled Data From 31 Published Series 3_6‘ 8'10-12' 15_18-20-39 
With Intramedullary Rod Fixation
of Femoral Fractures Treated
No./no. fractures (°/o)
Outcome criteria Open Closed
Nonunion 21/714(2.9) 10/2503 (0.4)
Delayed union 12/714(1.7) 14/2503 (0.6)
Deep infection 18/714(2.5) 30/2503 (1.2)
Superficial infection 18/714(2.5) 21/2529 (0.8)
Malunion -  angulation 7/422(1.7) 13/1782 (0.7)
-  rotation 11/422 (2.6) 164/2144 (7.7)
-  shortening 24/603 (4.0) 194/2185 (8.9)
Range of knee motion < 90° 46/417(11.0) 94/1801 (5.2)
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The clinical results from the time 
of the operation to final outcome 
are presented in Table IV. Operative 
details were appropriate only in 
cases in which fixation of the femo­
ral shaft fracture was the sole pro­
cedure. As with blood loss during 
surgery, the operative time (109 
versus 140 minutes) was less for 
the closed than the open technique.
There were seven cases of iatro­
genic comminution, four in the 
closed and three in the open treat­
ment group (Table IV). These were 
usually small, medial, butterfly frag­
ments related to the lateral entry 
point of the intramedullary rod 
proximally. This complication rep­
resents technical misadventure in 
either technique.
In three cases, closed rod inser­
tion was attempted, but when re­
duction could not be obtained the 
fracture site was opened. This hap­
pened early in the course of learn­
ing the closed technique. In one of 
these cases, a minimal amount of 
opening was required in order to
T a b le  I I I .  C h a ra c te ris tic s  o f  Fem ora l 
F ra c tu re s  T rea ted  W ith  In tra m e d u lla ry  Rod 
F ixa tion
No. of fra c tu res *
Open Closed
F e a tu re (n  =  3 8 ) (n =  20 )
C lo s e d  f ra c tu re s 30 17
O pen  fra c tu re s
G rade  1 4 0
G rade  II 4 1
G rade  III 0 2
S ite
P ro x im a l 10 2
M id -s h a f t 19 12
D is ta l 9 8
C o m m in u t io n
G rade  1 7 3
G rade  2 10 4
G rade  3 4 4
G rade  4 2 2
F ra c tu re  ty p e  
T ra n s v e rs e /s h o r t
o b liq u e 15 8
L o n g  o b liq u e 2 2
S p ira l 4 0
S e g m e n ta l 3 1
C o m m in u te d 23 13
'T h re e  o f th e  55 p a tie n ts had b ila te ra l
f ra c tu re s .
pass a guide wire through the sec­
ond level of a grossly unstable 
segmental fracture. This opening 
was considered to be biologically 
consistent with closed techniques. 
In the other two cases, technical 
failure of the closed technique on 
the part of the surgeon was handled 
by formal open rod insertion, and 
these two were considered as part 
of the open treatment group.
Union was delayed in 14 of 38 
cases in the open treatment group 
but not in any of the closed treat­
ment group. There were four non­
unions in the open treatment group 
and none in the closed group. All 
fractures had healed within 23 
months of injury, nonunions being 
treated by revision of fixation, with 
or without bone grafting.
The closed group had a shorter 
average time to the formation of a 
bridging callus (6.5 versus 8 weeks) 
and to full weight-bearing without 
aids (8 versus 12 weeks). Cases of 
delayed union and nonunion were 
not included in calculating the heal­
ing times.
Malunion (angulation, rotation,
Tab le  IV . C lin ica l R e su lts  W ith  
In tra m e d u lla ry  Rod In se rtio n  fo r  Fem ora l 
F rac tu res
No. of frac tu res  (% )
Open Closed
R esults (n =  38 ) (n  =  20)
B lo o d  lo ss  d u rin g  
su rg e ry , <  1 u n it 13  (72 ) 1 (9)
Ia tro g en ic
c o m m in u tio n 3 (7 .9 ) 4 ( 2 0 )
W o u n d  in fe c tio n 1 (2 .6 ) 1 (5)
D eep in fe c tio n 1 (2 .6 ) 1 (5)
A n g u la tio n  <  10° 5 ( 1 3 ) 2 ( 1 0 )
A n g u la tio n  >  10° 3 (7 .9 ) 0
R o ta tio n  >  10° 1 (2 .6 ) 1 (5)
S h o rte n in g  >  1 cm 4 (1 0 .5 ) 1 (5)
Fa iled  fix a tio n 2 (5 .3 ) 0
D e layed  un ion 14 (37 ) 0
N o n un io n 4 (1 0 .5 ) 0
R ange o f h ip  m o tio n  
>  9 0 ° 4 (1 0 .5 ) 1 (9 )
R ange o f knee 
m o tio n  
9 0 °  - 1 2 0 ° 4  (1 0 .5 ) 2 ( 1 0 )
<  9 0 ° 1 (2 .6 ) 0
shortening) occurred in both 
groups (Table IV). In general, ma- 
lunions in the open treatment 
group were the result of loss of 
reduction. In the closed treatment 
group, unstable fractures were gen­
erally treated with locked in­
tramedullary rods and so loss of 
reduction was not encountered. Ma- 
lunions were generally the result of 
fixation in a malreduced position.
The outcome score (Tables V and 
VI) was excellent in almost three- 
quarters of the patients in the 
closed treatment group but in less 
than one-third of the patients in the 
open group (p < 0.001). The aver­
age score was 2.7 in the open 
group and 0.85 in the closed group.
Discussion
Analysis of the literature showed 
superior results using the closed 
treatment technique, with higher 
rates of union and lower infection
T a b le  V . O u tcom e  S co ring  S ys te m  Based 
on F u n c tio n a l Im p a irm e n t and Fa ilu re  o f 
T re a tm e n t
Points Features
1 A n g u la tio n  <  10° , ro ta tio n  <  
1 0 ° , s h o rte n in g  <  1 cm , 
range o f knee m o tio n  <  fu ll 
b u t >  9 0 °
2 D e layed  un ion , su p e rfic ia l 
in fe c tio n
3 A n g u la tio n  >  10° , ro ta tio n  >  
1 0 ° , s h o rte n in g  >  1 cm , 
range  o f knee m o tio n  <  9 0 °
5 N o n u n io n , fa ile d  f ix a tio n , deep 
in fe c tio n
T a b le  V I. P a tie n t O u tcom e  fo r  Each 
F ra c tu re  (S co re d  A cco rd in g  to  S ys te m  in 
T a b le  V)
No. of frac tu res  (% )
Open Closed
O utcom e (m  =  38 ) (n =  20 )
E x ce lle n t (0 ) 11 (29 ) 14 (70)
G ood ( 1 - 2 ) 15 (39 ) 2 ( 1 0 )
Fa ir (3  -  4 ) 4 ( 1 1 ) 3 ( 1 5 )
P o o r (5 ) 8 ( 2 1 ) 1 (5 )
M ean  sc o re 2 .7 0 .8 5
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rates. Meta-analysis is an attempt to 
pool multiple series, thereby de­
creasing random sampling error and 
local bias. A diligent effort was 
made to include data from series in 
which similar analysis criteria and 
assessment would allow pooling. In 
no report was the unacceptable data 
contrary to the final result of the 
analysis. The pooled series were 
generally retrospective in nature 
and the overview results must be 
considered consistent with the limi­
tations of retrospective reviews. 
Even so, the results of the meta­
analysis are so strongly in favour of 
the closed treatment technique that 
a prospective controlled trial would 
be unwarranted.
The results of our hospital series 
are consistent with the published 
data. One of the difficulties in com­
paring results from one series to 
another is the lack of a quantitative 
assessment for fracture patients. 
We therefore developed a scoring 
system based on objective data re­
lated to outcome; union, alignment, 
joint motion and complications. 
When applied to this series, the 
average score was significantly bet­
ter in the closed treatment group. 
The area of greatest difference was 
in the frequency of delayed union 
and nonunion, which was markedly 
lower in the closed treatment 
groups (p < 0.005).
As recently trained surgeons 
enter practice, the standard of treat­
ment for femoral shaft fractures is 
increasingly the closed insertion 
technique. The established surgeon 
faces learning new techniques, as 
justified by improved outcome.
Several technical points will mini­
mize the difficulties of learning this 
procedure. They have been well 
documented and include the equip­
ment, patient position, placement of 
a distal femoral traction pin, entry 
site for the rod and locking of 
unstable fracture patterns.13 5'7'40 A 
fracture table and C-arm fluorosco­
py unit that are compatible with 
each other are required. These are 
generally available in institutions 
treating hip fractures.
There are several contraindica­
tions to placing the multiply injured 
patient in the lateral position. The 
supine position is used for all pa­
tients at our institution; technical 
problems that would prohibit femo­
ral rod fixation using this position 
have not been encountered. The 
patient should be placed with the 
trunk and pelvis in neutral axial 
alignment and the fractured lower 
extremity in neutral abduction- 
adduction. Adduction of the lower 
extremity tends to create tension in 
the iliotibial band, making reduc­
tion more difficult; it should be 
avoided. Sufficient traction should 
be maintained on the opposite leg 
to prevent tilting of the pelvis dur­
ing traction on the injured leg. 
Pelvic tilting limits access to the 
trochanteric area. The injured ex­
tremity is placed in 10° to 20° of 
flexion at the hip by elevating the 
traction through a distal femoral 
pin. This allows access posterior to 
the most lateral portion of the iliac 
crest.
Traction generally is best applied 
through a distal femoral pin placed 
at the physeal scar. Fluoroscopy is 
used to make certain that the Den­
ham pin is placed neutrally (with 
respect to varus and valgus) in 
relation to the joint line, and in line 
with the central axis of the canal in 
the anterior-posterior dimension. 
Accurate placement of the traction 
pin prevents the traction from be­
coming a deforming force during 
reduction. With the pin at the level 
of the physeal scar, the tip of the 
intramedullary rod is not obstructed 
by the traction pin, as it would be if 
the pin were placed more proximal-
ly-
The uninjured leg can be abduct­
ed sufficiently to allow anteropost­
erior and lateral fluoroscopy of the
trochanteric region, as in hip pin­
ning. This allows the surgeon to 
ensure that the entry point is in line 
with the centre of the medullary 
canal in both the anteroposterior 
and mediolateral planes. The iatro­
genic fractures in our series were 
related to unacceptable entry 
points. The entry point can be opti­
mized in the open treatment group 
by a complete exposure of the tro­
chanter and the piriformis fossa or 
by retrograde penetration with a 
large T-Bar reamer. In the closed 
treatment group, the entry point is 
confirmed accurately by fluorosco­
py. This eliminates iatrogenic frac­
ture due to eccentric entry points.
With accurate positioning of the 
distal femoral traction pin, often 
only a minor reduction maneuver is 
required to align the fracture for 
passing the guide wire, and this 
should be confirmed before “prep- 
ping” and draping. A curved guide 
wire is generally required for pass­
ing across the fracture site using 
closed techniques. The curve has 
two components. A long gentle 
curve throughout the guide wire 
will reliably place its tip at one 
endosteal surface. A second, shorter 
curve in the same direction as the 
long curve is placed in the distal 
few centimetres so that the guide 
wire can be manipulated into a 
slightly offset distal intramedullary 
canal. Reaming and rod insertion 
are technically similar in both open 
and closed techniques.
Generally, if progress of the rod 
is impeded for any reason during 
insertion, continued driving of the 
rod will likely cause iatrogenic frac­
turing. The problem must be identi­
fied and corrected. Many of the 
locked intramedullary devices are 
stiffer than nonlocking devices and 
often require a full millimetre of 
over-reaming to accommodate a 
mismatch between the shape of the 
femur and that of the rod. The 
insertion of locking screws involves
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other technical considerations. In 
short, the proximal siting devices 
are generally reliable. The distal 
locking screws can be reliably ins­
erted using the free-hand technique.
Closed intramedullary rod inser­
tion techniques are the method of 
choice. The superior results docu­
mented in the literature are achiev­
able, even during the learning peri­
od. The necessary equipment is 
widely available and the technique 
is well described. An effort to learn 
the closed technique is justified by 
the results.
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Claforan;
P R E S C R IB IN G  IN F O R M A T IO N  
Action
In vitro studies indicate that the bacterial action ol Claforan (cefotaxime sodium) a semi synthetic cephalosporin 
antibiotic, results from inhibition of cell wall synthesis.
Indications and Clinical Uses
T reatm ent: Claforan (cefotaxime sodium) may be indicated for the treatment of infections caused by susceptible 
strains of the designated micro organisms in the diseases listed below.
Lower respiratory tract in fe c tio n s : pneumonia and lung abscess caused by Streptococcus pneumoniae 
(formerly Diplococcus pneumoniae), other streptococci (excluding enterocci, e.g. S. faecalis), Straphylococcus 
aureus (penicillinase and non penicillinase producing), Escherichia coli, Hemophilus influenzae, (including 
ampicillin resistant strains) and unspecified Klebsiella species.
U rinary trac t in fec tions: caused by Escherichia coli, unspecified Klebsiella species (including K. pneumoniae), 
Proteus mirabilis, indole positive Proteus, Serratia marcescens and Staphylococcus epidermidis. Also, uncomplicated 
gonorrhea caused by N. gonorrhoeae including penicillin resistant strains.
B acte rem ia /S e p ticem ia : caused by Escherichia coli, unspecified Klebsiella strains and Serratia marcescens. 
Skin in fe c tio n s : caused by Staphylococcus aureus (penicillinase and non-penicillinase producing, S. epidermidis, 
Group A streptococci, Escherichia coli, Proteus mirabilis and indole positive Proteus.
Intra -abdom inal in fec tions: caused by Escherichia coli, and unspecified Klebsiella species.
Gynecologica l in fec tions: including pelvic inflammatory disease, endometritis and pelvic cellulitis caused by 
E. coli, Group A streptococci and Staphylococcus epidermidis] anaerobic bacteria including unspecified Peptococcus 
and Peptostreptococcus strains and some strains of Bacteroides fragilis. In several cases, although clinical cures 
were achieved, bacteriological follow up was not available.
Central nervous system in fe c tio n s : meningitis and ventriculitis caused by Haemophilus influenzae, Neisseria 
meningitidis, Streptococcus pneumoniae, Klebsiella pneumoniae and Escherichia coli. Claforan is not active 
against Listeria monocytogenes.
Clinical experience with Claforan in anaerobic infections is limited. Claforan has been used with some success in 
wound and intra-abdominal infections against some strains of unidentified Bacteroides and anaerobic cocci. 
Claforan has been shown to be active against some strains of Pseudomonas.
In the treatment of infections encountered in immunosuppressed and granulocytopenic patients, results of therapy 
with Claforan have not been impressive.
Claforan should not be considered in the treatment of enterococcal infections, i.e. Streptococcus faecalis. 
Specimens for bacteriologic culture should be obtained prior to therapy in order to isolate and identify the causative 
organisms and to determine their susceptibilities to Claforan. Therapy may be instituted before results of susceptibility 
studies are known; antibiotic treatment should be re-evaluated once these results become available.
Prophylactic U s e : The administration of Claforan perioperatively (preoperatively, intraoperatively and postoperatively) 
may reduce the incidence of certain infections in patients undergoing elective surgical procedures (e.g. abdominal 
or vaginal hysterectomy, gastrointestinal and genitourinary tract surgery) that may be classified as contaminated or 
potentially contaminated.
In patients undergoing caesarian section who are considered to be at increased risk of infection, intraoperative 
(after clamping the umbilical cord) and postoperative use of Claforan may also reduce the incidence of certain 
postoperative infections.
Effective use for elective surgery depends on the time of administration (see Dosage and Administration).
For patients undergoing gastrointestinal surgery, preoperative bowel preparation by mechanical cleansing as well as 
with a non absorbable antibiotic (e.g. neomycin) is recommended.
If there are signs of infection, specimens for culture should be obtained for identification of the causative organism 
so that appropriate therapy may be instituted.
Contraindications
Claforan is contraindicated in patients who have shown hypersensitivity to cefotaxime sodium, the cephalosporin 
or the penicillin groups of antibiotics.
Warnings
Before therapy with Claforan is instituted, it must be carefully determined whether the patient has had previous 
hypersensitivity reactions to cefotaxime, cephalosporins, penicillins or other drugs. Claforan should be given with 
caution to patients with Type 1 hypersensitivity reactions to penicillin. Antibiotics, including Claforan should be 
administered with caution to any patient who has demonstrated some form of allergy, particularly to drugs. If an 
allergic reaction to Claforan occurs, the drug should be discontinued and the patient treated with the usual agents 
(e.g. epinephrine, antihistamine, pressor-amines or corticosteroids).
Pseudom em branous colitis has been reported w ith  the use of cephalosporins (and other broad spectrum 
antib io tics); therefore, it is im portant to consider its diagnosis in patients who develop diarrhea during 
the adm in is tra tion  o f Claforan. This co litis  can range from  m ild to life-threatening in severity.
Treatment with broad spectrum antibiotics, such as Claforan, alters the normal flora of the colon and may permit 
overgrowth of Clostridium difficile or other Clostridia. It has been established that a toxin produced by Clostridium 
difficile is one primary cause of antibiotic-associated colitis.
Mild cases of colitis may respond to discontinuation of Claforan and replacement with a suitable specific antibiotic. 
Moderate to severe cases should be managed with fluid, electrolyte and protein supplemntation as indicated.
When the colitis is not relieved by discontinuance of Claforan administration or when it is severe, an antibiotic 
specifically effective in antibiotic-associated pseudomembranous colitis (e.g. vancomycin) or other suitable therapy 
may be indicated. Other possible causes of colitis should also be considered (see Adverse Reactions). 
Precautions
Claforan (cefotaxime sodium) should be prescribed with cauton in individuals with a history of lower gastro­
intestinal disease, particularly colitis.
The safety of Claforan in pregnancy has not been established. Consequently, use of the drug in pregnant women 
requires that the likely benefit from the drug be weighed against the possible risk to the mother and fetus.
Use of Claforan in women of child-bearing potential requires that the anticipated benefits be weighed against the 
possible risks.
Cefotaxime is excreted in human milk in low concentrations. Caution should be exercised when the drug is 
administered to nursing mothers.
Prolonged use of Claforan may result in the overgrowth of nonsusceptible organisms. Constant evaluation of the 
patient’s condition is essential. If super-infection occurs, therapy should be discontinued and appropriate measures 
taken.
Although Claforan rarely produces alterations in kidney function, evaluation of renal status is recommended, 
especially in severely ill patients receiving high doses.
Patients with markedly impaired renal function should be placed on the special dosage schedule recommended 
under Dosage and Administration, because normal dosage in these individuals is likely to produce excessive and 
prolonged serum antibiotic concentrations.
Positive direct Coomb's test is known to develop in individuals during treatment with the cephalosporin group of 
antibiotics, including cefotaxime sodium.
In laboratory tests a falso positive reaction to glucose may occur with reducing substances but not with the use 
of specific glucose oxidase methods.
Adverse Reactions
The most frequent adverse reactions with their frequency of occurrence are:
H ypersensitiv ity (1.8%): Rash, pruritus, fever. Local (5%): Injection site inflammation with intravenous 
administration. Pain, induration and tenderness after intramuscular injection. Gastrointestinal (1.7%): Colitis, 
diarrhea, nausea and vomiting. Symptoms of pseudomembranous colitis can appear during or after Claforan 
treatment. H em ic and Lymphatic System ( <  1%): Mild, reversible leukopenia, granulocytopenia and thrombo­
cytopenia have been reported. Some patients developed positive direct Coomb's test during treatment with 
Claforan. G en itourinary System ( <  1%): Moniliasis, vaginitis. Liver ( <  1%): Transient elevations in SGOT, SGPT,
serum LDH and serum alkaline phsphatase levels have been reported. Kidney ( <  1%): Increased serum creatinine 
and BUN have occasionally been observed. Central Nervous System (0.2%): Headache 
Symptoms and Treatment of Overdosage
Since no case of overdosage has been reported to date with Claforan, no specific information on symptoms or 
treatment is available. Treatment of overdosage should be symptomatic.
Dosage and Administration
Claforan (cefotaxime sodium) may be administered intramuscularly or intravenously after reconstitution (see Table 
with recommended mode of reconstitution according to route of administration).
Adults
The dosage of Claforan should be determined by susceptibility of the causative organisms, severity of the infection 
and condition of the patient.
Guidelines for Dosage of Claforan (cefotaxime sodium)
Type of Infection
Uncomplicated Gonorrhea 
Uncomplicated infections 
Moderately severe to severe infections 
Very severe infections (e.g. septicemia, CNS) 
Life-threatening infections
Daily Dose
(g) Frequency and Route
1 1 g IM (single dose)
2 1 g every 12 hours IM or IV
3-6 1-2 g every 8 hours IM or IV
6-8 2g every 6-8 hours IV
up to 12 2g every 4 hours IV
To prevent postoperative infection in contaminated or potentially contaminated surgery, recommended doses are 
as follows.
(a) 1 g IM or IV administered 1/2 to 1-1/2 hours prior to the initial surgical incision to ensure that adequate 
antibiotic levels are present in the serum and tissues at the start of surgery
(b) 1 g IM or IV administered 1-1/2 to 2 hours following the first dose; for lengthy operative procedures, additional 
intraoperative doses may be administered, if necessary, at appropriate intervals (1-1/2 to 2 hours) during surgery
(c) 1 g IM or IV administered within 2 hours following completion of surgery 
The total cumulative prophylactic dose should not exceed 6 g in a 12 hour period.
Caesarian Section Patients
The first dose of 1 g is administered IV as soon as the umbilical cord is clamped. The second and third doses 
should be given as 1 g IM or IV at 6 and 12 hours after the first dose.
Neonates, Infants, and Children
The following dosage schedule is recommended:
Neonates: 0-1 week of age 50 mg / kg IV q 12 h
1-4 weeks of age 50 mg / kg IV q 8 h
Infants and children (1 month to 12 years): For body weights less than 50 kg, the recommended daily dose is 
50 to 100 mg / kg IM or IV of body weight divided into 4 to 6 equal doses, or up to 180 mg / kg / day for severe 
infections (including central nervous system infections).
For body weights 50 kg or more, the usual adult dosage should be used.
The maximum daily dosage should not exceed 12 grams.
Administration of Claforan should be continued for a minimum of 48 to 72 hours after the patient defervesces or 
after evidence of bacterial eradication has been obtained; a minimum of 10 days of treatment is recommended for 
infections caused by Group A beta-hemolytic streptococci in order to guard against the risk of rheumatic fever or 
glomerulonephritis; frequent bacteriologic and clinical appraisal is necessary during therapy of chronic urinary 
tract infections and may be required for several months after therapy has been completed; persistent infections may 
require prolonged treatment. Doses less than those recommended should not be employed.
Dosage for Patients with Impaired Renal Function
In patients with estimated creatinine clearance of less than 20 mL / min / 1.73m2 the dose of Claforan should be 
halved (see Precautions).
If serum creatinine values alone are available, the following formula (based on sex, weight, and age of the patient) 
may be used to convert these values into creatinine clearance.
M ales: Weight (kg) x  (140 -  age)
72 x  serum creatinine 
Females: 0.85 x  above value
Administration
In tram uscu la r: Claforan should be injected well within the body of a relatively large muscle such as the upper 
outer quadrant of the buttock (i.e. gluteus maximus); aspiration is necessary to avoid inadvertent injection into a 
blood vessel.
Intravenous: The intravenous route is preferable for patients with bacteremia, bacterial spticemia, or other severe 
or life-threatening infections, or for patients who may be poor risks because of lowered resistance resulting from 
such debilitating conditions as malnutrition, trauma, surgery, diabetes, heart failure, or malignancy, particularly if 
shock is present or impending.
For bolus administration a solution containing 1 or 2 g of Claforan can be injected over a period of 3 to 5 minutes. 
Using an infusion system, it may also be given over a longer period of time through the tubing system by which 
the patient may be receiving other intravenous solutions. Butterfly* or scalp vein type needles are preferred for this 
type of infusion. However, during infusion of the solution containing Claforan, it is advisable to discontinue 
temporarily the administration of other solutions at the same site.
ADD-Vantage* Vial
When administering Claforan using the ADD-Vantage* Drug Delivery system, Claforan powder is added directly to a 
single-dose flexible plastic ADD-V&ntage* diluent container. Claforan 1 g or 2 g may be reconstituted in 50 mL or 
100 mL of 5% Dextrose Injection USP or 0.9% Sodium Chloride Injection USP 
Stability
Solutions of Claforan reconstituted in 5% Dextrose Injection USP or 0.9% Sodium Chloride Injection USP in the 
ADD-Vantage* flexible containers maintain satisfactory potency for 12 hours at room temperature 
Availability
Claforan (cefotaxime sodium) is supplied as a sterile, white to pale yellow powder, in vials containing 500 mg,
1.0 and 2.0 g of cefotaxime sodium and in ADD-Vantage* vials containing 1.0 and 2.0 g of cefotaxime sodium 
(expressed as acid on a dry basis).
S to ra ge : Claforan in the dry state should be stored at room temperature protected from light and heat.
Product monograph available on request.
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C.J. McNamee, MD, FRCSC;* C. Macarthur, MB, ChB;t L.D. Jewell, MD, FRCPC;t 
N.M. Kneteman, MD, FRCSC*
Multiple Small-Bowel Carcinoids 
Presenting With Gastrointestinal 
Hemorrhage: a Case Report
Gastrointestinal hemorrhage from a small-bowel lesion can be a problem 
diagnostically and therapeutically. The authors present a case of multiple 
small-bowel carcinoids, which were the cause of multiple upper gastrointestinal 
hemorrhages over a 15-year period. Despite advances in endoscopy and diagnostic 
imaging, accurate localization and definitive diagnosis remain elusive in such cases. 
Optimal treatment depends on careful clinical evaluation and timely laparotomy.
Une hemorragie digestive originant d’une lesion du grele peut poser un probleme, a 
la fois, diagnostique et clinique. Les auteurs decrivent le cas d’une femme de 63 ans, 
chez qui de multiples lesions carcinoldes du grele avaient ete la cause d’hemorragies 
digestives recidivantes au cours d’une periode de 15 ans. Malgre les progres de 
l’endoscopie et des techniques d’imagerie diagnostique, la localisation precise du 
foyer hemorragique et le diagnostic definitif demeurent difficiles a etablir dans de 
tels cas. Le traitement optimal depend d’une evaluation clinique soigneuse et d’une 
laparotomie pratiquee au bon moment.
P rimary neoplasms of the small intestine, both benign and ma­
lignant, are rare entities. One au­
topsy series of approximately 
17 000 cases identified only 93 
(0.5%) primary tumours.1 In clinical 
series malignant tumours predomi­
nate, with adenocarcinomas,2 endo­
crine (carcinoid) tumours3-5 and ma­
lignant lymphomas6 being the most 
frequent histologic types encoun­
tered. Small-bowel malignant tu­
mours account for less than 2% of 
all gastrointestinal carcinomas, with 
an annual incidence in Canada of 
1.6/100 000.7 Endocrine cell (car­
cinoid) tumours are classified as
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malignant because of their invasive, 
albeit slow, and metastatic poten­
tial.8 Carcinoids may arise in diverse 
sites including breast, liver, lung 
and thymus. Most, however, are 
primary in the gastrointestinal 
tract, anywhere from mouth to 
anus. The tumours arise from en- 
terochromaffin (Kulchitsky) cells, 
normally present in the gastrointes­
tinal mucosa. Small-bowel car­
cinoids may be asymptomatic and 
discovered incidentally at laparoto­
my or autopsy. Eventually, howev­
er, they are likely to produce clini­
cal symptoms because of local inva­
sive growth or by releasing secreto­
ry products. Abdominal pain or in­
termittent or partial intestinal ob­
struction are common.5 Elaboration 
of secretory products may give rise 
to the carcinoid syndrome.910 We 
report a case of multiple small-bow­
el carcinoids causing frequent mas­
sive gastrointestinal hemorrhages.
Case Report
A 63-year-old white woman pre­
sented with hypotension as a result 
of 6 hours of hematochezia. The 
hypotension responded to infusion 
of crystalloid and 2 units of packed 
red blood cells. Her medical history 
revealed seven admissions over 15 
years for management of gastroin­
testinal hemorrhage. Laparotomy 
for hemorrhage in 1971 had re­
vealed multiple small-bowel ectasias 
and a few scattered, mucosal nod­
ules (for which biopsies were not 
done). Subsequent hemorrhages 
had been attributed to these vascu­
lar malformations and managed 
conservatively. Subsequent colonos­
copy, gastroscopy and duodenos- 
copy with inspection of the upper 
small bowel had not revealed any 
obvious abnormalities. A previous 
technetium-labelled autologous red 
blood cell scan had demonstrated 
some extravasation into a distal 
ileal loop (Fig. 1), and selective 
mesenteric angiography during the 
current admission demonstrated 
pooling of blood from a distal jeju­
nal lesion (Fig. 2). No history con-
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sistent with the carcinoid syndrome 
was elicited.
At laparotomy, multiple upper je­
junal ectasias were identified but no 
associated luminal blood. Examina­
tion of the proximal and mid-ileum 
revealed multiple mucosal nodules 1 
to 2 cm in dimension with associat­
ed luminal blood and palpable mes­
enteric nodes. Palpation of the liver 
revealed no obvious masses. Exami­
nation of a frozen section of a 
mucosal nodule revealed a car­
cinoid. A segmental resection of 
ileum (61 cm) with a generous 
portion of mesentery (including all 
palpable nodes) was removed and 
primary anastomosis performed.
Gross examination of the excised 
segment of ileum revealed 32 firm, 
yellow, submucosal nodules rang­
ing in size from 0.3 cm to 2 X 2 X 
1 cm. The mucosa overlying the 
lesions was thin but intact. Fibrosis 
of the underlying muscularis 
propria deep to the lesions was 
noted. Microscopic examination of 
the nodules showed multiple car­
cinoids composed of solid nests of 
monotonous cells with small oval 
nuclei and inconspicuous cyto­
plasm; they were situated predomi­
nantly in the mucosa and sub­
mucosa (Figs. 3 and 4). Several of 
the larger tumours penetrated 
through the muscularis propria into 
the mesenteric fat. Lymphatic inva­
sion was clearly identified, and 11 
of 16 mesenteric nodes contained 
metastatic carcinoid. Electron mi­
croscopy showed the presence of 
neuroendocrine granules in tumour 
cells, confirmed by positive im- 
munocytochemical staining tech­
niques for neuron-specific enolase 
and chromgranin.
The patient had no further gas­
trointestinal hemorrhage over 20 
months of follow-up. Computed to­
mography of the liver showed no 
abnormality and serum and urine 
were negative for 5-hydroxyindole- 
acetic acid (5-H1AA).
Discussion
Small-bowel carcinoids are only 
rarely associated with hemorrh­
age.11 Invasive carcinoids tend to 
grow outward and produce a local 
fibroblastic reaction in the serosa 
and mesentery, often resulting in 
angulation or kinking of the bowel 
wall in these areas.9 In part as a 
result of this typical growth pat-
FIG. 1. Technetium-labelled autolo­
gous red blood cell scan demonstrating 
hemorrhage into distal loop of small 
bowel.
FIG. 2. Selective superior mesenteric 
arteriogram demonstrating pooling of 
blood from distal jejunal lesion, corre­
lating well with autologous red blood 
cell scan in Fig. 1.
tern, mucosal erosion with ulcer­
ation is uncommon, as is tumour 
necrosis.5 In addition to ulceration 
due to a mass effect, hemorrhage 
may also result because tumour 
paracrine vasoconstricting products 
cause local ischemia. Patients who 
present with hemorrhage associated 
with gastrointestinal carcinoids
FIG. 3. Low-power view of small intes­
tinal wall shows predominantly sub­
mucosal growth of carcinoid with in­
volvement of crypt zone of mucosa 
(arrow) (hematoxylin and eosin, origi­
nal magnification X 100).
FIG. 4. Detail of tumour. It grows in 
insular pattern with occasional cribri­
form spaces. Nuclear character is uni­
form with bland appearance (hematox­
ylin and eosin, original magnification 
X 160).
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often undergo multiple investiga­
tions before the correct diagnosis is 
made.1213
Diagnosis of small-bowel car­
cinoids requires clinical and labora­
tory correlation. Gastrointestinal 
symptoms and signs usually pre­
dominate. Abdominal pain or symp­
toms and signs of intermittent or 
partial intestinal obstruction are 
common with intussusception or 
volvulus occurring less frequently. 
The average duration of symptoms 
before the correct diagnosis is made 
is 4 years.4 Carcinoid syndrome 
with vasomotor disturbances, intes­
tinal hypermotility, bronchial con­
strictive episodes and right-sided 
cardiac involvement may be present, 
due to the elaboration of secretory 
products.910 For most small-bowel 
carcinoids, production of clinical 
symptoms is synonymous with 
spread beyond the primary site. 
Measurement of urinary 5-HIAA 
aids in the diagnosis of the car­
cinoid syndrome. This metabolite of 
serotonin is produced after passage 
through the pulmonary circulation. 
However, a positive finding implies 
extensive hepatic metastases, as the 
liver usually degrades the secretory 
products of small-bowel carcinoids. 
In the absence of hepatic metasta­
ses, selective venous serotonin sam­
pling may reliably determine the 
presence of a carcinoid.14
Laparotomy is the definitive 
means of demonstrating a small- 
bowel carcinoid. At the time of 
laparotomy, exploration of the re­
mainder of the gastrointestinal tract 
should be undertaken, because 30% 
of small-bowel carcinoids exist con­
currently with other malignant neo­
plasms.45-7 Surgical excision re­
mains the only method of cure. The 
5-year survival rate for mid-gut le­
sions is approximately 59%, even 
with distant metastases.15 This com­
pares favourably with adenocarcino­
ma (approximately 23% 5-year sur­
vival), indicating the less aggressive 
nature of the carcinoid.7
Our case demonstrates the diffi­
culty of identifying with accuracy 
the source of recurrent small-bowel 
hemorrhage. Past laparotomy re­
vealed that multiple jejunal vascular 
ectasias and subsequent hemorrh­
age had been attributed to these 
malformations; each episode was 
managed conservatively. The find­
ings at laparotomy 15 years later 
suggested that the previously noted 
mucosal nodules may have been 
involved in these recurrent episodes 
of bleeding. Although no precise 
bleeding point was identified on 
pathological examination, luminal 
blood was associated only with the 
carcinoids (and not the vascular 
malformations), and hemorrhaging 
ceased when this portion of the 
small bowel was resected. Small- 
bowel carcinoids are rare and he­
morrhage associated with such le­
sions is rarer still, but such tu­
mours may be considered in the 
absence of a definitive diagnosis for 
recurrent small-bowel hemorrhage. 
Despite advances in endoscopy and 
diagnostic imaging, accurate local­
ization and definitive diagnosis of 
small intestinal hemorrhage remain 
elusive. In such cases, optimal 
treatment depends on careful clini­
cal evaluation and close follow-up.
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Popliteal Artery Injury After Tibial 
Osteotomy: Report of Two Cases
F. Rubens, MD; J.L. Wellington, MD, FRCSC; A.G. Bouchard, MD, FRCSC
Operative injury to the popliteal artery after meniscal surgery on the knee has been 
described previously, but its occurrence after tibial osteotomy has not been reported. 
The authors describe two cases of the latter condition, both involving the formation 
of a false aneurysm at the site of injury. The pathogenesis of this condition, its 
clinical sequelae and its subsequent repair are discussed.
On a deja decrit des lesions peroperatoires de l’artere poplitee consecutives une 
chirurgie du menisque, mais sa survenue lors d’une osteotomie tibiale n’avait pas 
encore ete signalee. Les auteurs en decrivent deux cas, les deux impliquant la 
formation d’un faux anevrisme au siege de la lesion. On commente la pathogenese 
de cette affection, ses consequences cliniques et sa reparation subsequente.
possible due to the small size of the 
vessel and the large size of the 
defect. The injured segment was 
resected and replaced with an inter­
position saphenous vein graft.
The postoperative course was un­
complicated. The pedal pulses re­
turned, with complete resolution of 
the patient’s popliteal pain and the 
numbness of her foot.
Case 2
Trauma to the knee is associated with vascular complications in 
about 2% of cases,1 the majority of 
which, in North America, arise from 
motor vehicle accidents. Operative 
trauma to the popliteal artery has 
also been seen with meniscal re­
pairs2 and arthroscopy.3-4 The inci­
dence after meniscal surgery has 
been reported to be 2.4%,2 but its 
occurrence may be underreported 
because of the fear of litigation. We 
present two cases of popliteal artery 
trauma and false aneurysm forma­
tion arising after tibial osteotomy.
Case Reports
Case 1
A 17-year-old girl was transferred 
to our hospital 3.5 weeks after she 
underwent a right high-tibial oste­
otomy and placement of a table 
staple for a knee deformity.
One day after the initial surgery,
she had complained of increasing 
pain and swelling in the region of 
the popliteal fossa. Examination 
showed evidence of impaired circu­
lation; no pulses were felt in her 
right foot, which was pale and cool. 
The patient also complained of 
numbness on the right side of that 
foot. She could not fully extend her 
knee. A firm, pulsatile mass was 
palpable in the popliteal fossa.
Angiography on the day of ad­
mission to our hospital revealed a 
large false aneurysm, measuring 9 
X 5 cm, arising from the anterolat­
eral aspect of the distal third of the 
popliteal artery. The artery was 
splayed over the mass. The distal 
vessels were patent (Fig. 1). At 
surgery the following day, proximal 
control was obtained, and an S- 
shaped incision was made posterior­
ly over the popliteal fossa. The false 
aneurysm was exposed. A 1-cm de­
fect in the anterior aspect of the 
lower third of the popliteal artery 
was found. Primary repair was im-
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A 56-year-old man underwent a 
left tibial osteotomy for osteoarthri­
tis. In the immediate postoperative 
period he complained of pain and a 
“lump” in his cast, with increasing 
discomfort in his leg. His pain per­
sisted, and 6 months later he under­
went venography, which revealed a 
chronic deep-venous thrombosis. 
During reassessment in the clinic 
11 months after the initial surgery, 
the patient was still complaining of 
persistent pain in his calf when he 
walked. A bruit was discovered over
FIG. 1. Case 1. Lateral arteriogram 
showing large false aneurysm in popli­
teal space. Table staple is evident in 
proximal tibia. Popliteal artery is dis­
placed posteriorly; knee could not be 
extended completely.
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his calf and a widened popliteal 
pulse was noted.
He was admitted to hospital. A 
left femoral angiogram obtained the 
same day revealed a tear-drop 
shaped aneurysm originating from 
the popliteal artery, extending down 
the calf. This false aneurysm dis­
placed the popliteal artery posteri­
orly and laterally. There was good 
runoff in the lower leg, except in 
the mid-anterior tibial artery, where 
there was a severe focal stenosis 
(Fig. 2).
In the operating room, the pa­
tient was placed in a prone position 
and proximal control was obtained. 
The false aneurysm was then deliv­
ered through an S-shaped incision 
overlying the popliteal fossa. Unfor­
tunately, the tissue was quite friable 
and direct repair of the injury was 
not possible. Bypass grafts, from 
the popliteal artery to the tibi- 
operoneal trunk and to the anterior 
tibial artery, were constructed, 
using reversed greater saphenous 
vein.
The patient did well postopera- 
tively. He had complete resolution 
of his ambulatory pain, with return 
of his pedal pulses. At followup 6 
months later he was asymptomatic.
Discussion
Popliteal artery injury with for­
mation of a false aneurysm was first 
described in the medical literature 
in a series of battlefield casualties 
compiled by DeBakey and Sime- 
one.5 It has also been reported after 
some types of knee surgery,2' 4 but 
there have been no reports of injury 
after tibial osteotomy.
The popliteal artery enters the 
superior and medial part of the 
popliteal space through the tendi­
nous arch in the adductor magnus 
muscle. It then passes parallel to 
the semitendinosus until it reaches 
the middle of the limb. At that 
point, it descends to the distal bor­
der of the popliteus muscle, passing 
through the annulus of the soleus
FIG. 2. Case 2. (Left) Lateral arteriogram showing large tear-drop shaped false 
aneurysm with posterior displacement of popliteal artery. (Right) Femoral arterio­
gram, anteroposterior view, reveals aneurysm situated medially in popliteal fossa; 
popliteal artery is displaced laterally. Arrow indicates level of osteotomy.
muscle, then terminating by divid­
ing into the tibioperoneal trunk and 
the anterior tibial artery. It is initial­
ly lateral to the midline, up to the 
level of the intercondylar notch of 
the femur. There are extensive col­
lateral branches about the knee, 
with superior, middle and inferior 
genicular arteries. Theoretically, 
these should be sufficient to main­
tain blood flow to the lower extrem­
ity in the event of interruption of 
the popliteal artery, but ischemic 
lesions of the foot and toes may 
result in up to 45% of cases.1
Injury to the popliteal artery with 
knee trauma usually results from 
the generation of bony fragments. 
These can produce direct injury to 
the arterial trunk, or a displaced 
piece can cause compression in 
knee-displacement injury. Indirect 
compression due to tension hemato­
ma in the fibular groove may add to 
the effect of the direct trauma on 
the vessels. The usual injury in 
operative arterial trauma is stretch­
ing of the anterior tibial artery at 
the interosseous membrane with 
varus correction. Compression of 
the artery also occurs with valgus 
compression.
During tibial osteotomy, the bone 
is cut with a high-pressure oscillat­
ing saw and the repaired fragments 
may be stabilized with a nail-plate, 
which is secured by screws in holes 
bored with an operative drill. The 
knee is flexed to 90°, which should 
displace the artery away from the 
operative site, but injury from a saw 
or drill must be suspected in these 
cases.
The aneurysm enlarges rapidly 
because of its location in the midst 
of loose tissue and because of the 
absence of the muscle support com­
mon to the other vascular trunks of 
the extremity. The presence of a 
bifurcation means that tension is 
already increased in the main trunk. 
Most false aneurysms are found in 
the superficial aspect of the calf
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space, as they expand rapidly, meet­
ing little resistance.
A false aneurysm is often associ­
ated with a stiffness of the knee 
similar to arthritis, and the leg may 
be maintained in a semiflexed posi­
tion. A bruit overlying the artery is 
important in diagnosis.6 Distally, 
the foot is often pulseless; pulses 
were present in only 8 of 28 pati­
ents with popliteal artery injury 
reported by Krige and Spence.6
The posterior approach to the 
popliteal artery was introduced by 
Seeley and colleagues in 1953.7 
With this incision, up to 2.5 cm of 
the vessel can be excised and the 
ends brought together for a primary 
anastomosis, after freeing the artery 
for 5 to 7 cm in each direction.
The classically-accepted proce­
dure for popliteal artery injury after 
removal of the false aneurysm is 
excision of the damaged segment 
with subsequent vein grafting, 
using reversed saphenous vein, par­
ticularly if the defect is greater than 
1.5 cm.
Orthopedic and vascular sur­
geons should be aware that poplite-
\ - J t - .
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al artery injuries can occur after 
tibial osteotomy. Awareness would 
encourage them to investigate im­
mediately w ith arteriographic 
studies, particularly if, in the post­
operative period, the patient com­
plains of symptoms referable to the 
popliteal fossa. We believe that 
early recognition of arterial injury is 
essential for effective management.
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Laser Fulguration for Palliation of Rectal 
Tumours
Peter L. Birnbaum, MD, MSc; C. Dale Mercer, MD, FRCSC, FACS
Palliative therapy for rectal carcinoma includes control of bleeding, tenesmus, 
mucous discharge, obstruction and pain. These local symptoms can cause serious 
morbidity for patients with locally advanced or metastatic rectal cancer. As an 
alternative to surgical resection for palliation, the authors applied endoscopic laser 
fulguration in 15 patients with rectal tumours; 14 experienced immediate relief of 
symptoms. At 6.4 months’ follow-up, two patients had recurrent tenesmus and two 
required a colostomy.
A high degree of patient acceptance makes laser fulguration for rectal tumours an 
important modality for palliation; however, control of tenesmus may be temporary.
Le traitement palliatif du cancer du rectum comprend la suppression des saigne- 
ments, des tenesmes et de l’ecoulement muqueux, la reduction de 1’obstruction et le 
soulagement de la douleur. Ces symptomes locaux peuvent etre la cause d’une 
serieuse morbidite pour les patients souffrant d’un cancer rectal avance ou 
metastatique. Comme alternative a la resection chirurgicale a visees palliatives, les 
auteurs ont utilise la fulguration endoscopique au laser chez 15 patients porteurs 
d’un cancer rectal; 14 ont eu un soulagement immediat des symptomes. Apres 6.4 
mois de surveillance des suites therapeutiques, deux patients avaient eu une recidive 
des tenesmes et deux autres avaient necessity une colostomie.
La fulguration au laser des tumeurs rectales est bien acceptee des patients, d’ou 
son importance comme moyen palliatif; toutefois, le controle des tenesmes peut 
n’etre que temporaire.
Rectal cancer is the second lead­ing cause of cancer deaths. 
Patients who present early have an 
opportunity for curative resection. 
However, up to 20% of patients 
with rectal carcinoma present with 
advanced disease not amenable to 
curative resection.1 In such cases 
surgical resection of the primary 
tumour is often required to control 
local tumour symptoms of tenes­
mus, bleeding and intestinal ob­
struction. Operative options include 
sphincter-sparing procedures such 
as low anterior resection2 (made 
possible with stapling devices) and
local transanal or trans-sacral resec­
tion.3 Very low rectal tumours re­
quire abdominoperineal resection 
for palliation.1 Patient acceptance of 
a permanent colostomy is low, par­
ticularly in elderly patients whose 
debility from arthritis and loss of 
visual acuity make management of 
the colostomy difficult. It may be 
impossible to excise the primary 
rectal tumour in up to 5% of cases 
due to extensive abdominal disease 
with a frozen pelvis or advanced 
medical illness of the heart and 
lungs.1 Radical radiotherapy can be 
utilized for cure and for palliation
of local symptoms.4 Recently neo­
dymium : yttrium-aluminum-garnet 
(Nd-YAG) laser vaporization for rec­
tal tumours has become a therapeu­
tic option for palliation. This report 
presents our experience with sig- 
moidoscopic fulguration of rectal 
cancers with the Nd-YAG laser for 
palliation.
Patients and Methods
From 1986 to 1989 we used 
Nd-YAG laser fulguration for pallia­
tion of rectal tumours in 15 pa­
tients (7 women and 8 men); their 
average age was 75 ±  3 years 
(range from 67 to 93 years). Laser 
treatment was indicated for pallia­
tion in nine patients with diffuse 
metastases, for refusal of operation 
in four and because two patients 
were judged to be medically unfit 
for surgery. Presenting symptoms 
included bleeding and tenesmus in 
10 patients and large-bowel ob­
structive symptoms in 3; 2 were 
asymptomatic. The asymptomatic 
patients also underwent therapy be­
cause of the circumferential extent 
of the tumours and the likelihood 
of obstruction. Three patients had 
previously undergone bowel resec­
tion, one had had electrocautery 
treatment and two had received 
maximum radiotherapy.
On average the tumours were 
located 8 ± 1 cm from the anal 
verge. Adenocarcinoma was present 
in 14 patients and villous adenoma 
in 1. One or two cleansing enemas 
were given before treatment.
The Cooper Laser Sonics Molec- 
tron 8000 Nd-YAG, continuous 
wave, 1064 nm laser (Sigmacon
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Corp., Downsview, Ont.) was used 
with 50 to 80 W, pulse duration of 
0.5 seconds in the non-contact mo­
dality. The laser wave guide was 
inserted in the biopsy channel of 
the Olympus CFPIOS flexible sig­
moidoscope (Carsen Medical & Sci­
entific Co. Ltd., Markham, Ont.).
Electrocautery snare removal of 
the bulk of the exophytic tumour 
was done in one patient before 
Nd-YAG laser vaporization.
Results
Fourteen patients gained immedi­
ate relief of symptoms after laser 
treatment. One patient who did not 
improve had a large extraluminal 
tumour component encroaching on 
the bowel lumen. Energy utilization 
ranged from 1000 to 11 000 J 
(mean 5525 J) per session. Eight 
patients required general anesthesia 
and seven received neuroleptic seda­
tion. The mean hospital stay after 
laser therapy was 5 days. Four 
patients received their therapy on 
an outpatient basis. Seven patients 
underwent laser fulguration an av­
erage of 145 ± 75 days (range from 
3 to 485 days) after the initial 
procedure. Three patients requiring 
early repeat laser fulguration (with­
in 7 days) had large tumours neces­
sitating several sessions for ade­
quate debulking. Four patients who 
required late repeat laser fulgura­
tion had recurrent local tumour 
symptoms. There were no perfora­
tions and no excessive bleeding. 
Postoperative discomfort was mini­
mal and was related to the build-up 
of colonic gas from the coaxial 
stream of air through the fibre.
Of 13 patients followed up from 
3 to 19 months (mean 6 months) 
after initial laser fulguration, 3 died 
of carcinomatosis but had good 
palliation of local symptoms, 6 were 
completely free of local tumour 
symptoms, 2 suffered recurrent te­
nesmus and 2 required a colostomy.
Discussion
Endoscopic application of the Nd- 
YAG laser to vaporize upper and 
lower gastrointestinal tumours has 
provided an important nonoperative 
tool for palliation in patients with 
advanced local tumour. Our initial 
experience with this technique was 
using Nd-YAG laser vaporization 
for palliation in 18 patients with 
obstructing esophageal carcinoma; 
dysphagia was relieved in 16 of 
them.5
In this paper we used similar 
techniques and principles for pallia­
tion of rectal carcinomas. Standard 
palliative measures for these tu­
mours may subject elderly patients 
with concomitant medical illness to 
major surgical procedures. Surgical 
resections will provide excellent 
control of local tumour symptoms; 
however, they may leave the patient 
with a permanent colostomy. De­
spite the best efforts of physicians 
and stomal therapists, many pa­
tients do not want a permanent 
colostomy. Also, the ability to care 
for the colostomy may exceed the 
capabilities of many elderly patients, 
who choose to die from aggressive 
local or metastatic tumour rather 
than have a colostomy.
Other operative techniques are 
available for controlling local rectal 
tumour symptoms. Very low anteri­
or resections, which are made possi­
ble by the circular stapling device,6 
abdominosacral resection,7 and ab- 
dominoanal pull-through resection,8 
permit sphincter-sparing excision of 
low rectal carcinomas. A high de­
gree of technical expertise and the 
magnitude of the operative proce­
dure remain as obstacles to these 
therapeutic options in elderly frail 
patients.
Radiotherapy provides a nonoper­
ative modality for palliation of rec­
tal tumours. Small doses (20 to 30 
Gy) may provide effective control of 
symptoms. Larger doses (up to 50
Gy) are required to effect tumour 
regression.9 Endocavitary radiation 
was used in 57 patients for pallia­
tion of rectal carcinoma with a good 
local response, as judged by control 
of tenesmus and bleeding in 84%.4 
However, several difficulties with 
this technique restrict patient selec­
tion. Radiation to lesions adjacent 
to the transitional mucosa of the 
anal verge may cause severe procti­
tis. Lesions above the peritoneal 
reflection are inaccessible to in­
tracavitary radiotherapy. A circum­
ferential, bulky lesion may prevent 
proper placement of the procto­
scope required for delivery of radia­
tion.10
Electrocoagulation, first intro­
duced in 1935, has been applied for 
curative therapy of low-lying rectal 
carcinomas displaying favourable 
morphologic and pathologic fea­
tures." As a palliative tool, Hughes 
and colleagues12 found elec­
trocoagulation ineffective in con­
trolling tenesmus, bleeding and mu­
cous discharge. Electrocautery 
snare debridement of broad-based 
tumours of the rectum before Nd- 
YAG laser vaporization of the base 
of the polyp can provide tissue for 
accurate diagnosis and reduces the 
volume of tumour requiring laser 
treatment.13 One of our patients had 
electrocautery snare removal before 
laser fulguration of the base.
Endoscopic Nd-YAG laser fulgu­
ration is becoming an important 
modality for effective palliation of 
rectal carcinoma. Ideally, palliation 
should relieve obstruction and te­
nesmus and prevent bleeding and 
mucous discharge. Minimal risk, 
widespread patient applicability and 
reduced hospital stay are also im­
portant. The Nd-YAG laser utilizes 
a fiberoptic delivery system with 
tissue penetration of the beam to a 
depth of up to 4 mm. These physi­
cal characteristics make the Nd- 
YAG laser particularly well suited 
for rapid coagulation of a large
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tumour mass.14 The argon laser 
with a wavelength of 10.6 gm, a 
fiberoptic delivery system and pene­
tration depth of 1 mm has also been 
used for colorectal tumours. Bow­
ers15 found that the argon laser was 
satisfactory for benign colonic pol­
yps but had insufficient penetration 
depth for malignant tumours of the 
rectum. They now use the Nd-YAG 
laser for treatment of all rectal 
cancers. Although the likelihood of 
perforation is greater with the Nd- 
YAG laser, none occurred in their 
series of 14 rectal tumours, and in 
our series of 15 patients there were 
no perforations. Air insufflation 
during laser fulguration to cool the 
fibre tip will thin the bowel wall and 
potentially increase the possibility 
of perforation. Newer water-cooled 
fibres result in less colonic disten­
sion and thereby reduce the likeli­
hood of perforation. Cautious ful­
guration restricted to the tumour 
mass, taking care to avoid normal 
bowel, will also reduce this risk. In 
a series of 115 patients who under­
went photoablative Nd-YAG therapy 
for colorectal tumours, Low and 
colleagues16 demonstrated similar 
therapeutic response rates of tu­
mours treated above and below the 
peritoneal reflection. The complica­
tion rate was not increased even 
though 45% of the colonic lesions 
were located in the thin-walled ce­
cum.
Effective palliation must provide 
the patient with a subjective im­
provement. McGowan, Barr and 
Krasner17 demonstrated the effec­
tiveness of laser therapy in improv­
ing the quality of life in 14 patients 
with inoperable colorectal cancer. 
Their prospective study showed 
that patients with diarrhea, rectal 
bleeding, mucous discharge or pain 
secondary to the tumour mass ben­
efited most from laser vaporization. 
In contrast, pain due to tumour 
invasion of the sacral plexus, a 
tumour mass in the anal canal with
sphincter dysfunction and malig­
nant cachexia were relative con­
traindications to laser therapy. In 
our study 14 patients (93%) 
achieved immediate relief of symp­
toms. In seven patients (50%) a 
second laser fulguration was re­
quired to control local tumour 
symptoms, providing an average du­
ration of improvement of 4.8 
months. Rectal tumours with ob­
struction from an extraluminal 
component are a relative contraindi­
cation to laser fulguration. We were 
unable to provide relief to one pa­
tient who presented with predomi­
nantly extrinsic mass. We also 
found that patients with tenesmus 
were not palliated as well as those 
with bleeding or obstructive symp­
toms. Our results compare favoura­
bly with those of Brunetaud and 
associates18 who achieved a 90% 
immediate success rate with an av­
erage duration of improvement of 
9.3 months in 142 patients with 
rectosigmoid cancer.
A cost-benefit study19 showed 
that the cost of endoscopic laser 
therapy is significantly less than 
other methods of palliation and that 
hospital stay, intensive care time 
and complications are significantly 
greater in patients who undergo 
palliative surgery for rectal cancer. 
This cost advantage more than off­
sets the initial capital cost of the 
laser and its ancillary equipment.
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D exon Plus Versus Maxon Fascial 
Closure in Morbid Obesity: a Prospective 
Randomized Comparison
Mervyn Deitel, MD, FRCSC; Ritha Alhindawi, MD, PhD; Mohamed Yamen, MD; Toan B. To, MD; 
Claude J. Burul, MD, FRCSC
A monofilament polyglyconate suture (Maxon) was developed as a longer-lasting 
suture associated with less potential for infection than braided polyglycolic acid 
suture (Dexon). The authors compared Dexon Plus and Maxon in a prospective 
randomized study of 84 consecutive morbidly obese patients who underwent vertical 
banded gastroplasty. Linea alba was closed with continuous running suture, 
reinforced with a few interrupted, sutures. After more than 2 years’ follow-up, one 
seroma (2.4%), one wound infection (2.4%) and no hernias were found in the Dexon 
group. In contrast in the Maxon group there were three seromas (7.1%), four wound 
infections (9.5%) and four incisional hernias (9.5%, p < 0.05). The hernias were 
noted between 2 and 10 V2 months after the operation in two patients who had had 
wound infections and in two who had had seromas. When Maxon was used, the 
needle occasionally pulled off the suture and the ends beyond the knot projected 
rigidly. Dexon Plus was easier to handle in very fatty wounds.
Le fil en monofilament de polygluconate (Maxon) a ete mis au point pour offrir une 
suture de plus longue duree et moins susceptible aux infections que le fil tresse 
d’acide polyglycolique (Dexon). Les auteurs ont compare les sutures Dexon Plus et 
Maxon dans une etude prospective et randomisee, chez 84 patients souffrant 
d’obesite pathologique qui on subi une gastroplastie par bande verticale. La ligne 
blanche a ete refermee a l’aide d’une suture a points continus renforcee de quelques 
points non continus. Apres une periode de surveillance d’au moins 2 ans, un serome 
(2.4%), une infection de plaie (2.4%) et aucune hernie ont ete observes dans le 
groupe Dexon Plus. Par opposition, dans le groupe Maxon, on avait enregistre trois 
seromes (7.1%), quatre infections de plaies (9.5%) et quatre hernies dues a l’incision 
chirurgicale (9.5%, p < 0.05). Les hernies ont ete observees de 2 a 10 mois apres 
l’operation, chez deux patients qui avaient eu une infection de plaie et chez deux 
autres qui avaient eu un serome. Avec la suture Maxon, Taiguille a, occasionnelle- 
ment, tire la suture et les extremites au-dela du noeud rigide. La suture Dexon Plus 
etait plus facile d’utilisation dans les tissus tres adipeux.
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M orbid obesity is a risk factor for postoperative wound com­
plications.1 General surgeons, and 
those doing surgery for morbid obe­
sity in particular, are interested in 
finding an ideal suture material for 
abdominal wound closure. McNeil 
and Sugerman2 found no advantage 
of nonabsorbable suture over 
Dexon Plus (braided polyglycolic 
acid coated with poloxamer 188) 
closure in morbid obesity. Dexon 
Plus lasts 90 days in tissues and is 
absorbed by hydrolysis. It retains 
good tensile strength for about 18 
days (4 days longer than Vicryl 
[polyglactin-910]),3 which is longer 
than the critical period (15 days) of 
tissue healing.4 The hydrolysis of 
Dexon is delayed in acidic pH such 
as in ischemia and infection;5 more­
over, the degradation products of 
Dexon have a bactericidal action.6 
Davis & Geek developed Maxon 
(monofilament polyglyconate) as a 
longer-lasting (180 days, having 
good tensile strength for 4 to 6 
weeks) absorbable suture with less 
potential for infection than Dexon.7 
In a prospective randomized study 
we compared the efficacy of Dexon 
Plus and Maxon for the fascial 
closure in morbidly obese patients.
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Patients and Methods
The study comprised a consecu­
tive series of 84 morbidly obese 
patients (at least 45 kg over their 
ideal weight) who underwent verti­
cal banded gastroplasty (VBG) 
(clean-contaminated surgery). All 
were operated on by one surgeon 
(M.D.) in our hospital between Au­
gust 1986 and April 1987. The 
patients were allocated for closure 
with No. 1 Dexon Plus or with No. 
1 Maxon by drawing a randomized 
card. Patients with previous upper 
abdominal incisions were not in­
cluded in the study. All patients 
received antibiotic prophylaxis (2 g 
cefazolin) preoperatively, repeated 
once postoperatively. An upper mid­
line incision ending above the um­
bilicus was used. The fascia was 
closed in a single layer of continu­
ous running suture, reinforced with 
a few interrupted sutures, by a 
senior resident supervised always by 
the same surgeon (M.D.). No subcu­
taneous sutures were inserted. Skin 
incisions were closed with staples. 
All patients were followed up for 
more than 2 years by two surgeons 
(R.A. and T.B.T.) who were blinded 
to the closure material used, and 
wound complications (seroma, in­
fection and incisional hernia) were 
recorded (Table I). A collection was 
considered to be a seroma when it 
contained a clear yellow watery flu­
id, and a wound infection when the 
content was pus, usually associated 
with fever and increased leukocyte 
count.
The results were analysed by the 
X 2 test with Yates’ correction.
Results
An analysis of age, sex and 
weight in both groups did not show 
any difference. We noted with No. 1 
Maxon that the needle not infre­
quently pulled off the suture, and 
the ends beyond the knot projected 
rigidly. The mean skin-to-skin oper­
ative time was 37 minutes.
The overall incidence of immedi­
ate postoperative complications (se­
roma or infection) was 10.7%. 
Wound complications occurred in 2 
(4.8%) of 42 patients in the Dexon 
Plus group compared with 7 
(16.7%) of 42 patients in the Maxon 
group. Deep subcutaneous wound 
infection occurred in one patient of 
the Dexon Plus group and in three 
of the Maxon group. One other 
patient in the Maxon group had a 
superficial wound infection. Two 
wound infections were due to a- 
hemolytic streptococcus, in one, 
culture grew Staphylococcus au­
reus, and in another Klebsiella and 
one was a mixed aerobic-anaerobic 
infection. All seromas were cul­
tured; one showed a light growth of 
Staphylococcus epidermidis, the 
rest were negative. The wound in­
fections were treated with drainage 
and healed within 3 weeks. The 
seromas were treated after release 
with a dry dressing or light com­
presses and healed within 2 weeks.
In the four patients in the Maxon 
group who had ventral hernia, two 
had had deep wound infections and 
two had had seromas. Hernias in 
these patients were noted at 2, 3, 5 
and 10.5 months after VBG. One 
hernia was discovered during ab­
dominal lipectomy. All hernias were 
repaired electively or at the time of 
lipectomy.
The differences in seromas and 
wound infections were not signifi­
cant. However, the occurrence of 
incisional hernia was higher in the 
Maxon group (p < 0.05) than in the 
Dexon group.
Discussion
Morbid obesity is known to be 
associated with wound complica­
tions and incisional hernias. Buck- 
nail, Cox and Ellis8 found that 
35.7% of patients in their series of 
1129 patients who underwent 
major laparotomy and subsequently 
had a ventral hernia were obese. In 
our study the overall incidence of 
incisional hernia was 4.7%, which is 
comparable to that reported in the 
literature.9 All four hernias oc­
curred in the Maxon group, in 
which we had found more postoper­
ative seromas and wound infections. 
These hernias occurred in two pa­
tients who had had seromas and in 
two who had had wound infections, 
reinforcing the tenet that wound 
complications are associated with 
later hernias. The total incidence of 
wound infection and seroma in both 
groups was 5.9% and 4.7% respec­
tively, rates comparable to those 
reported in the literature for surgi­
cal procedures performed on obese 
patients.9 The higher rate of the 
complications in the Maxon group 
may be due to the rigid ends pro­
jecting beyond the knot, which, 
with the movement of the abdomi­
nal wall, could create a dead space 
leading to fluid collection. The stiff­
ness of Maxon has been confirmed 
by Chu and Kizil.10
It can be difficult to recognize a 
fascial defect in adipose patients, 
and in one patient the hernia was 
discovered and repaired at the time 
of lipectomy. Dexon Plus was asso-
Tab le  1. Wound Complications in Dexon Plus and Maxon Groups
Dexon P lus M axon
No. of patients 42 42
Age, yr 34 ± 9 36 ±8
Female-male ratio 36.6 39.3
Wound infection, no. (%) 1 (2.4) 4 (9.5)
Seroma, no. (%) 1 (2.4) 3(7.1)
Hernia, no. (%) 0 4 (9.5)
Dehiscence 0 0
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ciated with fewer incisional hernias 
and was easier to handle in very 
fatty wounds.
We are indebted to Sigmund Krajden, 
MD, FRCPC (Microbiology) and Max­
well Patterson, MD, FRCPC (Chief of 
Laboratories) for assistance.
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Histamine H2 Receptor Antagonist
ACTIONS AND 
CLINICAL PHARMACOLOGY
PEPCID® (famotidine) is a competitive inhibitor of 
histamine H2-receptors. The primary clinically 
important pharmacologic activity of PEPCID® is 
inhibition of gastric ju ice secretion. PEPCID® 
reduces the acid and pepsin content, as well as the 
volume, of basal, nocturnal, and stimulated gastric 
secretion.
INDICATIONS AND CLINICAL USE
PEPCID® (famotidine) is indicated in the treatment 
of the following conditions where a controlled 
reduction of gastric secretion is required for ulcer 
healing:
1. Treatment of acute duodenal ulcer;
2. Prophylactic use in duodenal ulcer;
3. Treatment of acute benign gastric ulcer;
4. Treatment of pathological hypersecretory 
conditions (e.g., Zollinger-Ellison syndrome).
PEPCID® I.V. is indicated in some hospitalized 
patients with pathological hypersecretory con­
ditions or intractable ulcers, or as an alternative to 
the oral dosage forms for short-term use in patients 
who are unable to take oral medication.
CONTRAINDICATIONS
H ypersens itiv ity  to  any com ponent of this 
medication.
PRECAUTIONS
Patients with Severe Renal Insufficiency
Dosing intervals may need to be prolonged in 
patients w ith  advanced renal insu ffic iency 
(creatinine clearance <10 mL/min.) to adjust for the 
longer elimination half-life of famotidine. (See 
CLINICAL PHARMACOLOGY and DOSAGE AND 
ADMINISTRATION.)
Drug Interactions
Studies with famotidine in man, in animal models, 
and in vitro have shown no significant interference 
with the disposition of compounds metabolized by 
the hepatic microsomal enzymes, e g., cytochrome 
P450 system. Compounds tested in man have 
included w arfarin , theophy lline , phenytoin, 
diazepam, am inopyrine and antipyrine. Indo­
cyanine green as an index of hepatic blood flow 
and/or hepatic drug extraction has been tested and 
no significant effects have been found.
Use in Gastric Ulcer
Gastric malignancy should be excluded prior to 
initiation of therapy of gastric ulcer with PEPCID®. 
Symptomatic response of gastric ulcer to PEPCID® 
therapy does not preclude the presence of gastric 
malignancy.
Use In Pregnancy
Reproductive studies have been performed in rats 
and rabbits at oral doses of up to 2000 and 
500 mg/kg/day, respectively (approximately 2500 
and 625 times the maximum recommended human 
dose, respectively), and have revealed no evidence 
of impaired fertility or harm to the fetus due to 
PEPCID®. There are, however, no adequate or well- 
controlled studies in pregnant women.
Since the safe use of PEPCID® in pregnant women 
has not been established, the benefits of treatment 
with PEPCID® should be weighed against potential
risks.
Nursing Mothers
Studies performed in lactating rats have shown that 
PEPCID® is secreted in breast milk. It is not known 
whether this drug is secreted in human milk. 
Nursing mothers should either stop this drug or 
should stop nursing.
Pediatric Use
Safety and effectiveness in children have not been 
established.
Use in Elderly Patients
No dosage adjustment is required based on age (see 
HUMAN PHARMACOLOGY, Pharmacokinetics).
ADVERSE REACTIONS
PEPCID® (famotidine) is usually well tolerated; 
most adverse reactions have been mild and 
transient. The adverse reactions listed below have 
been reported during clinical trials in 2333 patients. 
In those controlled clinical trials in which PEPCID® 
was compared to placebo, the overall incidence of 
adverse experiences in the group which received 
PEPCID®, 40 mg at bedtime, was similar to the 
placebo group. No antiandrogenic or other adverse 
hormonal effects have been observed.
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The following adverse reactions have been reported 
at a rate of greater than 1% in patients on therapy 
with PEPCID® in controlled clinical trials, and may 
be causally related to the drug: headache (4.6%), 
dizziness (1.2%), constipation (1.2%) and diarrhea 
( 1.6% ) .
Other reactions have been reported in clinical trials 
but occurred under circumstances where a causal 
relationship could not be established. However, in 
these rarely reported events, that possibility cannot 
be excluded. Therefore, these observations are 
listed to serve as alerting information to physicians.
Gastrointestinal 8.0%
Nausea 1.6%
Vomiting 0.9%
Anorexia 0.5%
Abdominal discomfort 0.3%
Dry mouth 0.2% Jk /**
Nervous System/Psychlatric 7.3%
Insomnia 0.6% ~A i
Somnolence 0.4%
Anxiety 0.3%
Paresthesia 0.3%
Depression 0.2%
Libido decreased 0.1% A *
Respiratory 4.4%
Bronchospasm <0.1%
Body as a Whole 3.0%
A A
Fatigue 0.6%
Asthenia 0.3%
Fever 0.2% M
Musculoskeletal 1.7%
Musculoskeletal pain 0.1%
-i
Arthralgia 0.1%
Skin 1.7%
A m
Pruritus 0.4%
Rash 0.3% -A . 4
Alopecia 0.2%
Flushing 0.2% J .
Acne 0.1%
Dry skin 0.1% v i  4
Cardiovascular 1.0%
>  ^ 1
Palpitations 0.2% ■a  H
Special Senses 0.9%
Taste disorder 0.1% k
Tinnitus 0.1%
Orbital Edema <0.1% v J
Urogenital 0.9%
The adverse reactions reported for PEPCID® 
Tablets may also occur with PEPCID® I.V. In 
addition, transient irritation at the injection site has 
been observed with PEPCID® I.V.
Laboratory Abnormalities 
Laboratory parameters may be affected during 
treatment with PEPCID®, but the changes are 
usually not considered serious. Among the 
laboratory changes that were reported during 
clinical trials were increases in AST, ALT, BUN, and 
serum creatinine. These changes were rarely of 
clinical significance.
r ,y  in ,  it Ain 4 c ;  ,oon
Only three patients had to be discontinued from 
therapy because of laboratory adverse experiences, 
however laboratory abnormalities were present at 
baseline.
SYMPTOMS AND TREATMENT 
OF OVERDOSAGE
There is no experience to date with deliberate 
overdosage. Doses of up to 640 mg/day have been 
employed in patients with pathological hyper­
secretory conditions with no serious adverse 
effects. In the event of overdosage, treatment 
should be symptomatic and supportive. Un­
absorbed material should be removed from the 
gastrointestinal tract, the patient should be 
monitored, and supportive therapy should be 
employed.
The oral LD50 of famotidine in male and female rats 
and mice was >5000 mg/kg.
DOSAGE AND ADMINISTRATION 
DUODENAL ULCER 
Acute Therapy
The recommended adult oral dosage of PEPCID® 
(famotidine) for acute duodenal ulcer is 40 mg once 
a day at bedtime. Treatment should be given for 
4-8 weeks, but the duration of treatment may be 
shortened if healing can be documented. Healing 
occurs within 4 weeks in most cases of duodenal 
ulcer.
Maintenance Therapy
For the prevention of recurrence of duodenal ulcer, 
it is recommended that therapy with PEPCID® be 
continued with a dose of 20 mg once a day at 
bedtime, for a duration of up to 6-12 months 
depending on the severity of the condition.
BENIGN GASTRIC ULCER 
Acute Therapy
The recommended adult oral dosage for acute 
benign gastric ulcer is 40 mg once a day at bedtime. 
Treatment should be given for 4 to 8 weeks, but the 
duration of treatment may be shortened if healing 
can be documented.
PATHO LO G ICAL HYPERSECRETO RY C O N ­
D IT IO N S  (SU CH  AS ZO LL IN G E R -E L L IS O N  
SYNDROME)
The dosage of PEPCID® in pa tien ts  w ith  
pathological hypersecretory conditions varies with 
the individual patient. The recommended adult oral 
starting dose for pathological hypersecretory 
conditions is 20 mg q6h. In some patients, a higher 
starting dose may be required.
Doses should be adjusted to individual patient 
needs and should continue as long as clinically 
indicated. Doses up to 160 mg q6h have been 
adm inistered to some pa tien ts  w ith  severe 
Zollinger-Ellison syndrome
Intravenous Administration
In some hospitalized patients with pathological 
hypersecretory conditions or intractable ulcers, or 
in patients who are unable to take oral medication, 
PEPCID® I V. may be administered. The recom­
mended dosage is 20 mg every 12 hours.
Intravenous injection therapy should be changed to 
oral treatment as soon as the acute situation is 
under control.
Concomitant Use with Antacids
Antacids may be given concomitantly if needed.
Dosage Adjustment for Patients with Severe Renal 
Insufficiency
In patients with advanced renal insufficiency, i.e., 
with a creatinine clearance less than 10 mL/min., 
the elimination half-life of PEPCID® may exceed 
12 hours reaching approximately 24 hours in anuric 
patients.
To avoid excess accumulation of the drug, the 
dosing interval of PEPCID® may be prolonged to 
36-48 hours as indicated by the patient’s clinical 
response.
PHARMACEUTICAL INFORMATION
COMPOSITION
Tablets
Each tablet for oral administration contains either 
20 mg or 40 mg of famotidine.
Injection
Each mL of the solution for intravenous injection 
contains 10 mg of famotidine and the following 
inactive ingred ients: L -aspa rtic  acid 4 mg, 
mannitol 20 mg, and Water for Injection, q.s., 1 mL. 
The multidose injection also contains benzyl 
alcohol 0.9% added as preservative.
RECONSTITUTION  
Parenteral Products
Dilution of PEPCID® I.V. 
for Infusion
P E P C ID ®  I.V . 
S o lu tio n
V o L .. .a  of 
C o m p atib le  
I.V . S o lu tion
F inal
V o lu m e
F in a l
C o n cen tra tio n
R a te  o f 
In fu s io n
2 m L 3 m L 5  m L 4  m g /m L N o t le s s  th a n  
2  m in u te s
2  m L 8 m L 10  m L 2  m g /m L N o t le s s  th a n  
2  m in u te s
2  m L 10 0  m L 102 m L 0 .1 9 6  m g /m L 1 5 -3 0  m in u te s
PEPCID® I.V. Solutions are compatible with:
Water for Injection
0.9% Sodium Chloride Injection 
5% Dextrose Injection 
10% Dextrose Injection 
Lactated Ringer's Injection 
Sodium Bicarbonate Injection 5%
STABILITY AND STORAGE 
RECOMMENDATIONS 
PEPCID® I.V. Solution
Store at 2 - 8°C. Protect from light. If solution 
freezes, bring the solution to room temperature; 
a llow  s u ff ic ie n t tim e  to  so lu b ilize  a ll the 
components.
Diluted PEPCID® I.V. Solutions should be used 
within 24 hours due to the possibility of microbial 
contamination during preparation.
NOTE: Parenteral drug products shou ld  be 
inspected visually for particulate matter and 
discolouration p rio r to adm inistra tion 
whenever solution and container permit.
DOSAGE FORMS AND AVAILABILITY
Tablets PEPCID® (fa m o tid in e  ta b le ts ) are 
D-shaped, film-coated tablets supplied as follows:
No. Ca 8102 - 20 mg be ige c o lo u re d , 
coded 963. Available in bottles of 100 tablets.
No. Ca 8103 - 40 mg light brownish orange, 
coded 964. Available in bottles of 100 tablets.
No. Ca3539 - PEPCID® I.V., 10 mg per 1 mL, is a 
clear, colourless solution and is available as a non- 
preserved unit dose containing 2 mL of injectable 
solution. Available in 10 x 2 mL vials.
No. Ca3541 - PEPCID® I.V., 10 mg per 1 mL, is a 
clear, colourless solution and is available as a 
preserved m ultip le dose conta in ing 4 mL of 
injectable solution. Available in 4 mL vials.
HUMAN PHARMACOLOGY
In both normal volunteers and hypersecretors, 
PEPCID® inhibited basal nocturnal and daytime 
gastric secretion, as well as secretion stimulated by 
a variety of stimuli, such as pentagastrin and food.
After oral administration, the onset of the anti- 
secretory effect occurred within one hour; the 
maximum effect was dose-dependent, occurring 
within one to three hours. Duration of inhibition of 
secretion was 10 to 12 hours. After intravenous 
administration, the maximum effect was achieved 
within 30 minutes. Single intravenous doses of 10 
and 20 mg inhibited basal nocturnal secretion fora 
period of 10-12 hours. The 20 mg dose was 
associated with the longest duration of action in 
most subjects. Single oral doses of 20 and 40 mg 
inhibited basal nocturnal acid secretion in all 
subjects; mean gastric acid secretion was inhibited 
by 86% and 94%, respectively, for a period of at least 
10 hours. Similar doses given in the morning 
suppressed food-stimulated acid secretion in all 
subjects, with mean suppression of 76% and 84%, 
respectively, 3 to 5 hours after drug, and of 25% and 
30%, respectively, 8 to 10 hours a fte r drug; 
however, in some subjects who received the 20 mg 
dose, the antisecretory effect was dissipated earlier, 
within 6-8 hours. There was no cumulative effect 
with repeated doses. The basal nocturnal intra- 
gastric pH was raised by evening doses of 20 and 
40 mg of PEPCID® to mean values of 5.0 and 6.4, 
respectively. When PEPCID® was given in the 
morning, the basal daytime interdigestive pH at 3 
and 8 hours after 20 or 40 mg of PEPCID® was 
raised to about 5.0.
Fasting and postprandial serum gastrin levels may 
be s ligh tly  elevated du ring  periods o f drug 
antisecretory effect, and with chronic therapy an 
increase in gastric bacterial flora may occur. Gastric
emptying and exocrine pancreatic function are not 
affected by PEPCID®.
Other effects
Systemic pharmacologic effects of PEPCID® in the 
CNS, cardiovascular, respiratory o r endocrine 
systems have not been found to date. Serum 
prolactin levels do not rise after intravenous bolus 
doses of 20 mg PEPCID® and no antiandrogenic 
effects have been detected.
Pharmacokinetics
PEPCID® is incompletely absorbed. The bioavaila­
bility of oral doses is 40-45%. Bioavailability may be 
slightly increased by food, or slightly decreased by 
acntacids; however, these effects are of no clinical 
consequence. PEPCID® undergoes minimal first- 
pass metabolism. After oral doses, peak plasma 
levels occur in 1-3 hours. Plasma levels after 
multiple doses are similar to those after single 
doses Fifteen to 20% of PEPCID® in plasma is 
protein bound. PEPCID® has an elimination half-life 
of 2.5-3.5 hours. PEPCID® is eliminated by renal 
(65-70%) and metabolic (30-35%) routes. Renal 
clearance is 250-450 mL/min., indicating some 
tubular excretion.
Twenty-five to 30% of an oral dose and 65-70% of an 
intravenous dose are recovered in the urine as 
unchanged com pound. The on ly  m etabolite 
identified in man is the S-oxide. There is a close 
relationship between creatinine clearance values 
and the elimination half-life of PEPCID®. In patients 
with severe renal insufficiency, i.e., creatinine 
clearance less than 10 mL/min., PEPCID® elim i­
na tion h a lf - l i fe  may exceed 20 hours and 
adjustment of dosing intervals may be necessary 
(see PRECAUTIONS, DOSAGE AND ADMINIS­
TRATION). In e lde rly  patients, there are no 
clinically significant age-related changes in the 
pharmacokinetics of PEPCID®.
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ORIGINAL ARTICLES
a Case ReportNonparasitic Splenic Cysts: 
and Review
P. Ehrlich, BSc; C.G. Jamieson, MB, BS, FRCSC, FACS
Cysts of the spleen are rare but usually benign. The authors describe the case of a 
young woman with a splenic cyst who underwent splenectomy.
Ultrasonography and computed tomography have helped improve the 
preoperative diagnosis of nonparasitic splenic cysts, and as the use of 
ultrasonography increases, so will the finding of incidental splenic cysts. Whether 
all splenic cysts enlarge is unknown, and it is uncertain whether all small 
asymptomatic cysts need treatment. The cysts may enlarge, become infected or 
rupture. Total splenectomy has been the most common treatment in the past, but, 
because of the risk of postsplenectomy sepsis, partial splenectomy may be preferred 
when technically possible.
Les kystes de la rate sont rares mais habituellement benins. Les auteurs decrivent le 
cas d’une jeune femme, porteuse d’un kyste de la rate, qui a subi une splenectomie.
L’echographie et la tomographie axiale ont contribue a ameliorer le diagnostic 
preoperatoire des kystes spleniques non parasitaires et, avec l’utilisation croissante 
de l’echographie, on peut s’attendre a voir augmenter la detection des kystes 
spleniques fortuits. On ignore si tous les kystes spleniques augmentent de taille, et 
on ne sait si tous les petits kystes asymptomatiques necessitent un traitement. Les 
kystes peuvent croitre, s ’infecter ou se rupturer. Dans le passe, la splenectomie 
totale a ete le traitement le plus courant. Toutefois, a cause du risque de sepsie 
post-splenectomie, une splenectomie partielle peut etre preferable lorsqu’elle est 
techniquement possible.
A lthough nonparasitic splenic cysts are uncommon, the first 
case was reported in 1829 by An- 
dral, and the first surgical treat­
ment by Pean in 1 8 6 7 . We report 
a case of a benign splenic cyst and 
review the published reports of this 
condition.
Case Report
A 25-year-old nulliparous woman 
presented with splenomegaly. Her
medical history was unremarkable 
as was her family history. She had 
been taking an oral contraceptive 
for 10 years.
The incidental finding of spleno­
megaly was first noted by her family 
doctor. She had complained of 
crampy intermittent abdominal pain 
in the left lower and right upper 
quadrants for the previous 3 
months and had also complained of 
intermittent diarrhea and constipa­
tion. There were no symptoms of 
weight loss, fever, chills or night
sweats. There was no history of 
trauma or foreign travel.
On physical examination there 
was a palpable mass 4 cm below the 
left costal margin, but no other 
abnormalities and no palpable lym- 
phadenopathy. Hematologic indices 
were all normal. Ultrasonography 
suggested a splenic cyst.
At laparotomy a large hard 
spleen was found adherent to the 
diaphragm and containing multiple 
cysts. The liver and other intra­
abdominal organs appeared normal 
and there was no retroperitoneal 
lymphadenopathy. Splenectomy was 
uncomplicated.
The spleen weighed 1585 g and 
contained multiple unilocular cysts 
with a large central cyst that mea­
sured 15 cm and was filled with 
clear yellow fluid. Culture of this 
fluid failed to demonstrate any or­
ganisms. The epithelial lining was 
composed of a single layer of strati­
fied squamous cells with one single 
area of keratinization. There were 
areas in the large cyst without 
epithelial lining, and other areas 
showed signs of previous hemorrh­
age into the wall of the cyst. The 
features were considered to be con­
sistent with an epidermoid cyst. 
There was no evidence of an infec­
tious or traumatic process.
The patient made an uncompli­
cated recovery.
Discussion
Primary cysts of the spleen are 
uncommon. Worldwide, parasitic 
(i.e., hydatid) cysts are more com-
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NONPARASITIC SPLENIC CYSTS
mon than nonparasitic cysts,6 but 
these are rare in North America. 
Fowler’s original classification3 in­
cluded subcategories of nonparasit­
ic cysts such as epithelial, inflam­
matory and neoplastic. A revised 
and more practical grouping by 
Martin7 includes congenital and 
neoplastic cysts.
A classification of the types of 
splenic cysts is shown in Fig. 1. 
Splenic cysts can be divided into 
“true” and “pseudo” cysts, the 
difference being the presence or 
absence of an epithelial lining.
True cysts comprise two large 
categories, parasitic and nonparasit­
ic cysts. The nonparasitic cysts in­
clude neoplastic, congenital, vascu­
lar and infectious varieties. Pseudo­
cysts are generally the result of 
trauma. Congenital cysts constitute 
25% of nonparasitic cysts6 and are 
epithelial cysts, described as epider­
moid, dermoid or simple cysts, of 
which epidermoid is the most com­
mon. The cysts may be single or 
multiple, and may be uni- or mul- 
tilocular. Ough, Nash and Wood in 
1981® reported on studies in the 
development of congenital splenic 
cysts. After examining fetal and 
adult spleens, they concluded that 
most epithelial cysts (excluding der­
moid cysts) are of the same entity. 
They proposed that the spleen, like 
other abdominal organs, is lined 
with pluripotential mesothelium; a 
cyst is formed when there is invagi­
nation of the splenic capsule during
development. The cells, being pluri­
potential, result in a variety of 
epithelia, which may in turn result 
in focal metaplasia. Thus, they sug­
gested the term “mesothelial cysts 
of the spleen with squamous meta­
plasia”.
The cause of the progressive ex­
pansion of cysts is unknown, al­
though trauma may cause bleeding 
in an already enlarged spleen. Pri­
mary dermoid cysts of the spleen 
are exceedingly rare and many are 
thought to originate from other 
sources.3
Pseudocysts (described as having 
no epithelial lining) are generally a 
result of trauma.3 Excluding para­
sitic cysts they constitute 75% of all 
splenic cysts. It is thought that 
trauma results in bleeding which 
leads to encapsulation, expansion 
and persistence of a cavity. True 
cysts also may undergo degenera­
tion as a result of pressure from 
hemorrhage secondary to trauma 
and may lose their cellular lining.8
Splenic cysts are most common 
in the second or third decade of life. 
The symptoms of a splenic cyst are 
related to the presence of a mass. 
An asymptomatic painless mass is 
the presenting feature in 30% to 
45% of cases, sometimes as an 
enlarging abdomen noticed by the 
patient’s parents.5 The symptoms 
are primarily gastrointestinal, and 
the classic description is that of a 
dragging sensation in the abdo­
men,8 which may be a recurrent 
intermittent dull pain unrelieved by 
food or antacids. The pain is vague 
and associated with early satiety. 
Pulmonary symptoms including 
pleuritic chest pain, shortness of 
breath and left shoulder pain 
are not uncommon9 and may result 
from low-grade inflammation, re­
sulting in adhesions of the spleen to 
the diaphragm. The spleen may 
compress the left kidney,1 leading 
to renal colic and displacement. 
Hypertension has been reported asFIG. 1. Classification of splenic cysts.
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secondary to renal artery compres­
sion.10 Menstrual and bladder symp­
toms may result from the enlarged 
spleen,5 and a relationship to the 
menstrual cycle and pregnancy has 
been described.1
The major complications include 
infection and rupture.11 The spleen 
may rupture spontaneously or as a 
result of trauma, and up to 25% of 
splenic cysts may present in this 
way.2 Trauma may be the primary 
cause of the cyst or may complicate 
a cyst already present and result in 
further enlargement. The trauma 
may be a recent or a remote event,1 
with the average interval between 
the trauma and splenomegaly being 
approximately 18 months.12 A sple­
nic cyst may bleed spontaneously, 
resulting in either a slow or rapid 
enlargement, or acute abdominal 
pain.11
If a splenic cyst is suspected, 
hydatid disease must be considered 
before surgery. A history of resi­
dence in an endemic area may raise 
this possibility, and serologic inves­
tigations are indicated.78 Hemato­
logic investigations are usually nor­
mal with a nonparasitic splenic cyst. 
Although hypersplenism has been 
reported, most authors feel this is 
coincidental rather than causal.713 
A chest film may show an elevated 
left hemidiaphragm or a left pleural 
effusion.179 Abdominal x-ray films 
and barium studies may show dis­
placement of the left kidney, stom­
ach or splenic flexure of the colon. 
Liver-spleen isotope scans are often 
normal.1 Angiography may distin­
guish a tumour from a cyst but is 
rarely necessary. Typically it shows 
intrasplenic vessels surrounding an 
avascular space.13 The primary radi­
ologic tools are ultrasonography 
and computed tomography.113-15 On 
ultrasonography, splenic cysts are 
homogeneous echo-free lesions 
with a smooth well-defined acoustic 
wall, but ribs, bowel gas, fat and 
multiple cysts may limit this tech­
nique. Computed tomography helps 
define the mass and rule out other 
disease; typically it shows a round 
mass having the density of water 
with no enhancement with contrast. 
Even with modern imaging tech­
niques the diagnosis of benign sple­
nic cysts may be difficult to estab­
lish.
Surgery is the treatment of 
choice for nonparasitic splenic 
cysts. Fowler’s review in 19403 rec­
ommended total splenectomy rather 
than puncture, incision and drain­
age, or marsupialization. The un­
derstanding and awareness of post­
splenectomy sepsis has resulted in 
revised methods of surgical treat­
ment.16-19 The risk of postsplenec­
tomy sepsis and young age of the 
patients has resulted in alternative 
surgical methods.20-27 Partial sple­
nectomy (when technically possible) 
and autotransplantation have been 
reported as successful. If total sple­
nectomy is anticipated, pneumococ­
cal vaccine should be given preoper- 
atively.
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ORIGINAL a r t ic l es
T h e Inguinal Sarcoma: a Review of Five 
Cases
R.S. Bell, MD, FRCSC;* B. O’Sullivan, MB, FRCPC;t J.L. Mahoney, MD, FRCSC;$
C. Nguyen, MD, FRCSC;§ F. Langer, MD, FRCSC;* C. Catton, MD, FRCPCt
A review of five patients who presented during a 3-year period with sarcoma arising 
in the inguinal canal demonstrated that the lesion is frequently mistaken for a 
hernia. In three of the patients incomplete excision of the inguinal mass resulted in 
spread of the lesion beyond the inguinal canal. The authors suggest that neoplastic 
lesions discovered in the inguinal canal should be evaluated by a small incisional 
biopsy followed by wide resection if sarcoma is confirmed on pathological 
examination. Preoperative irradiation and re-excision should be considered if 
widespread microscopic disease remains after excisional biopsy.
L’etude de cinq patients vus au cours d’une periode de 3 ans, alors qu’ils etaient 
porteurs d’un sarcome originant du canal inguinal, demontre que cette lesion est 
souvent prise pour une hernie. Chez trois de ces patients, l’excision incomplete de la 
masse inguinale a entra ne une extension au dela du canal inguinal. Les auteurs 
proposent que les lesions neoplasiques decouvertes dans le canal inguinal soient 
evaluees par excision-biopsie suivie d’une resection large si un sarcome est confirme 
a l’examen pathologique. Une irradiation preoperatoire et une deuxieme excision 
doivent etre envisagees si un envahissement microscopique demeure apres l’exci- 
sion-biopsie.
S oft-tissue sarcomas are relative­ly rare (400 to 500 new cases 
annually in Canada). Despite this, 
the diagnosis is generally straight­
forward to the knowledgeable sur­
geon, since there are few diseases, 
except for sarcoma, which present 
as a subfascial mass in an extremi­
ty. However, in certain anatomical 
locations these sarcomas are diffi­
cult to diagnose; sarcomas in the 
inguinal canal are perhaps the best 
example. In the past 3 years, we 
have seen five such cases, each of 
which was originally thought to be 
an inguinal or femoral hernia. The 
initial management of four of the 
five patients markedly complicated 
their definitive care and we there­
fore present brief case histories for
each patient as well as suggestions 
for appropriate treatment.
Case Reports
Case 1
A 52-year-old woman presented 
with a painless inguinal mass that 
was diagnosed as a direct inguinal 
hernia. Exploration through a stan­
dard transverse hernia approach re­
vealed a tumour, which was re­
moved en bloc. Despite a diagnosis 
of high-grade m: 'ignant fibrous his­
tiocytoma, no further treatment or 
follow-up was offered until the pa­
tient presented 2 years later with a 
recurrent mass. Computed tomog­
raphy demonstrated a 4-cm lesion 
adjacent to the pubic tubercle and 
involving the femoral vessels (Fig. 
1). Preoperative irradiation (50 Gy) 
was given followed by wide resec­
tion of the inguinal canal, femoral 
vessels and abdominal wall. Vascu­
lar reconstruction was with Gor-tex 
(W.L. Gore & Associates, Flagstaff, 
Ariz.), and the external oblique apo­
neurosis was advanced to the thigh 
fascia, following a generous relax­
ing incision. Wound dehiscence oc­
curred 3 weeks after surgery and a 
contralateral myocutaneous abdom­
inal rectus flap was required for 
wound closure. Thirty-two months 
later, the patient remained free of 
local and systemic disease and had a 
good functional result; her only 
major complaint was swelling of the 
thigh.
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Case 2
A 28-year-old man underwent in­
guinal exploration for a presumed 
direct inguinal hernia. A high-grade 
malignant fibrous histiocytoma was 
found and removed; the margins of 
the specimen were positive for ma­
lignancy. Because of the obvious 
microscopic tumour residuum in 
the wound, he received radiothera­
py (50 Gy) to the entire inguinal 
wound, then underwent wide resec­
tion of the inguinal canal and sper­
matic cord. The abdominal wall was 
closed by advancing the external 
oblique aponeurosis to the deep 
thigh fascia, following a relaxing 
incision. Several foci of sarcoma 
were found in the specimen, but the 
resection margins were disease-free. 
There were no complications post- 
operatively and the patient was well 
28 months later.
Case 3
A 31-year-old man underwent 
surgery for a presumed femoral 
hernia. A tumour was found, but no 
attempt was made to remove it.
Incisional biopsy demonstrated a 
high-grade liposarcoma. Planning 
of radiotherapy preoperatively and 
of surgery was greatly assisted by 
the presence of residual tumour 
mass. Although the lesion approxi­
mated the fascia of the femoral 
canal, this plane was not violated at 
the initial operation, and this fascia 
was employed as a tumour margin 
in performing a wide resection. A 
contralateral rectus myocutaneous 
flap was used in abdominal wall 
closure. The patient was disease- 
free at 18-month follow-up.
Case 4
A 59-year-old man underwent 
marginal resection of a high-grade 
epidermoid sarcoma discovered in 
the inguinal canal at a planned 
hernial repair. No further treatment 
was offered until 3 months later 
when the patient returned with a 
6-cm fixed mass extending from the 
pubic tubercle to the corpus caver- 
nosum. Systemic staging studies 
were negative for metastases and 
the patient received radiotherapy 
(50 Gy). Repeat staging studies be­
fore surgery revealed two pulmo­
nary lesions. Because of the prox­
imity of the mass to the penis, wide 
resection with orchiectomy, partial 
resection of the corpus cavernosum 
and reconstruction using a contra­
lateral rectus abdominis flap was 
performed. The patient’s postopera­
tive course was uncomplicated. The 
lung lesions progressed despite che­
motherapy and he is currently alive 
with evident disease.
Case 5
A 72-year-old man had partial 
resection of a malignant fibrous 
histiocytoma discovered at inguinal 
herniorrhaphy. The tumour re­
curred rapidly, and two more partial 
resections, accompanied by adju­
vant chemotherapy were performed. 
The tumour grew to massive size, 
with painful involvement of the 
penis before the patient was re­
ferred for palliative radiotherapy 
(Fig. 2). Preoperative irradiation 
was stopped at 40 Gy when the 
lesion ulcerated through the skin. 
Wide resection was then undertak­
en with emasculation combined 
with bilateral external iliac dissec­
tion and bilateral inguinal canal and 
abdominal wall resection. The ab­
dominal wall was reconstructed 
using a rectus femoris myocutane­
ous flap in combination with scrotal 
skin. A perineal urethrostomy was 
used for bladder drainage. Patho­
logical examination of the operative 
specimen confirmed that the mar­
gins of resection contained healthy 
tissue. Six months after surgery the 
patient died suddenly and no autop­
sy was performed. Immediately be­
fore his death, examination and 
chest radiography showed him to be 
disease-free.
Discussion
Although inguinal sarcomas haveFIG. 1. Case 1. Recurrent lesion at pubic tubercle extending to femoral vessels.
310 CJS, VOL. 33. NO. 4. AUGUST 1990
INGUINAL SARCOMA
received little or no attention in the 
literature, our experience with five 
cases in 3 years suggests that this 
subject should be familiar to sur­
geons who perform inguinal herni­
orrhaphies.1' 3 We suggest that the 
presence of a firm, irreducible mass 
in the inguinal canal should be 
considered as a tumour rather than 
a hernia and that a more limited 
approach to the lesion be undertak­
en until the surgeon is sure that the 
mass is not a neoplasm. This is 
especially important because most 
tumours arising in the inguinal 
canal are sarcomas.13
If a tumour is encountered in the 
inguinal or femoral canal, an inci­
sional biopsy should be performed 
through as small an incision as 
possible, and the wound should be 
closed. Excision of the lesion 
should not be undertaken through 
the same wound used to biopsy the 
lesion.1 We have shown, in a retro­
spective review of 100 patients with 
soft-tissue sarcoma, that excision 
accompanied by histologically posi­
tive resection margins results in 
local recurrence of the sarcoma in 
50% of patients, despite the provi­
sion of postoperative adjuvant ra­
diotherapy.4 Excision of a sarcoma 
after exposure of the lesion will 
inevitably result in contamination of 
the wound by microscopic disease. 
Since the dissection necessary to 
perform a marginal resection is 
often extensive, microscopic disease 
may well be spread beyond the 
fascial limits of the inguinal canal. 
This extension of tumour outside 
the inguinal canal was seen in three 
of our patients. Tumour extension 
in case 1 encompassed the femoral 
vessels, and in cases 4 and 5 recur­
rent tumour was found medially at 
the pubic tubercle and even extend­
ed to the contralateral inguinal 
canal and base of the penis. The 
value of limited exposure in per­
forming a biopsy is demonstrated in 
case 3. If the surgeon had attempt­
ed to excise the lesion arising in the 
femoral canal, the femoral vessels 
would likely have been contaminat­
ed, requiring a much more complex 
definitive resection.
The presence of the tumour in 
situ after incisional biopsy assists 
the radiation oncologist in planning 
preoperative radiotherapy and facili­
tates the planning of the definitive 
surgical resection on the basis of 
computed tomography and magnet­
ic resonance imaging. Because ade­
quately wide resection of the ingui­
nal region requires extensive dissec­
tion of the retroperitoneal iliac and 
femoral vessels and the femoral 
nerve to free these structures from 
the site of tumour origin, we prefer 
to irradiate the site of tumour ori­
gin before resection. If postopera­
tive irradiation is used, it is neces­
sary to include the entire surgical 
field that may be contaminated by 
microscopic disease. In the case of 
lesions arising in the inguinal canal, 
a treatment field would be much 
larger postoperatively. Preoperative 
irradiation not only decreases the 
volume o f normal tissue exposed to 
irradiation but also avoids irradia­
tion of the peritoneal contents. Al­
though our early experience with 
preoperative irradiation in difficult 
tumours was associated with a sub­
stantial incidence of wound dehis­
cence and infection,5 our recent use 
of vascularized tissue transfer from 
outside the irradiated field has re­
duced our incidence of wound com­
plications markedly.6
The use of vascularized tissue 
transfers necessitates that histologi­
cally tumour-free margins be 
achieved at resection to prevent 
contamination of the donor site. 
Accordingly, detailed pathological 
assessment of the lesion according 
to a rigorous protocol is undertak­
en in the surgical pathology suite 
before the donor muscle is har­
vested. For lesions of the inguinal 
canal, we prefer to use a contralat­
eral rectus abdominis myocutane- 
ous transfer (since the ipsilateral 
inferior epigastric vessel is usually
FIG. 2. Case 5. Massive recurrent sarcoma extending to both inguinal canals and 
surrounding penis and testicles.
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sacrificed at resection). For massive 
lesions, such as in case 5, which 
require resection of both inguinal 
canals and both inferior epigastric 
arteries, a rectus femoris myocu- 
taneous flap is preferred.
In summary, optimal manage­
ment of inguinal canal sarcomas is 
exemplified by our case 3. A pre­
sumed femoral hernia was explored 
through a limited incision which 
revealed a tumour. A small incision­
al biopsy was performed and the 
patient referred to a multidiscipli­
nary centre for management. Preop­
erative staging studies demonstrat­
ed the femoral triangle fascia to be 
intact, permitting a wide resection 
with tumour-free margins and pres­
ervation of the femoral vessels after 
preoperative irradiation.
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Any patient who has demonstrated some form of 
allergy, particularly to drugs, should receive 
antibiotics including MEFOXIN® with caution.
If an allergic reaction to MEFOXIN® occurs, 
administration of the drug should be dis­
continued. Serious hypersensitivity reactions 
may require treatment with epinephrine and 
other emergency measures.
PRECAUTIONS
The total daily dosage should be reduced when 
MEFOXIN® is administered to patients with 
transient or persistent reduction of urinary 
output due to renal insufficiency (see DOSAGE 
AND ADMINISTRATION) because high and 
prolonged serum antibiotic concentrations can 
occur from usual doses.
In patients treated with MEFOXIN® a false­
positive reaction to glucose in the urine may 
occur with Benedict's or Fehling’s solutions but 
not with the use of specific glucose oxidase 
methods.
Using the Jaffe Method, falsely high creatinine 
values in serum may occur if serum concen­
trations of cefoxitin exceed 100£ig/mL. Serum 
samples from patients treated with MEFOXIN® 
should not be analyzed for creatinine if with­
drawn within two hours of drug administration.
High concentrations of cefoxitin in the urine 
may interfere with measurement of urinary 17- 
hydroxy-corticosteroids by the Porter-Silber 
reaction, and produce false increases of modest 
degree in the levels reported.
Increased nephrotoxicity has been reported 
fo llow ing  concom itant adm in is tra tion of 
cephalosporins and aminoglycoside antibiotics.
Prolonged use of MEFOXIN® may result in the 
overgrowth of non-susceptible organisms. 
Repeated evaluation of the patient's condition is 
essential and if super-infection occurs during 
therapy, appropriate measures should betaken. 
Should an organism become resistant during 
antibiotic therapy, another antibiotic should be 
substituted.
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Use in Pregnancy
The safety of MEFOXIN® in the treatment of 
infections during pregnancy has not been 
established. If the administration of MEFOXIN® 
to pregnant patients is considered necessary, its 
use requires that the anticipated benefits be 
weighed against possible hazards to the fetus. 
Reproductive and teratogenic studies have been 
performed in mice and rats and have revealed no 
evidence of impaired fertility or harm to the fetus 
due to MEFOXIN®.
Nursing Mothers
Cefoxitin is excreted in human milk.
Children
In children 3 months of age or older, higher 
doses of MEFOXIN® (100 m g/kg/day and 
above) have been associated with an increased 
incidence of eosinophilia and elevated SGOT.
ADVERSE REACTIONS
MEFOXIN® is generally well tolerated. Adverse 
reactions rarely required cessation of treatment 
and usually have been mild and transient.
Local Reactions
Thrombophlebitis has occurred with intra­
venous administration. Some degree of pain and 
tenderness is usually experienced after intra­
muscular injections using water. Induration has 
occasionally been reported.
Allergic
M aculopapular rash, u rtica ria , pruritus, 
eosinophilia, fever and other allergic reactions 
have been noted.
Gastrointestinal
Symptoms of pseudomembranous colitis can 
appear during or after antibiotic treatment. 
Nausea and vomiting have been reported rarely. 
Blood
Eosinophilia, leukopenia, neutropenia, hemo­
lytic anemia, and thrombocytopenia and bone 
marrow depression have been reported. Some 
individuals, particularly those with azotemia, 
may develop positive direct Coombs tests 
during therapy with MEFOXIN®.
Liver Function
Transient elevations in SGOT, SGPT, serum 
LDFI, and serum alkaline phosphatase and 
jaundice have been reported.
Cardiovascular Function 
Hypotension.
Renal Function
Elevations in serum creatinine and/or blood 
urea nitrogen levels have been observed. As 
with the cephalosporins, acute renal failure has 
been reported rarely. The role of MEFOXIN® in 
changes in renal function tests is difficult to 
assess, since factors predisposing to prerenal 
azotemia or to impaired renal function have 
often been present.
TREATMENT OF OVERDOSE
Other than general supportive treatment, no 
specific antidote is known. MEFOXIN® can be 
eliminated by dialysis in patients with renal 
insufficiency.
DOSAGE AND ADMINISTRATION
MEFOXIN® may be administered intravenously 
or intramuscularly as required. (See complete 
m onograph on A D M IN IS TR A T IO N  and 
RECONSTITUTION.)
Intravenous Administration 
The intravenous route is preferable for patients 
with bacteremia, bacterial septicemia, or other 
severe or life-threatening infections, or for 
patients who may be poor risks because of 
lowered resistance resulting from such debili­
tating conditions as m alnutrition, trauma, 
surgery, diabetes, heart failure, or malignancy, 
particularly if shock is present or impending. 
TREATMENT DOSAGE 
Adults
The usual adult dosage is 1 g or 2 g of 
MEFOXIN® every 6 to 8 hours. Dosage and 
route of administration should be determined by 
severity of infection, susceptib ility  of the 
causative organisms, and condition of the 
patient. The usual adult dosages are shown in 
the Table below.
Usual Adult Dosage
Type of Dally Frequency
Infection Dosage and Route
Uncomplicated 3-4 g 1 g every 6-8 h
forms* of in- I.V. or I.M.
fections such as
pneumonia,
urinary tract
infection, soft
tissue infection
Moderately 6-8 g 1 g every 4 h
severe or severe or
infections 2 g every 6-8 h I.V.
Infections 12 g 2 g every 4 h
commonly or
needing anti- 3 g every 6 h I.V.
biotics in higher 
dosage (e.g. gas 
gangrene)
'Including patients in whom bacteremia is absent or 
unlikely
Therapy may be started while awaiting the 
results of susceptibility testing.
Antibiotic therapy for group A beta-hemolytic 
streptococcal infections should be maintained 
for at least 10 days to guard against the risk of 
rheumatic fever or g lomerulonephritis. In 
staphylococcal and other infections involving a 
collection of pus, surgical drainage should be 
carried out where indicated.
Adults with Impaired Renal Function
MEFOXIN® may be used in patients w ith 
reduced renal function but a reduced dosage 
should be employed and it is advisable to 
monitor serum levels in patients with severe 
impairment.
In adults with renal insufficiency, an initial 
loading dose of 1 g to 2 g should be given. After 
a loading dose, the following recommendations 
for maintenance dosage may be used as a guide:
MAINTENANCE DOSAGE OF 
MEFOXIN® IN ADULTS 
WITH REDUCED RENAL FUNCTION
RENAL
FUNCTION
CREATININE
CLEARANCE
mL/min
DOSE FREQUENCY
Mild
impairment 50-30 1-2 g every 8-12 h
Moderate
impairment 29-10 1-2 g every 12-24 h
Severe
impairment 9-5 0.5-1 g every 12-24 h
Essentially 
no function <5 0.5-1 g every 24-48 h
In patients undergoing hemodialysis, the 
loading dose of 1 - 2 g should be given after each 
hemodialysis, and the maintenance dose should 
be given as indicated in the Table above.
Neonates (Including Premature Infants), Infants 
and Children (See WARNINGS for Neonates 
under ADMINISTRATION in the complete 
monograph.)
Premature Infants 
with Body Weights 
Above 1500 g 20-40 mg/kg every 12 h I.V.
Neonates
0- 1 week of age
1- 4 weeks of age
20-40 mg/kg every 12 h I.V. 
20-40 mg/kg every 8 h I.V.
Infants
1 month to 2 years 
of age
20-40 mg/kg every 6 h or 
every 8 h I.M. or I.V.
Children 20-40 mg/kg every 6 h or 
every 8 h I.M. or I.V.
In severe infections, the total daily dosage in 
infants and children may be increased to 
200 mg/kg, but not to exceed 12 g per day. 
MEFOXIN® is not recommended for the therapy 
of meningitis. If meningitis is suspected, an 
appropriate antibiotic should be used.
At presen t the re  is in s u ff ic ie n t data to 
recommend a specific dosage for children with 
impaired renal function. However, if the adminis­
tration of MEFOXIN® is deemed to be essential 
the dosage should be modified consistent with 
the recommendations fo r adults (see Table 
above).
PROPHYLACTIC USE
For prophylactic use, a three-dose regimen of 
MEFOXIN® is recommended as follows:
Vaginal or abdominal hysterectomy and 
abdominal surgery
2 g adm inistered in tram uscularly or intra­
venously just prior to surgery (approximately 
one-half to one hour before initial incision).
The second and third 2 g doses should be 
administered at 2-6 hour intervals after the 
initial dose.
Cesarean Section
The first dose of 2 g should be administered 
intravenously as soon as the umbilical cord has 
been clamped. The second and third 2 g doses 
should be given intravenously or intramus­
cularly four hours and eight hours after the first 
dose.
AVAILABILITY
MEFOXIN® is supplied as sterile powder in 
boxes of 10 vials:
3356 Ca - 1 g cefoxitin as sodium salt
3357 Ca - 2 g cefoxitin as sodium salt 
Storage
MEFOXIN® in the dry state should be stored 
below  30°C. The dry material as well as 
solutions tends to darken, depending on storage 
conditions; product potency, however, is not 
adversely affected
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ORIGINAL ARTICLES
Prospective and Retrospective Analysis 
of Colonoscopy Findings in Patients With 
a History of Colorectal Carcinoma 
in First-Degree Relatives
Wojciech Brzezinski, MD;* W.J. Orrom, MD, MSc, FRCSC;t E. Wiens, MD, FRCSCJ
The frequency of colorectal neoplasia was assessed by colonoscopy in 48 patients 
with a history of colorectal cancer in a first-degree relative. Twelve of these patients 
were found to have polyps in the colon, including 1 who had invasive cancer. 
Patients with multiple first-degree relatives who have a history of colorectal cancer 
were found to be at increased risk, 56% having colonoscopic findings positive for 
polyps. Of the 12 patients with positive colonoscopic findings, 5 (42%) had multiple 
lesions. These findings are similar to those reported in recent pedigree studies and 
further support a genetic basis for common colorectal cancer. First-degree relatives 
of patients with colorectal cancer should be considered a high-risk group for 
colorectal neoplasia. Screening with colonoscopy is recommended.
La frequence des neoplasies du colon et du rectum a ete evaluee par colonoscopie 
chez 48 sujets dont un parent du premier degre avait souffert d’un cancer colorectal. 
Des polypes du colon ont ete decouverts chez 12 personnes; dans 1 cas, il y avait 
presence d’un cancer invasif, alors que 5 sujets etaient porteurs de polypes 
multiples. Ceux qui avaient plusieurs parents du premier degre victimes de cancers 
colorectaux, avaient eux-meme un risque accru; des polypes ont ete observes chez 
56% d’entre-eux. Ces resultats sont similaires a ceux qui ont ete rapportes lors 
d’etudes genealogiquts recentes et apportent des arguments supplementaires a 
l’appui d’une base genetique au cancer colorectal. Les auteurs croient que les 
personnes qui ont un parent du premier degre avec des antecedents de cancer 
colorectal doivent etre consideres a risque eleve, et ils proposent des directives pour 
l’utilisation de la colonoscopie comme moyen de depistage dans de tels cas.
Heredity plays an important role in the development of colorec­
tal cancers. An association of the 
polyposis syndromes with colorectal 
cancer has been known for over two 
decades. In the last decade other 
hereditary forms of colorectal can­
cer have been well documented
from detailed pedigree studies. 
Lynch and colleagues1 described he­
reditary nonpolyposis colorectal 
cancer, which includes a large num­
ber of hereditary syndromes (e.g., 
cancer family syndrome). These en­
tities characteristically show an in­
creased number of cases of right­
sided colonic malignant disease, 
young age of the affected patients 
and often multiple primary tumours 
(colonic and noncolonic).1-5 It seems 
that an autosomal dominant pattern 
of transmission is responsible in 
these syndromes.67 In all cases of 
colorectal cancer, hereditary cancer 
syndromes are responsible for ap­
proximately 5% to 6%.4 8 In compar­
ison, familial polyposis syndrome is 
responsible for less than 1% of all 
cases.8
The problem of increased risk of 
colorectal cancer in first-degree rel­
atives of patients with this disease 
was assessed as early as 1958, 
when it was found to be three times 
greater than in the general popula­
tion.9 In 1976, Lovett10 reported a 
family history of colonic cancer in 
26% of patients with this disease. 
Studies by Burt and colleagues11 
published in 1985 implicated an 
inherited autosomal dominant sus­
ceptibility in a large kindred, with 
numerous cases of colorectal can­
cer. A similar result was obtained 
when another 33 family members 
were studied in a similar way.12
The goal of this study was to 
determine the prevalence of neo­
plastic changes in the first-degree 
relatives of patients who had colo­
rectal malignant disease and to out­
line a surveillance program for this 
group of patients.
Patients and Methods
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COLONOSCOPY IN RELATIVES OF COLORECTAL CANCER PATIENTS
March 1989, patients with a history 
of colorectal cancer in a first-degree 
relative were studied. The patients 
were over 25 years of age because 
adenomatous polyps rarely occur in 
younger patients.13 There were 48 
patients (28 women, 20 men) with a 
mean age of 53 years (range from 
31 to 86 years).
A complete history was obtained 
from each patient. All were asymp­
tomatic for colorectal disease. No 
formal documentation of their fami­
ly history of colorectal cancer was 
sought.
A complete examination of the 
colon was performed using an 01- 
mypus CF-1T20L 168-cm colono- 
scope (Olympus Corp., Lake Suc­
cess, NY) after a 2-day preparation 
of the colon. The entire mucosa was 
systematically examined, and all 
polyps found, their location and 
size were recorded. In patients with 
multiple lesions, every attempt was 
made to remove or at least biopsy 
all lesions. In 3 of the 48 examina­
tions the right colon was not 
reached. All three had no positive 
findings.
The histologic slides were exam­
ined independently.
Results
The type of family relationships 
is shown on Table I. Twelve pa­
tients (25%) had positive findings 
on colonoscopy; 2 of them had a 
hyperplastic polyp only, 9 had tubu­
lar adenomas and 1 invasive carci­
noma. In 5 of the 12 patients 
polyps were multiple, including the 
patient with carcinoma, who also 
had multiple adenomatous polyps 
(42% of positive colonoscopies).
The majority of adenomas were 1 
cm in dimension or larger (Table II) 
and most were found on the left 
side of the colon (Table III).
Nine of the 48 patients in the 
study had multiple first-degree rela­
tives with colorectal cancer. Five of 
them (56%) had positive findings on 
colonoscopy (4 with adenoma and 1 
with hyperplasia) and are included 
with the 12 patients who had posi­
tive colonoscopies.
Discussion
Inherited susceptibility to colo­
rectal cancer is perhaps one of the 
most important factors in the 
pathogenesis of this disease. Rou­
tine screening of the general popu­
lation for colorectal neoplasia is not 
cost-effective. It is clear that pre­
vention rather than treatment of the 
fully developed disease, would be 
more beneficial for the patients, as 
well as for cost-conscious govern­
ments. Efforts concentrated on 
screening the high-risk groups 
could improve patient survival and 
cost-effectiveness.
Our analysis of unrelated patients 
with a history of colorectal cancer 
in a first-degree relative revealed a 
frequency of colorectal neoplasms 
of 25%, more than twice the in­
crease over the controls reported by 
Burt and colleagues11 (9%) and Can- 
non-Albright and associates12 (12%), 
as well as the prevalence in the 
general population reported by Ujs- 
zaszy and associates13 (8.9%). The 
patients with multiple first-degree 
relatives involved appear at even 
greater risk (56% positive colono­
scopies in our study). These obser­
vations support a genetic basis for 
common colorectal cancer. A simi­
lar result was obtained when a 
larger, prospective, community- 
based study was undertaken and 
analysed.14 There is growing evi­
dence in the literature that hyper­
plastic polyps may represent an 
early stage of colonic neoplasia.15 
Therefore, we elected to classify 
patients with hyperplastic polyps as 
having colonoscopy positive for 
neoplasia.
We propose the following guide­
lines for screening and follow-up of 
patients with a history of colorectal 
cancer in first-degree relatives.
•  Patients should be pursued 
for entry into a surveillance pro­
gram.
•  Initial colonoscopy should be 
done at the age of 40 years. Earlier 
examination should not be discour­
aged especially if a particularly 
strong family history exists.
•  After a positive examination, 
repeat colonoscopy every 1 to 2 
years is recommended until nega­
tive.
•  After a negative colonoscopy, 
examination should be repeated in 5 
years (polyp cancer transformation 
does not occur in less that 5 
years.16
•  Careful follow-up is important 
since the increased risk of colorec­
tal neoplasia is life-long.
We thank the Medical Records Depart­
ment, Royal Alexandra Hospital, Ed­
monton, for help in preparing the data 
and Ms. Dorothy Olson for preparation 
of the manuscript.
Table 1. Family Relationships (48 Patients)
Relationship No. (%)
Father 19(40)
Mother 21 (44)
Brother 7(15)
Sister 9(19)
Table II. Polyp Size
Tubular Hyperplastic
Size, cm adenomas polyps
< 0.5 3 1
0.5 -  0.9 1 1
> 1 5 0
Totals 9 2
Table III. Location of Lesions
Location No.
Rectum 2
Left colon 8
Transverse colon 2
Right colon 3
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This book is intended to provide an 
overview of the vestibular system and 
its disorders. I think the authors have 
done a credible job. The text is divided 
into three sections: the vestibular sys­
tem (anatomy and physiology), evalua­
tion of the dizzy patient and manage­
ment of common neurotologic disor­
ders.
The section on the vestibular system 
is easy to read and, I thought, quite 
complete without getting too deeply 
into detailed neurophysiology and los­
ing me in the process. It clearly outlines 
vestibular function and all the vestibu­
lar reflexes that must be understood in 
order to sort out vestibular disorders 
and the tests available to assist in their 
diagnoses.
The section on assessment of the 
dizzy patient appropriately focuses on 
the clinical features. As is the case in 
clinical practice, the focus is on accu­
rate history-taking followed by otoneu- 
rologic examination. Numerous condi­
tions associated with (and frequently 
confused with) vestibular disease are 
discussed. Nystagmus and its many 
forms are clearly described. The type of 
neurologic examination required in the 
dizzy patient is defined.
The principles of electronystagmog­
raphy (ENG) and the standard test 
procedure are helpful in outlining the 
role and limitations of ENG. A clear 
advantage of ENG is its superior ability 
to elicit and document pathologic nys­
tagmus or vestibulocular dysfunction. A 
separate chapter is dedicated to new 
techniques of rotational testing and 
mention is made of posturography and 
vestibular-evoked potentials.
I was pleased to see auditory func­
tion included in the assessment of the 
dizzy patient. The chapter correctly 
focuses on the role of routine pure-tone 
audiometry and the newer, more accu­
rate, techniques of brainstem evoked 
response audiometry (BERA). Little 
mention is made of older, outdated 
special auditory tests.
The final section on dizziness and 
management of common disorders cov­
ers most pathologic conditions of the 
vestibular system. More detail could 
have been provided in certain areas, 
particularly in those common disorders 
of benign postural vertigo and Me­
niere’s disease. There could have been 
more discussion about the various med­
ical and surgical techniques available 
for managing Meniere’s disease and 
some of the controversies surrounding 
them. The book, however, is more of an 
overview than a definitive text on each 
subject. Therefore the authors have a 
difficult task in avoiding excessive de­
tail.
I enjoyed reading this book. My 
practice in otolaryngology includes, but 
does not focus on, otoneurology. I 
found the book to be informative, and it 
restored some long-forgotten features 
of vestibular physiology and testing. 
The text would be most useful to 
trainees in otolaryngology and neurolo­
gy and informative to generalists who 
also manage dizzy patients. It should be 
included in any general hospital library 
and the departmental libraries of oto­
laryngology and neurology. It will be 
a good reference text for all practition­
ers of otolaryngology and neurology. It 
is moderately expensive but of good 
value.
Paul F. Odell. MD, FRCSC
Chairman,
Department o f Otolaryngology,
University o f Ottawa,
Ottawa, Ont.
CURRENT CRITICAL PROBLEMS IN 
VASCULAR SURGERY. Edited by 
Frank J. Veith. 587 pp. Illust. Quality 
Medical Publishing Inc., St. Louis, Mo. 
1989. $69.95 (US). ISBN 0 -9 4 2 2 1 9 -  
01-5
Vascular surgery is still a relatively 
young specialty, and it has evolved so 
quickly that it is difficult for a busy
vascular surgeon to keep up with all 
the advances. This book presents a 
good update on trends in many vascular 
topics. It covers the complete practice 
of a vascular surgeon from manpower 
issues to the use of lasers and comput­
ers.
This is not a textbook. It is not a 
book for the junior trainee looking for 
basic knowledge in the vascular field 
but is an excellent reference book for 
the fellow or vascular surgeon who 
wants to reach his own conclusions 
about controversial topics. Most of the 
difficult topics are discussed by authors 
with a specific interest in the area. The 
majority are from North America. Even 
though answers to every question 
raised are not supplied, controversial 
issues are discussed, supporting data 
are supplied for each side of the argu­
ment and the author’s own preference 
is given. Previous and ongoing studies 
used in solving the controversial issues 
are also presented and discussed.
This is a well-organized book with 
109 concise chapters focused on the 
different aspects of vascular surgery. 
The writing is lucid and the liberal use 
of diagrams, tables and figures, with 
high-quality photographs, greatly en­
riches the text.
The strength of this book is the 
highlighting of potential new horizons 
or areas into which vascular surgeons 
might expand their activity. The present 
edition admirably fulfils the goal out­
lined by the author: addressing the 
technical progress, innovations, impor­
tant precautions and new horizons in 
vascular surgery. As mentioned in the 
preface, the information presented in 
this book is essential knowledge for 
vascular surgeons and others who want 
to keep pace with all that is new and 
important in the treatment of vascular 
diseases.
I highly recommend this book to any 
senior trainee or vascular surgeon. It is 
well worth the price.
J-F. Morin, MD, FRCSC
Cardiovascular surgery,
The Montreal General Hospital,
Montreal. HQ  
H3G 1A4
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FIBROLAMELLAR HEPATOCELLULAR CARCINOMA: AGGRES­
SIVE SURGERY RESULTS IN LONG-TERM SURVIVAL. P. Sheiner, 
B. Langer, B.R. Taylor, P. Greig. Department of Surgery, University 
of Toronto, Toronto General Hospital, Toronto, Ont.
Fibrolamellar carcinoma is an unusual variant of hepatocellular carcino­
ma, occurring in younger patients, unassociated with hepatitis B virus 
infection or underlying cirrhosis and with distinct pathological features. 
Between 1982 and 1989, nine patients underwent resection for 
fibrolamellar carcinoma. The average age was 32 years (19 to 57 years). 
All were hepatitis-B negative. Operations included right liver resection 
(five), left lobectomy (two), left lateral segmentectomy (one), extended 
resection with lymph-node dissection (one). Three patients are free of 
disease 26, 54 and 84 months postoperatively. One patient had a formal 
re-resection 8 months after segmentectomy because of positive margins 
and has been disease-free for 72 months. Four patients had recurrence 
at 13, 15, 41 and 72 months after the first resection. Two had further 
resections (one formal right lobectomy, one radical nephrectomy) and 
have been disease-free for another 42 and 42 months. One patient with 
massive recurrence in the liver had a liver transplant and is disease-free 
at 7 months. One patient with extensive disease at initial operation 
expired at 14 months. Seven out of nine patients (77.8%) are alive and 
disease-free at 26 to 84 months since diagnosis (average 69 months).
Fibrolamellar carcinoma has a natural history that lends itself to 
radical surgical therapy. Our experience suggests an aggressive ap­
proach is worthwhile, including (a) radical surgical resection even with 
extensive disease, (b) re-resection for recurrent disease and (c) liver 
transplantation when necessary for complete removal of all tumour.
246
THE PREOPERATIVE APACHE II SCORE IN RIGHT HEPATEC- 
TOMIES FOR LIVER TUMOURS. M. Gagner, C. Vons, D. Franco, 
J.W. Braasch. Department of Surgery, Hotel-Dieu de Montreal, 
Montreal, Hopital Paul-Brousse, Villejuif, France and Lahey Clinic, 
Burlington, Mass.
The APACHE II score, a severity of disease classification comprises the 
sum of points given for age (A), physiological assessment (PA) and 
chronic health evaluation (CHE) and has been shown to predict 
mortality in intensive care unit patients. The objective was to evaluate 
the ability of the APACHE II score to predict morbidity and mortality in 
major surgery for liver tumours. We reviewed the charts of 65 patients 
who had right hepatectomy for liver tumours between January 1980 
and September 1989. The patients were divided into three groups 
according to the preoperative APACHE II score; low (0 to 3), mid (4 to 
7) and high (8 or more). The postoperative morbidity and operative 
mortality increases as the preoperative APACHE II score increases. 
Patients in the low-score group had a morbidity of 37% and no 
mortality: those in the mid-score group had a morbidity of 55% and a 
3% mortality and those in the high-score group had a morbidity of 83% 
and a 17% mortality. We also looked at the APACHE II score minus the 
age points (APACHE II —A) to look at the effect of only PA and CHE.
The patients with no points for PA and CHE (age being the only risk) 
have a much lower morbidity (20%) and no mortality as opposed to 
those who have points for PA or/and CHE, who have a threefold risk (p 
< 0.01 Fisher’s exact test). We conclude that the preoperative APACHE
II score correlates with postoperative morbidity and mortality in major 
surgery for liver tumours. The effect of chronic health evaluation points 
and physiologic assessment points on morbidity and mortality are 
greater than the effect of age points alone. It may be used by clinicians 
to predict morbidity and mortality and may identify a high-risk group of 
patients who perhaps should be considered for therapeutic alternatives.
247
THE ROLE OF LOCAL EXCISION FOR ADENOCARCINOMA (CA) 
OF THE AMPULLA OF VATER. B.S. Papsin, M. Abecassis, B. 
Langer, B.R. Taylor, P.D. Greig. Department of Surgery, University 
of Toronto, Toronto General Hospital, Toronto, Ont.
The standard operation for adenocarcinoma (CA) of the ampulla has 
been pancreatoduodenectomy. Radical local excision is a useful tech­
nique for treating benign ampullary lesions and has been suggested as 
an alternative to pancreatoduodenectomy for ampullary CA, especially 
in small lesions discovered early by endoscopic retrograde cholangiopan­
creatography. Reported 5-year survival with this technique is from 17% 
to 50%. From 1962 to 1989. 22 patients underwent local resection of 
small ampullary lesions suspected of being carcinoma. Seven of these 
lesions were invasive adenocarcinoma, nine adenoma, one adenoma with 
carcinoma-in-situ, two neuroendocrine tumours, two papillitis, one 
hamartoma. One patient with CA was converted to a pan­
creatoduodenectomy because of positive margins found after local 
excision. Two patients developed postoperative pancreatitis. There was 
no operative mortality. Two patients having "palliative" local excisions 
for CA died of recurrent disease at 6 and 37 months. Two of four 
patients having “curative" local excisions for CA have died of recurrent 
disease at 1 and 12 years. One has recurrent carcinoma at 10 years, and 
one is alive and well at 12 years. During the same period 48 patients 
had pancreatoduodenectomy for ampullary CA with an operative 
mortality of 4%, and 5-year survival of 26%.
We conclude that local excision is appropriate treatment for benign 
tumours of the ampulla and for CA in patients who cannot tolerate 
pancreatoduodenectomy. Because of the high incidence of local recur­
rence, pancreatoduodenectomy should remain the standard treatment 
for proven ampullary carcinoma.
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NUCLEAR SHAPE AS A PROGNOSTIC DISCRIMINANT IN COLO­
RECTAL CARCINOMA. B. Mitmaker, L.R. Begin, P.H. Gordon. 
Department of Surgery and Department of Pathology, Sir Mortimer B. 
Davis-Jewish General Hospital, McGill University, Montreal, PQ
In a search for a more reliable prognostic discriminant, a retrospective 
analysis of 100 patients with colorectal carcinoma, having undergone 
curative resection and followed for at least 5 years, was assessed by 
nuclear morphometry. Each case was staged according to Dukes’ 
classification and graded histologically. For all patients in this series, 
the perimeter, area and shape of 50 interphase nuclei were determined 
for both the normal and transitional colonic mucosae as well as for the 
carcinoma itself. The information was obtained through the use of an 
image analysis system by tracing the nuclear profiles (magnification X 
1000) as digitized on a video screen. The nuclear shape factor was 
defined as the degree of circularity of the nucleus, a perfect circle
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recorded as 1.0. A nuclear shape greater than 0.84 was associated with 
poor outcome. Multiple linear regression models showed that the single 
parameter of nuclear shape was the most highly significant predictor of 
survival (p < 0.0001). This variable remained highly significant even 
when corrected for sex, age, histologic grade and Dukes’ classification. 
These findings indicate that a nuclear shape factor > 0.84 as 
determined by nuclear morphometry is an independent pathological 
variable of great importance in the prognosis of large-bowel cancer.
249
MANAGEMENT OF BREAST CANCER IN THE ELDERLY: PREJU­
DICE BASED ON AGE? M.C.K. Chan, E.E. Sterns. Department of 
Surgery, Queen’s University, Kingston, Ont.
Pressure on the health care system, the increasing number of elderly 
patients and the prevalence of breast cancer in this age group has raised 
questions as to how these patients should be managed.
This study was undertaken to compare long-term results of treatment 
of localized breast cancer in women over 70 years (n = 161) with those 
between 55 and 70 years (n = 236). Nodal status, tumour size and 
histology were the same in both groups. Surgical management was 
similar except that axillary dissection was performed less frequently in 
patients over 70 (p = 0.005). Radiotherapy reduced local recurrence 
from 14% to 7% (p = 0.01), but fewer women over 70 were treated with 
radiotherapy following local excision (“lumpectomy").
The overall (ov), disease-specific (ds) and disease-free (df) survival (%) 
at 5 and 10 years is as follows:
55 to 70 yr Over 70 yr
Time span, yr OV ds df OV ds df
5 81 87 76 70 81 81
10 60 72 62 39 75 75
Evidence suggests that most women over 70 tolerate treatment for 
breast cancer as well as those 55 to 70 and achieve comparable ds and 
df survival. This suggests that women over 70 treated with local 
excision should be offered adjuvant radiotherapy to reduce risk of local 
recurrence on the same principles as women under 70, and alternative 
methods of management must be judged against this background.
250
THE ASSOCIATION OF CYCLICAL MASTOPATHY WITH PRE­
MENOPAUSAL BREAST CANCER. P.J. Goodwin, G. DeBoer, R.M. 
Clark, P. Catton, S. Redwood, N. Hood, N.F. Boyd. Mount Sinai 
Hospital, University of Toronto, Toronto, Ont.
A case-control study was conducted to examine the association of 
cyclical breast symptoms with breast-cancer risk in 192 premenopausal 
women with axillary-node-negative breast cancer, diagnosed at least 6 
months previously, and 192 healthy age-matched controls employed at 
one of three large companies. Women with irregular menses, current 
use of oral contraceptives or previous systemic therapy for breast cancer 
were excluded. Subjects recorded breast pain and swelling in each 
breast on a scale of 0 (absent) to 4 (severe) as well as the presence or 
absence of menstrual flow on a daily basis during one menstrual cycle. 
They also provided information on diet and risk factors for breast 
cancer. Mean age, length of menstrual cycle and duration of menses 
were similar in cases and controls. When the noncancerous (or matched) 
breast was considered, cases and controls had similar scores for breast 
pain on day 10 of the cycle. Cases had significantly greater pain scores 
2 days prior to menses (p < 0.03). Cases also had larger premenstrual 
increases in pain than controls, although this difference was of
borderline significance. Differences in swelling were less marked. After 
adjustment for parity, previous breast biopsy, first-degree relative with 
breast cancer, prior smoking and oral contraceptive use, the association 
of cyclical breast pain with breast cancer was significant (p < 0.05). It is 
concluded that cyclical mastopathy is associated with breast-cancer risk 
in premenopausal women.
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NON-TERTIARY SURGERY IN MANITOBA: COMPARISON OF 
PROVINCIAL WITH TEACHING HOSPITAL DATA. R.J. Blanchard. 
Department of Surgery, University of Manitoba, Winnipeg, Man.
The objective of this study was to determine whether the surgical 
experience available in Manitoba’s two teaching hospitals was relevant 
to the nontertiary surgical needs in the province.
The following methods were employed: (a) Manitoba Health Services 
Commission (MHSC) data for all operations in the province during 1985 
and 1986 were downloaded into a PC computer: (b) all operations 
performed in the two teaching hospitals were similarly downloaded and 
separated into specialty sections (programs) prior to downloading; (c) 
for both databases, the procedures were lumped into categories such as 
"thyroid surgery” ; (d) provincial operations were separated into special­
ty groups; (e) each operation was labelled either “ tertiary" or “nonterti­
ary’’.
In Manitoba there were 110 608 nontertiary operations performed in 
the 2 years, approximately 5500 operations per 100 000 population per 
year. Proportions in the four commonest surgical specialties were: 
general surgery 44%, gynecology and operative obstetrics 29%, orthope­
dics 17% and urology 10%. Of the 20 commonest operations in the 
province. 10 are not usually included in general surgery training 
programs. There were less than 10 procedures per resident for some 
common operations.
The teaching hospitals had relatively even numbers of different 
operations whereas the frequency spectrum in the province showed a 
steep curve.
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THE ROLE OF GRADED COMPRESSION ULTRASOUND IN THE 
PATIENT WITH SUSPECTED ACUTE APPENDICITIS. C. Barba, A. 
Hreno, M. Atri. Montreal General Hospital, McGill University, Montre­
al, PQ
A controlled prospective study was conducted to determine the role of 
ultrasound (US), using graded compression technique in the manage­
ment of a patient with suspected acute appendicitis who presented to 
our institution over a period of 11 months.
Patients were divided into two groups. Forty-one patients did not 
have US and the diagnosis relied on clinical judgement. The accuracy in 
this group was 78% for the diagnosis of acute appendicitis. Forty-six 
patients had US and the accuracy of the procedure was 91%. The 
patients included in the latter group presented a more atypical 
presentation when the presence of peritoneal signs was compared with 
the former group (85.6% versus 21.7% for a p = 0.0001).
Our results revealed that US clearly affected the management of 54% 
(n = 24) of the patients who had this procedure. Women constitute the 
majority of this group (67%). Laparotomy was avoided in seven of these 
patients. In five, surgery strongly relied on the US result. Appendecto­
my was accelerated in two patients. Ultrasound helped to narrow the 
diagnosis in 10 patients. Without the use of US the accuracy in the 
diagnosis of appendicitis drops significantly from 84.8% to 69.6% (p = 
0.0007).
We conclude that graded compression US is an important tool in the 
management of a patient with suspected acute appendicitis. It should be 
used in a patient with an atypical presentation, especially in high-risk 
patients. Childbearing women are also a group for which this procedure 
is indicated.
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SUBTOTAL COLECTOMY (STC) FOR ULCERATIVE COLITIS: 
COMPLICATIONS RELATED TO THE RECTAL REMNANT. F.M. 
Carter, Z. Cohen, R.S. McLeod. Department of Surgery, Toronto 
General Hospital, University of Toronto, Toronto, Ont.
Complications related to the retained rectal remnant were reviewed in 
136 patients undergoing subtotal colectomy (STC) for acute ulcerative 
colitis. Fifty-five patients (group 1) had a closed rectal stump brought 
up into the subcutaneous tissue and 30 (group 2) had an open mucous 
fistula. These were compared with an intrapelvic Hartmann pouch 
performed in 51 patients (group 3). All patients eventually had a pelvic 
pouch procedure. Age. duration and activity of disease, and preoperative 
steroid use were similar in all groups.
There was no mortality. Twenty group 1 patients (36%) spontaneous­
ly opened and 8 (14%) developed local wound infections. One patient 
(2%) had retraction below the fascia of an opened rectal remnant leading 
to pelvic sepsis. Two group 2 patients (7%) and six group 3 patients 
(12%) developed pelvic septic complications. Subsequent pelvic dissec­
tion was difficult in 20% of group 3 patients versus 4% and 0% in 
groups 1 and 2 patients (p < 0.05). Persistent rectal disease activity was 
present in 41% of group 3 versus 27% in groups 1 and 2 (p < 0.05).
Our study suggests that exteriorization of the closed rectal stump 
following STC is associated with fewer pelvic septic complications, 
minimal local morbidity, and is not associated with increased disease 
activity in the retained rectum.
254
MULTIVISCERAL RESECTION FOR CARCINOMA OF THE COLON 
AND RECTUM. M.J. Lopez. Washington University School of Medi­
cine, Department of Surgery, Barnes Hospital and Ellis Fischel State 
Cancer Center, St. Louis and Columbia, Mo.
Among 1042 patients explored for colorectal cancer between 1964 and 
1980. 69 (6.6%) underwent curative multivisceral resection for contigu­
ous invasion by the primary tumour. Follow-up was complete. There 
were 47 women and 22 men. Surgical procedures included total pelvic 
exenteration (11), abdominoperineal resection (31). low anterior resec­
tion (7), sigmoid resection (9), left colectomy (6) and right colectomy 
(5). En-bloc resection included 129 other viscera. The surgical morbidity 
and mortality were 31.8% and 2.8% respectively. Surgical margins of 
resection were positive in five patients. Clinical recurrence in this 
subgroup was evident between 8 and 22 weeks postoperatively. and the 
mean survival was 8.2 months. Tumour invasion of the contiguous 
organ was demonstrated in 60 specimens and only adherence in 9. The 
5-year survival rates for patients with and without lymph-node metasta- 
ses were 7.6% and 78%, respectively. At 10 years, the overall survival 
rate was 50.7% (35 of 69) and cancer-related mortality 36% (25 of 69). 
It is concluded that survival in locally advanced colorectal carcinoma is 
more dependent on lymph-node status than on the extent of local 
invasion. Effective disease control and long-term survival can be 
achieved by multivisceral resection.
255
EXTRACORPOREAL BLOOD FLOW IN MICROGRAVITY. K. 
McCuaig, C. Lloyd, J. Gosbee, W. Snyder. Department of Surgery, 
University of Alberta and NASA Johnson Space Center, Houston, Tex.
Knowledge of venous, capillary and arterial blood flow in microgravity is 
required to modify hemostatic techniques for bleeding control in case of 
traumatic injuries or surgical procedures on Space Station Freedom and 
a Mars mission. To stimulate human arterial, venous and capillary 
bleeding, fresh whole bovine blood was injected by two operators at 
calculated flow rates (3.5. 7 and 14 ml for venous and 2, 14 and 28 ml 
for arterial) in 10 seconds with empirical controls in a lucent glove box 
during zero gravity parabolic flights on a NASA KC-135 aircraft. A 
pig's foot was used to mimic capillary bleeding. Hemostasis with
sponges and laerdal suction was evaluated by video and still photogra­
phy. Evaluation of the arterial and venous were conducted at the three 
rates with three parabolas and capillary was evaluated with five 
parabolas and two methods (pig’s foot and sponge).
Influenced by surface tension, the slow venous bleeding coated 
syringe surfaces and formed a dome over the skin laceration bleeding 
site. Arterial and venous bleeders broke into uniform spheres with 
low-velocity spheres bouncing off absorbent pad and suction tip. 
Conventional dabbing with gauze fragmented blood into small spheres. 
Capillary oozing was better controlled by wicking up blood with gauze. 
Repeated arterial bleeding opacified the glove box wall. This simulation 
demonstrated unique characteristics of extracorporeal blood flow and 
inadequacies of common methods of hemostasis in microgravity.
256
LASER DOPPLER ASSESSMENT OF BLOOD FLOW IN NORMAL 
AND ISCHEMIC RAT BOWEL. P. Mitchell, J. Heine, R. Lafreniere, 
W. Atherton, I. Jadusingh, S. Huchcroft, C. Jadik. Department of 
Surgery, University of Calgary, Calgary, Alta.
Improved accuracy and objectivity in the evaluation of intestinal viabiity 
has been reported by some investigators using laser Doppler. We 
undertook to evaluate the role of the laser Doppler in predicting 
ischemic changes in rat small bowel.
We found that the normal mean laser Doppler blood-flow reading for 
rats was 31.3 ml/min-100 g - ' (95% Cl 28.2, 34.4). We devascularized 
segments of small bowel ranging from 1 to 14 cm in length and 
compared the pathologic grade of ischemia to the absolute laser 
Doppler reading, laser Doppler Index (LDI). and to the LDI/Iength of 
ischemic segment.
Using multiple linear regression analysis we found that the best 
predictor of pathology (necrosis) was the LDI/length (R = 0.8, p < 
0.0001), although each of the other factors was also significantly 
correlated — absolute laser Doppler reading (R = 0.5, P = 0.0142) and 
LDI (R =  0.6, P = 0.0023).
This study confirms that the laser Doppler flowmeter is a useful 
method ot assessing bowel ischemia, particularly when the length of the 
ischemic segment is accounted for.
257
SPLENIC ABSCESS: 10-YEAR CLINICAL EXPERIENCE. A.R. Har- 
rop, T.W. Theman. Department of Surgery, University of Alberta, 
Edmonton, Alta.
Splenic abscess is a rare entity with fewer than 400 cases reported. 
Prior to 1978 no reported cases had undergone CT scanning or 
ultrasonography: this represents a watershed period with respect to 
these diagnostic measures. This review examines the experience with 
splenic abscess in five general hospitals since 1978.
There were 16 cases of splenic abscess (10 men, 6 women), occurring 
in all age groups (age 22 to 83). Predisposing factors included 
preceding pyogenic infection (11 patients), disease in contiguous organs 
(2), immunocompromised state (2), preceding abdominal trauma (2) and 
unknown (2) (includes combinations). Symptoms were generally nonspe­
cific; however, the combination of fever and abdominal pain was present 
in 12 patients. The most common combination of clinical signs was 
fever and left upper quadrant tenderness (eight patients). Mean duration 
of symptoms prior to diagnosis was 3 weeks.
CT scanning was the most specific method of diagnosis (7/7) 
followed by ultrasound (6/9). There were two cases diagnosed at 
laparotomy and three discovered at autopsy. Bacteriology was varied, 
with representation by gram-positive (three), gram-negative (six) and 
anaerobic organisms (four). There were three sterile abscesses. Blood 
cultures corresponded to abscess cultures when both were positive 
(nine).
Splenectomy was curative (nine) with no recurrence of sepsis or 
mortality. Patients treated with antibiotics alone (four) all died of 
ongoing sepsis. Percutaneous drainage (two) was followed by abscess
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recurrence in one patient (resolved after splenectomy) and freedom from 
sepsis (more than 1 year) in the other. Splenotomy (one) was associated 
with morbidity (chronic drainage) but not mortality.
Splenic abscess is a rare occurrence but the mortality is high if the 
condition is not diagnosed or adequately treated. Suspicion should be 
raised on the basis of clinical presentation in predisposed patients. 
Confirmation of diagnosis is by CT scan or ultrasound. Definitive 
treatment is splenectomy.
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PLATELET ACTIVATING FACTOR (PAF) ENHANCES MACRO­
PHAGE (MO) PROCOAGULANT ACTIVITY (PCA) INDUCTION BY 
ENDOTOXIN (LPS). D.S. Kucey, O.D. Rotstein. Department of 
Surgery, University of Toronto, Toronto, Ont.
Fibrin deposition plays a critical role in the pathogenesis of abscess 
formation. Several bacteria are known to stimulate MO-mediated fibrin 
deposition (i.e., PCA). Since the lipid autocoid PAF is generated during 
the inflammatory response, it was hypothesized that PAF might 
modulate MO PCA induction in response to LPS. Thioglycolate-elicited 
murine peritoneal MOs were incubated with LPS (10 jig/ml) for 2 to 6 
hours following a 30-minute preincubation in PAF 10~7M or control 
medium. The ability of treated MO to shorten clotting time (i.e., PCA) 
was measured, and times were converted to PCA units using a 
thromboplastin standard.
Procoagulant activity (mU/2 X 106 cells) 
Duration of incubation, h
Group 2 4 6
Medium alone 52 ± 12* 41 ± 9 95 ± 13
LPS, 10 Mg/ml 193 ± 69 380 ± 78 810 ±  100
PAF alone 68 ± 20 71 ± 16 224 ± 41
PAF preinc. 355 ± 122t 658 ± 144+ 1252 ± 159+
*Mean + SEM, n = 4.16. tp  < 0.05 versus LPS alone. Jp < 0.01 
versus LPS alone.
Medium alone did not induce PCA while PAF alone caused a small 
stimulation. At all time points, preincubation with PAF enhanced MO 
PCA induction by LPS. This priming effect was observed with PAF 
I0 "7 to 10"9M. Thus, PAF augments the ability of MO to mediate 
fibrin deposition following stimulation with LPS. These data suggest 
that local PAF generation may serve to modulate the magnitude of the 
inflammatory response at the site of infection.
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VALUE OF CULTURES TAKEN AT OPERATION FOR UPPER 
GASTROINTESTINAL PERFORATIONS. D. Katyal, O.G. Thurston. 
University of Alberta, Edmonton, Alta.
The microbiologic flora encountered in perforations of the upper 
gastrointestinal tract presents a bewildering variety of organisms, 
including weak pathogens and yeasts. This study was undertaken to 
determine the significance and predictive value of cultures taken at 
operation for repair of upper gastrointestinal perforations.
Fifty-two adult patients treated between 1984 and 1989 met the 
criteria of having a perforation of the esophagus (5), stomach (12), 
duodenum (34) or proximal jejunum (1) and had a bacterial culture 
taken from the perforation at the time of operation for repair. The 
hospital courses of these patients were reviewed with particular 
attention to septic complications and outcome.
Thirty-two patients had a positive culture from the perforation site. 
Sixteen of these patients (50%) developed a septic complication(s) and 
10 (31%) died. Twenty patients had no growth from the perforation site 
and 6 (30%) developed a septic complication and there were no deaths (p 
< 0.01). If Candida or yeast organisms were present in the positive
culture the septic complication rate rose to 71% and the mortality rose 
to 47% (p < 0.05). The culture taken at operation identified organisms 
present in subsequent septic complications 59% of the time but was of 
no value 41% of the time. In addition, six patients with no growth in the 
operative culture developed septic complications.
This study indicates that cultures taken from upper gastrointestinal 
perforations are only marginally useful in identifying a high-risk group 
of patients for septic complications and death.
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ACUTE VENOUS INJURY: COMPARISON OF TOTAL VENOUS 
AND ARTERIAL OCCLUSION. P. Wizman, C.L. Kerrigan. Microvas- 
cular Research Laboratories, Royal Victoria Hospital, McGill Universi­
ty, Montreal, PQ
It has been postulated that venous injury is more deleterious to muscle 
or skin survival than either arterial or global ischemia. Twenty-four 
female white Landrace pigs each had bilateral buttock 10 X 18 cm and 
latissimus dorsi 10 X 20 cm island flaps raised. All flaps were subjected 
to 2 hours of complete pedicle occlusion. A 12-hour period of 
reperfusion followed, after which the animals were randomized to 
secondary ischemic intervals of 3, 5, 7 and 9 hours (n = 6). One side of 
each animal received arterial clamping while the other was subjected to 
venous clamping for the same ischemic interval. Skin and muscle 
survival were determined 24 hours after the secondary ischemic injury. 
Laser Doppler flowmetry (LDF) was documented at hourly intervals 
during secondary ischemia, within 1 hour following reperfusion and 24 
hours post-secondary ischemia. Skin survival was assessed using 
intravenous fluorescein followed by Wood’s lamp illumination. Muscle 
survival at 3 and 5 hours was measured using nitroblue tetrazolium salt 
staining: however, this was difficult to interpret at longer intervals. 
Histologic analysis was used, in these cases to confirm muscle death. 
Cutaneous and myocutaneous flaps showed less necrosis in the arterial 
versus the venous group (p < 0.05) at each interval. At 3 and 5 hours, 
mean muscle mass survival in arterial versus venous was 98.2 ±  1.3% 
versus 58.9 ±  12.9%, p =  0.02 and 57.5 ±  13.6% versus 4.2 ±  3.0%, p 
= 0.006 respectively. The histologic sections showed total necrosis in 
the venous flaps and greater than 90% necrosis in the arterial flaps 
subjected to 7 and 9 hours of ischemia. Laser Doppler flowmetry 
readings of viable flaps, expressed in arbitrary units during secondary 
ischemia, were 0.69 ±  0.1, 1.35 ±  0.17 and 4.37 ± 0.32, on immediate 
reperfusion were 5.82 ±  0.5, 1.68 ±  0.44 and 4.33 ± 0.38. and at 24 
hours were 4.1 ± 0.31, 4.2 ± 0.5 and 5.26 ± 0.36 for arterial venous 
and reference groups respectively. Venous injury was significantly more 
detrimental to both skin and muscle survival. In viable venous flaps, 
LDF shows that flow is markedly diminished on immediate reperfusion; 
however, by 24 hours, flow in both arterial and venous groups 
normalizes to 80% of control skin.
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CARDIAC COMPLIANCE AND EFFECTS OF HYPERTONIC SA­
LINE. D. Croft, Y.M. Dion, M. Dumont, D. Langlois, S. Marcoux. 
Department of Surgery, Hopital St-Francois d’Assise, Universite 
Laval, Quebec, PQ
The purpose of this study is to verify the hypothesis that a 1.8% 
hypertonic saline solution (HS) could allow a better cardiac performance 
than the regular Ringer's lactate solution (RL) during and after major 
abdominal surgery.
Twenty-eight patients were randomly allocated to one of two groups. 
Patients in group I (n =  13) received RL and those in group II (n =  13) 
HS. All patients were studied preoperatively, peroperatively and postop- 
eratively for 72 hours.
The two groups were comparable for age. length of surgery and 
length of aortic cross-clamping. Preoperatively, natremia. serum os- 
molarity. pulmonary capillary wedge pressure (PCWP) and ventricular 
end-diastolic volume index (LDEDVI) were similar in both groups. A 
significant difference was noted, during and after surgery, between the
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sodium levels of the two groups (p = 0.1) which, however, remained 
within normal limits. Serum osmolarity remained similar for the two 
groups (p = 0.49). During and after surgery, PCWP (p = 0.01) and 
CVP (p = 0.7) remained within 3 torr of the initial values with 
non-significant difference between the two groups. Group II received 
significantly less liquid than group I (p = 0.002). Cardiac compliance 
decreased in both groups but significantly more in group I (p =  0.04). 
No untoward effect was noted from HS infusion.
In conclusion, it appears that cardiac compliance is significantly less 
altered when the hypertonic solution is administered. The hypertonic 
solution could be particularly useful in patients with compromised 
cardiac function who undergo major abdominal surgery.
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ISLET BANKING: TRANSPLANTATION OF CRYOPRESERVED 
CANINE ISLET AUTO- AND ALLOGRAFTS. F.A. Daudi, G.L. 
Warnock, M.S. Cattral, M.G. Evans, R.V. Rajotte. Department of 
Surgery and Department of Medicine, University of Alberta, Edmon­
ton, Alta.
remains controversial. Cholecystojejunostomy can reobstruct if the 
cystic duct inserts distally. Choledochojejunostomy can be difficult with 
a distended gallbladder in situ. We describe a technique of anastomos­
ing Hartmann’s pouch of the gallbladder to the right hepatic duct, 
followed by stapled Roux-en-Y jejunal anastomosis to the gallbladder in 
10 patients. The procedure is significantly shorter (usually under 2 
hours), technically easier and provides reliable long-term biliary drain­
age.
Average age, yr 67
M/F 6 /4
Follow-up, yr > 2
Average hospital stay, d 11
Specific complications < 30 d nil
General complications: 
atelectasis 2
prolonged ileus 1
gastrointestinal bleed 1
Long-term complications: 
cholangitis 1
Clinical islet-cell transplantation would be facilitated by the ability to 
cryopreserve allogeneic tissue. This study investigates two problems 
that limit this approach: the quantity of frozen-thawed (FT) islets 
needed and their function after alloimplantation. Purified FT islets were 
autografted into the spleen of apancreatic recipients: group 1, untreated 
dogs (n = 10); group 2, into cyclosporine A (CsA) treated dogs (n = 7). 
Islets were frozen slowly, stored at -  196°C, then thawed rapidly. 
Incremental islet volumes of 3 to 4, 4 to 5 and more than 5 *d/kg 
resulted in corresponding plasma glucose (PG, mg/dl) levels of 130 ± 
18, 191 ±  10, 163 ±  18 mg/dl in group 1 and 267 ±  22, 164 ± 19 
and 166 ±  22 in group 2. At 30 days PG was less than 150 mg/dl in all 
dogs that received more than 5.0 n \/kg . Frozen-thawed islets were then 
allografted (6.6 ± 0.6 jd/kg) into outbred dogs treated with CsA at low 
doses (group 3, 5 to 10 m g/kg--', n = 5) or high doses (group 4, 10 to 
20 m g/kg-d-1, n = 7). Untreated controls failed at 5 ±  1 days. Four of 
five (group 3) and 4 of 7 (group 4) dogs were initially normoglycemic 
but PG rose to more than 150 after 4 days, requiring exogenous insulin. 
One group 3 dog remained normoglycemic without insulin. All group 4 
grafts secreted insulin after 30 days: basal splenic arteriovenous 
gradient was 43.4 ± 1 6  mU/L and increased to 54.5 ±  20 mU/L after 
intravenous glucagon. Mean CsA whole blood trough levels were 642 ± 
32, 707 ±  43 and 1159 ± 45 n g /L  for groups 2, 3 and 4 respectively. 
These data demonstrate that FT islets induce normoglycemia after 
autoimplantation but similar quantities of allogeneic islets have insuffi­
cient function to induce normoglycemia.
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CHOLECYSTOCHOLEDOCHOJEJUNOSTOMY: A QUICK AND EF­
FECTIVE METHOD OF BILIARY DECOMPRESSION FOR CARCI­
NOMA OF THE PANCREAS. C.H. Scudamore, C.R. Shackleton, A.D. 
Forward. Department of Surgery, University of British Columbia, 
Vancouver, BC
The most appropriate method of biliary decompression for patients 
presenting with obstructing nonresectable tumours of the pancreas
Despite the theoretical disadvantage of an additional anastomosis, 
our pilot study has shown that this method is a quick, safe and reliable 
method of biliary drainage for patients presenting with malignant 
obstruction of the distal common bile duct.
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THYROID FOLLICULAR NEOPLASMS: FACTORS THAT PREDICT 
THYROID FOLLICULAR CANCER. N.L. Davis, M. Gordon, G.L 
McGregor, R.E. Robins. Department of Surgery, University of British 
Columbia, Vancouver, BC
Needle aspiration biopsy is routinely used in the evaluation and 
diagnosis of thyroid nodules. The cytologic diagnosis of “follicular 
cytology” is considered an indication for thyroid exploration and 
appropriate resection. In the case of a follicular adenoma, lobectomy is 
considered adequate management; however, a total thyroidectomy is 
preferred for treatment of follicular cancer. Unfortunately needle 
aspiration biopsy usually does not discern these two neoplasms. This 
study was designed to identify epidemiologic and clinical parameters 
that could be applied preoperatively to identify patients at increased risk 
of having a follicular carcinoma.
A retrospective review of 400 patients initially treated at Vancouver 
General Hospital and the Cancer Control Agency of British Columbia 
between the years 1965 and 1985 was completed. Patients with thyroid 
follicular adenomas were compared to patients with follicular cancer. All 
data obtained were analysed by univariate and multivariate methods. 
Statistically significant factors (p < 0.05) distinguishing patients with 
thyroid follicular cancer included age greater than 50 years, nodule size 
greater than 3 cm and a history of neck radiation. Sex, family history of 
goitre or thyroid cancer, alcohol and tobacco use and exogenous 
estrogen intake all were not significant in distinguishing the two patient 
populations. Preoperative identification of risk factors associated with 
follicular thyroid cancer can be used to plan appropriate thyroid 
resection.
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THE SURGICAL MANAGEMENT OF DISTAL (PEPTIC) ESOPHA­
GEAL STRICTURE: A REPORT OF 75 CASES. A.A. Conlan, C.A. 
Hammond, P.M. Marchand. University of Witwatersrand, Johannes­
burg, SA and Queen’s University, Kingston, Ont.
A retrospective study was undertaken to assess the early and late results 
of surgery for distal (peptic) esophageal stricture (DPOS). During the 
period 1957 to 1989, 75 patients underwent surgical therapy for DPOS. 
Thirty-six were men, 33 women and 6 children. Sixty-four patients had 
prominent dysphagia, 32 had episodes of esophageal obstruction. 
Sixteen had severe weight loss. Fifty-two demonstrated hiatus hernia on 
x-ray study. Stricture was confirmed in all at endoscopy. Preoperative 
dilation was completed in 33 but was difficult or incomplete in 39 
others. It was abandoned in three. No perforations were recorded.
Surgical groups were: group 1 — dilation and antireflux operation 
(48 patients); group 2 — dilation, esophagoplasty (Collis) and antireflux 
procedure (16 patients), group 3 — stricture resection with visceral 
interposition (11 patients) (colon 8, stomach 3). Two hospital deaths 
occurred (myocardial infarction, mediastinitis). Hospital morbidity in­
cluded esophageal leakage two. upper gastrointestinal bleeding one, 
bolus obstruction one. Twenty-eight patients had significant postopera­
tive dysphagia (one to three dilations in the first 6 weeks). Follow-up 
evaluation criteria were: good — essentially symptom-free, satisfactory
— occasional symptoms or a dilation, poor — prominent symptoms of 
dysphagia or reflux. Group 1, follow-up 1 to 300 months (mean 42.5)
— good 26. satisfactory 16, poor 6; group 2, follow-up 1 to 65 months 
(mean 32) — good 10, satisfactory 5; group 3, follow-up 1 to 84 
months (mean 22.5) — good 4, satisfactory 4, poor 2. The majority had 
good results with dilation and antireflux procedure, alone or with 
gastroplasty.
52
SELECTION OF PATIENTS FOR LUNG TRANSPLANTATION. M. 
Scavuzzo, D. Morrison, Toronto Lung Transplant Group. University 
of Toronto, Toronto, Ont.
Since 1983 we have performed 27 single lung transplantations (SLT) 
and 18 double lung transplantations (DLT). Stringent recipient selection 
criteria were used. We carried out a retrospective review of the 550 
documented referrals from 1984 until August 1989. Fifty-six (10%) of 
these patients died prior to assessment. One hundred and fifty-one 
(27%) are currently awaiting or undergoing assessment. Two hundred 
and sixty-six (48.4%) of the referrals were refused due to failure to meet 
selection criteria. One hundred and fifty-five of 266 patients failed to 
meet two or more of the criteria:
include: 8 with pulmonary fibrosis, 6 with cystic fibrosis; 1 with chronic 
obstructive pulmonary disease and 1 with pulmonary hypertension. 
Rigid selection criteria likely improve the results of SLT and DLT. 
Patients with pulmonary fibrosis or cystic fibrosis should have greater 
priority for available donors.
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PROLONGED PRESERVATION WITH UNIVERSITY OF WISCON­
SIN SOLUTION. S.E. Fremes, Ren-Ke Li, R.D. Weisel, D.A.G. 
Mickel, L.D. Tumiati, R.D. Furukawa. Center for Cardiovascular 
Research, Toronto Hospital, Toronto, Ont.
Previous studies from this institution have suggested that University of 
Wisconsin Solution (UWS) is preferred for prolonged cardiac preserva­
tion. University of Wisconsin Solution contains adenosine (5 mmol/L) 
which could maintain adenine nucleotides better than other storage 
fluids. Human cardiomyocytes were isolated from left-ventricular biop­
sies. Cells (five to six dishes/group) were rinsed of culture media and 
placed in one of four solutions: Stanford cardioplegia (STA), phosphate- 
buffered saline (PBS), modified Euro-Collins (COL) and UWS. Metabo­
lites were assessed using HPLC after 24 hours of storage at 0°C and 
compared with the baseline (BASE).
Adenosine triphosphate (ATP) and diphosphate (ADP) decreased with 
each solution compared with BASE, but were maintained best with 
UWS. Adenosine monophosphate (AMP) increased with UWS but 
decreased in all other groups. Adenosine (ADO) increased only with 
UWS.
A T P A D P A M P ADO
BA SE
STA
P B S
C O L
U W S
0 .5 3 6  ±  0 .2 0 4 t  
0 .0 0 7  ±  0 .002*+  
0 .0 1 0  ±  0 .001*+  
0 .0 0 4  ±  0 .003*+  
0 .0 5 1  ±  0 .0 2 2 *
0 .1 6 1  ±  0 .0 6 1 +  
0 .0 1 7  ±  0 .0 0 2 * +  
0 .0 0 8  ±  0 .0 0 5 * +  
0 .0 0 7  ±  0 .0 0 3 * +  
0 .0 4 4  ±  0 .0 2 1 *
0 .0 1 5  ±  0 .0 1 5 +  
0 .0 0 1  ±  0 .0 0 1 * +  
0 .0 0 3  ±  0 .0 0 4 * +  
0 .0 0 2  ±  0 .0 0 1 * +  
0 .0 9 5  ±  0 .0 6 0 *
0 .0 2 2  ±  0 .0 0 8 +  
0 .0 4 2  ±  0 .0 4 2 +  
0 .0 2 3  ±  0 .0 1 3 +  
0 .0 4 4  ±  0 .0 2 0 +  
2 .9 6 3  ±  1 .5 7 0 *
n m o l / Mg D N A . m ea n  ±  SD. *p <  0 .0 5  v e rs u s  B A SE , t p  <  0 .0 5  v e rs u s  U W S.
Adenosine in the UWS cells was largely degraded to inosine (UWS: 
1.78 ± 0.91; BASE; 0.029 ±  0.01, p < 0.01 and hypoxanthine (UWS: 
1.71 ± 0.725: BASE: 0.003 ±  0.002, p < 0.01). Inosine (0.12 ± 0.045) 
increased with COL while hypoxanthine was increased with PBS (0.054 
±  0.027) and STA (0.51 ±  0.019) in comparison to BASE.
University of Wisconsin Solution maintains adenine nucleotides better 
than other storage fluids and may improve the clinical results of cardiac 
transplantation.
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No. of Too Svstem ic
D iagnosis patien ts old S teroids Debilitated disease
Restrictive 98 2 3 (23 .5 )* 3 4 (3 4 .7 ) 30 (30.6) 26 (26 .5)
O bstructive 89 4 2 (4 7 .2 ) 2 8 (3 1 .5 ) 1 8 (2 0 .2 ) 1 6 (1 8 .0 )
V ascular 35 3 (8.6) 1 (2.9) 1 (2.9) 8 (2 2 .9 )
Bronchiectasis 13 4 (30.8) 0 2 (1 5 .4 ) 4 (3 0 .8 )
Cystic tibrosis 16 0 1 (6.3) 3 (1 8 .8 ) 4 (2 5 .0 )
M iscellaneous 15 3 (2 0 ) 4 (2 6 .7 ) 5 (3 3 .3 ) 3 (2 0 .0 )
Totals 266 7 5 (2 8 .2 ) 6 8 (2 5 .6 ) 5 9 (2 2 .2 ) 61 (22 .9)
n =  %.
Of 73 patients accepted for SLT or DLT. 44 have been transplanted, 
13 are waiting and 16 died prior to transplantation. These 16 patients
HEMODILUTION REDUCES PULMONARY REPERFUSION INJU­
RY. J.D. Puskas, T. Oka, E. Mayer, W. Wisser, G.A. Patterson. 
Toronto General Hospital, University of Toronto, Toronto, Ont.
A reduction in ischemia-reperfusion (IR) injury after lung transplanta­
tion would improve lung function and increase the supply of donor 
organs by allowing longer preservation times. Two groups (n = 4) of 
New Zealand White rabbits underwent extraction of heart-lung blocks 
after pulmonary artery (PA) flush with Euro-Collins solution (50 ml/kg) 
at 10°C. Prostaglandin (PGE-1, 30 #ig) was given prior to flush into the 
PA and was added to the flush solution. Lungs were stored at 10°C for 
18 hours before assessment in an ex-vivo ventilation/perfusion appara­
tus. Left lungs alone were ventilated with room air and perfused (40 
ml/min) with fresh venous rabbit blood at 37°C via a PA cannula.
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Blood gases of left ventricular effluent, PA pressure (PAP) and tracheal 
airway pressure (AwP) during reperfusion and wet/dry weight ratios 
were measured. In Group 1, lungs were reperfused with whole blood for 
20 minutes (hematocrit 38%). In Group 2, lungs were reperfused with 
blood diluted with Ringer's lactate (hematocrit 10%) for 10 minutes, 
followed by whole blood for 10 minutes. Pa02 at the end of the 
20-minute assessment period was significantly higher in the hemodilut- 
ed group (88.3 ± 14.3 versus 44.1 ±  20.8 mm Hg, mean ±  STD: p = 
0.006). While PAP, AwP, Paco2 and wet/dry weight ratios were lower 
in the hemodiluted group, these differences did not reach statistical 
significance. We conclude that an initial 10-minute period of hemodilut­
ed reperfusion reduces IR injury associated with whole blood perfusion 
in this 18-hour ex-vivo rabbit lung reperfusion model.
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2-hour arrest period. Hearts were randomized into two groups. Group 1 
received CWBC (1 mL/g-min_1, myocardial temperature = 37°C) 
during the arrest period. Group 2 received intermittent cold blood 
cardioplegia (ICBC) (500 mL every 30 minutes, temperature = 15°C). 
The blood cardioplegia consisted of blood and Fremes solution (4:1) 
with resulting K+ = 15 meq/L. Data is expressed as percentage change 
from control.
C ro u p N Es Ed CVR m v o 2 A TP L acta te
ICBC 7 7 8  ± 8 127 ±  22 76  ±  16 9 5  ±  52 61 ±  23 115 ± 7 0
CW BC 7 8 6  ±  9* 143 ±  41 8 2  ±  13 114  ±  73 107 ±  22* 138 ±  9
The CWBC group had significantly better preservation of systolic 
elastance and ATP than the ICBC group (* p 0.05 by f-test). The other 
variables did not reach statistical significance. Continuous warm blood 
cardioplegia may be useful for myocardial protection.
PHARMACOLOGICAL INTERVENTION IN THE PREVENTION OF 
ISCHEMIA-REPERFUSION INJURY IN SWINE MODEL OF 
HEART-LUNG TRANSPLANTATION. A.K. Qayumi, W.R.E. Jamie­
son, A. Poostizadeh, H. Salari. Department of Surgery and Depart­
ment of Medicine, University of British Columbia, Vancouver, BC
Preservation of heart-lung and lung for transplantation remains a major 
concern. This experimental endeavour evaluated the role of pharmaco­
logic interventions to improve the antioxidant status and functional 
capacity of heart and lungs exposed to 6 hours of hypothermic ischemia 
followed by reperfusion. Fifty-six swine were divided into four groups, 
seven donors and seven recipients in each group. The initial protection 
was Tyers iso-osmolar potassium cardioplegia for heart and modified 
Collins-dextrose-magnesium solution for lung. The groups, according to 
intervention, were as follows: Group A — control without intervention; 
group B — lazaroid (a 21-aminosteroid analogue), 10 mg/kg; group C 
— high molecular weight deferoxamine, 50 m g/kg and group D — 
CV-3988 (antagonist of platelet-activating factor), 10 mg/kg. The 
evaluations were performed at three time periods — T1 pretransplanta­
tion (donor), and T2 30 minutes and T3 2 hours post-transplantation 
(recipient) by functional, biochemical and pathomorphologic assess­
ments. The CV-3988 group demonstrated superior heart and lung 
function (p < 0.001), namely, Cl. SI, dp/dT, PVR. Po2. AaG and AaR, 
as well as diminished extravascular lung water, consequently decreased 
pulmonary edema. The deferoxamine group performed second to the 
CV-3988 group. The lazaroid group did not show any protective effect, 
and was not different from the control group. The study revealed that 
platelet-activating factor plays an important role in ischemia-reperfusion 
injury possibly by means of activation of polymorphonuclear neutrophils 
and formation of oxygen free radicals. The antagonism of platelet­
activating factor is a useful interventional therapy to prevent the 
manifestations of ischemia-reperfusion in heart and lung following 
transplantation.
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WARM BLOOD CARDIOPLEGIA IN A PORCINE MODEL. A. Panos, 
S.J. Kingsley, A.P. Hong, T.A. Salerno, S.V. Lichtenstein. St. 
Michael’s Hospital, Toronto, Ont.
Historically, hypothermia has been the fundamental component of 
myocardial protection due to its reduction of cardiac oxygen (02) 
demand. Yet it has detrimental side-effects. Since 90% of myocardial 0 2 
consumption MV02 is due to electromechanical work, the major drop in 
(MV02) occurs with potassium (K+) arrest alone without hypothermia. 
Thus, continuous warm blood cardioplegia (CWBC) should protect 
better than current methods of nonperfused hypothermic arrest.
An ex-vivo blood-perfused porcine heart model was used to assess 
cardiac metabolism and function. MV02, tissue ATP and lactate levels, 
left ventricular end-diastolic (Ed) and end-systolic (Es) elastance, and 
coronary vascular resistance (CVR) were measured before and after a
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NEONATAL MYOCARDIAL PROTECTION: COMPARISON OF DIF­
FERENT COOLING RATES. T. Hosseinzadeh, R.C-J. Chiu, C.I. 
Tchervenkov. The Montreal General Hospital, McGill University, 
Montreal, PQ
It has been suggested that rapid-core cooling before circulatory arrest 
may be harmful to the newborn myocardium. Our objective was to 
determine whether rapid (R) cooling prior to ischemic arrest is indeed 
detrimental to the immature heart. Isolated Langendorff hearts (n = 
5 /gp) from neonatal piglets, 5 to 6 days old, were perfused with 
oxygenated Krebs buffer solution (38.5°C) for 20 minutes. This was 
followed by either 20 minutes of slow (S) cooling or 5 minutes of R 
cooling to 15°C, at which time global ischemia was induced and 
maintained for 2 hours at 15°C. All hearts then underwent 30 minutes 
of reperfusion at 38.5°C. Similar experiments were performed with the 
addition of a single dose of cardioplegia (CPG = St. Thomas’ solution) 
immediately after cessation of aortic flow to induce immediate cardiac 
arrest. Post-ischemic recovery of cardiac function was measured as a 
percent of pre-ischemic control levels (% mean ±  SEM).
Group LVP LVEDP +dp/dT -d p /d T
Rapid cooling 80 ± 3* 8 ±  5* 77 ±5* 84 ±4*Slow cooling 61 ± 2 33 ± 7 61 ± 4 63 ± 2Rapid + CPG 72 ± 3t 36 ± 12 71 ± 5 t 74 ± 4Slow + CPG 57 ± 3 33 ± 18 57 ± 4 62 ± 3
*p < 0.05 versus S cooling gp, tp  < 0.05 versus S cooling gp + CPG.
In all parameters, post-ischemic recovery was significantly better in 
the R cooling group versus the S cooling group. This difference was 
maintained in the presence of CPG, which did not improve post-ischemic 
recovery versus hypothermia alone. Contrary to clinical impression, we 
conclude that R cooling is not detrimental and may be desirable to S 
cooling in better protecting the immature heart.
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SUCCESSFUL MANAGEMENT OF LIFE-THREATENING MEDIAS- 
TINITIS IN HEART AND HEART-LUNG TRANSPLANT RECIPI­
ENTS. A.H. Menkis, K.R. Reid, R.J. Novick, P.W. Pflugfelder, W.J. 
Kostuk, F.N. McKenzie. The University of Western Ontario, Universi­
ty Hospital, London, Ont.
The incidence of mediastinitis after conventional cardiac surgery is 0.7% 
to 1.4% with a mortality of 10% to 70%. One would expect greater 
mortality from these infections in the immunosuppressed heart (HT) or 
heart-lung (H/L) patient. We have successfully managed three HT and
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two H /L  patients (of 220 HT and 15 H /L  transplants) with mediastini- 
tis in the last 2'/2 years. The patients presented 3 to 10 weeks 
postoperatively with wound erythema, sternal instability, chest pain, 
malaise, pyrexia and leukocytosis. Four had purulent mediastinitis; one 
H /L patient presented with an infected false aneurysm arising from the 
aortic stenosis. Operative management included sternal debridement, 
high-pressure irrigation with an antibiotic solution and the use of a 
closed irrigation system for 2 to 4 weeks. Omental pedicles were used in 
two cases; in one H /L  with a Dacron patch repair of the false aneurysm 
and in one HT transplant (TX). Intravenous antibiotics were given for 2 
to 4 weeks. Long-term oral antibiotics were maintained after discharge. 
No deaths occurred due to sepsis in follow-up to 2t/2 years. One H/L 
patient died of obliterative bronchiolitis 2 years after TX. We conclude 
that mediastinal infections can be successfully managed in the im- 
munosuppressed TX patient when a closed irrigation system is used in 
conjunction with appropriate intravenous and oral antibiotics. Omental 
pedicle grafts are used selectively, particularly when prosthetic materials 
or a residual cavity is present.
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PHARMACOLOGICAL CONSIDERATION FOR CONTROL OF OXY­
GEN CYTOTOXICITY IN PREVENTION OF PARAPLEGIA. A.K. 
Oayumi, M.T. Janusz, W.R.E. Jamieson. Department of Surgery, 
University of British Columbia, Vancouver, BC
The efficacy of pharmacologic agents for the prevention and control of 
oxygen-free radical damage in ischemia-reperfusion injury of the spinal 
cord was assessed in a swine model simulating surgery on the 
thoracoabdominal aorta. The swine model of spinal cord ischemia was 
induced by aortic cross-clamping for 30 minutes followed by 4 hours of 
reperfusion. Proximal hypertension was controlled by afterload reduc­
tion. The study groups were as follows: A — control (n = 7), B — 
deferoxamine 50 m g/kg over 3 to 4 hours prior to ischemia (n = 7). C
— allopurinol 50 m g/kg daily pre-treatment for 3 days (n = 7) and D
— superoxide dismutase 50 000 units prior to removal of aortic 
cross-clamp and 10 000 units/min for 10 minutes of reperfusion (n = 
7). The assessment comprises neurologic criteria (0 to 4, 0 = 
paraplegia, 4 = normal), spinal cord blood flow (microspheres) and 
ulrastructure (electron microscopy).
Tarlov criteria 0 1 2 3 4 Mean p value
Control (A) 7 _ _ _ -  0 < 0.05
Deferoxamine (B) - - 1 6 -  2.8 < 0.05
Allopurinol (C) - 6 1 - -  1.1 < 0.05
Superoxide dismutase (SOD) 7 - -  2.0 < 0.05
Deferoxamine > SOD > allopurinol > control, p < 0.05.
The spinal cord blood flow fell significantly in all groups during 
ischemia and responded to hyperemic levels during reperfusion. The 
blood flow patterns did not correlate with the neurologic findings. The 
degree of ultrastructural damage correlated with neurologic findings. 
The study demonstrated that modification of spinal cord injury induced 
by ischemia is possible with pharmacologic intervention of oxygen 
cytotoxic injury, deferoxamine, superoxide dismutase and allopurinol 
provided varying degrees of neurologic recovery, deferoxamine was 
superior to allopurinol and superoxide dismutase.
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exposed to prolonged hypothermia has been shown to develop changes 
in relaxation properties during reperfusion. A state of contracture was 
apparent at 4°C but to a lesser extent at 12°C which may be attributed 
to altered calcium metabolism. To further elucidate the effect of 
hypothermia on myocardial calcium homeostasis, human atrial append­
ages were stored for 4 to 24 hours in saline at 0, 4, 12 and 22°C. They 
were homogenized from a pool weighing 2.5 g, fractionated by 
ultracentrifugation to obtain sarcoplasmic reticulum (SR) and mito­
chondria (M) and assayed for Ca ATPase. The Ca ATPase was 
concentrated more than 10-fold in the SR (11.2 fimo\ P./h-mg 
protein-1) and less than 2 fold in the M (1.04) when fractionated from 
the homogenate (0.64). Storage at 12°C preserved the Ca ATPase the 
best, whereas at 22°C there was a decrease in the activity after only 4 
hours of storage. The appendages which had not been stored were 
fractionated as well. The fresh-frozen homogenate, SR and M were 
assayed for Ca ATPase at 0, 4, 12, 22 and 37°C in order to determine 
the temperature coefficient (Qio). Between 4°C and 12°C there was a 
threefold change in the Qio when compared with 12°C and 22°C. These 
results indicate that myocardial storage temperature affects recovery of 
Ca ATPase. Excessively cold temperature led to poor recovery of Ca 
ATPase function, which may be an explanation for abnormal relaxation 
of stored myocardium.
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HYPOTHERMIA: DOES IT PROVIDE SIMILAR PROTECTION IN 
ALL NEONATAL HEARTS? W. Vincenti, T.A. Salerno, C. Wittnich. 
Division of Cardiovascular Surgery, St. Michael’s Hospital, Toronto, 
Ont.
Despite the use of hypothermia, pediatric cardiac surgeons continue to 
experience high mortality in newborn heart surgery. This study 
examines the effects of hypothermia on neonatal heart metabolism and 
tolerance to global ischemia measured by the time to onset of ischemic 
contracture (TIC), an indicator of irreversible ischemic damage. After 
control right ventricular biopsies, each neonatal (3-day, n = 36) heart 
was excised and placed in one of three temperature-regulated baths 
(37.5 ± 0.5°C, 19.0 ± 0.5°C, 12.0 ±  0.5°C). A compliant balloon was 
inserted into the left ventricle and onset (2 mm rise in LV pressure) TIC 
was recorded and sequential biopsies were taken. Data were analysed by 
Student’s t-test or ANOVA. Hypothermia significantly prolonged TIC, 
(29.5 ± 1.7, 37°C) decreased lactate build-up (22.1 ± 2.9 to 6.3 ± 
0.7*. 5.8 ± 0.6) and slowed ATP decline (2.0 to 1.1, 0.5* pm ol/g-h-1). 
A subgroup of hearts (n = 5 each) was identified with shorter TICs than 
the group means and low ATP stores preischemia.
1 9 ° C  (n =  1 4 ) 1 2 ° C  (n  =  1 3 )
C o n t r o l  A T P T IC  ( o n s e t ) C o n t r o l  A T P  T IC  ( o n s e t )
T o ta l  g r o u p  
" A t  r i s k "
3 . 8 6  ±  0 . 3 3  
2 . 0 2  ±  0 .4 4 *
1 5 0 .0  ±  6 .4  
6 5 . 0  ±  8 .0 *
3 . 9 7  ±  0 . 2 4  2 8 3 . 0  ±  4 6 . 4  
2 . 4 5  ±  0 .4 5 *  1 6 7 .0  ±  4 .0 *
M e a n  ±  S E M , A T P  ( ^ m o l / g ) .  T IC  (m in ) . * p  <  0 .0 1  f r o m  t o t a l  g r o u p  v a lu e .
The protection offered by hypothermia in these hearts is therefore 
not accurately portrayed by the mean TIC at 19°C and 12°C and 
ischemic contracture developed rapidly. These at-risk hearts are identi­
fied by low ATP stores even prior to ischemia. This may prove useful in 
identifying those hearts which cannot tolerate a longer period of 
ischemia.
62
TEMPERATURE AFFECTS HUMAN SARCOPLASMIC RETICULUM TEMPERATURE AND SOLUTION COMPOSITION AFFECT OUT-
CALCIUM ATPASE. R.S. Labow, E. Meek, P.J. Hendry, W.J. Keon. COME OF DONOR HEART PRESERVATION. P.J. Hendry, R.S.
Department of Cardiothoracic Surgery, University of Ottawa Heart Labow, D. Ayres, M. Watson, W.J. Keon. Department of Cardiothorac-
Institute, Ottawa Civic Hospital, Ottawa, Ont. ic Surgery, University of Ottawa Heart Institute, Ottawa, Ont.
In assessing methods of donor heart preservation, human myocardium The optimal technique for donor heart preservation using hypothermic
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intra- or extracellular solutions remains controversial. The purpose of 
this study was to assess six different crystalloid solutions at two 
different temperatures (12°C and 4°C) using human right atrial 
trabeculae contracting isometrically in vitro. Muscles were preserved in 
either St. Thomas’ solution (ST), modified Krebs-Henseleit (MKH, K+ = 
16 meq/L), Krebs-Henseleit (KH, K+ = 4.5 meq/L), saline, Euro 
Collins (EC) or Belzer solution (B) for 24 hours, after which muscles 
were restimulated and recovery of function was followed for 30 minutes. 
Developed force (DF) was best preserved in ST (103.3 ± 6.2% of 
control) compared with saline which had the worst DF (2.8 ± 1.3%) (p 
< 0.0001). Recovery of muscles preserved in MKH, KH, EC and B all 
demonstrated intermediate performance. Recovery of DF was not 
affected by temperature (p = 0.13). While the solution did not affect 
recovery of resting force (RF), those muscles cooled to 4°C had a high 
RF compared with those at 12°C (220.0 ±  74.4 versus 142.4 ± 42.4% 
of control, respectively) (p < 0.04). In conclusion, solution composition 
is important for restoration of contractile function in preserved donor 
myocardium, whereas temperature affects the preservation of relaxation 
properties. St. Thomas' solution provided the best protection of atrial 
myocardium while 4°C led to impaired relaxation.
63
WARM CARDIOPLEGIA FOR CORONARY SURGERY. S.V. Lichten­
stein, A. Panos, S.J. Kingsley, A.P. Hong, T.A. Salerno. St. Michael’s 
Hospital, University of Toronto, Toronto, Ont.
Historically, hypothermia has been the most important component of 
myocardial protection. It reduces myocardial oxygen requirements, but 
has other unwanted side-effects. We have used continuous, cold, blood 
cardioplegia (CCBC) since 1985. In the absence of ischemia, hypo­
thermia may be unnecessary. Therefore, we developed a technique of 
continuous warm oxygenated blood cardioplegia (CWBC). Consecutive 
patients having coronary artery bypass (CABG) surgery in 1988 (N = 
121, 95 male. 26 female, age 62 ± 10 years) were compared to a similar 
cohort undergoing CABG using CCBC in 1987 (N = 133, 111 male, 22 
female, age 61 ± 9 years). Ninety-five percent of patients were NYHA 
class III or IV, and 60% had left ventricular grades 3 or 4. Thirty-five 
percent of the CCBC and 36% of the CWBC group had urgent 
operations. The number of grafts constructed was CWBC = 3.3 ± 1 .0  
versus CCBC = 3.4 ± 0.9. Ninety-nine percent of CWBC patients had 
spontaneous normal sinus rhythm (NSR) after aortic cross-clamp 
removal. Pump time was CCBC = 84 ± 20 versus CWBC = 99 ± 29 
min (p = 0.05), cross-clamp time was CCBC = 67 ± 19 versus CWBC 
= 79 ±  25 min (p = 0.05).
Group No. Deaths NSR IABP MI
CCBC 133 3(2.2) 14(10) 12(9) 9(7)
CWBC 121 1 (0.8) 120 (99)* 1 (0.9)’ 2(2)
% in bracket * p = 0.01.
Continuous warm blood cardioplegia patients had spontaneous 
recovery of NSR, a decreased need for IABP support and a reduced 
perioperative infarction rate. Continuous warm blood cardioplegia has 
become our method of choice for myocardial protection during cardiac 
surgery.
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RISK ANALYSIS OF PREOPERATIVE MYOCARDAL INFARC­
TION. S.E. Fremes, G.T. Christakis, R.D. Weisel, J. Ivanov, B.S. 
Goldman, T.A. Salerno, T.E. David. University of Toronto, Toronto, 
Ont.
Patients with postinfarction angina face an increased risk of operative 
mortality. Between January 1982 and December 1987, clinical, angio­
graphic and operative data were collected prospectively in 588 unstable
patients with a preoperative myocardial infarction (MI) within 30 days of 
surgery. There were 438 (74.5%) males and 150 (25.5%) females. The 
mean age was 60.1 ± 10.2 years and 19.7% were more than 70 years. 
Urgent surgery was performed in 452 patients (76.9%). Triple-vessel 
disease was present in 402 patients (68.4%), and 197 patients (34.8%) 
had diminished ventricular function (ejection fraction less than 40%). 
Operative mortality was 11.1% in the entire group (65), 8.3% in patients 
with a non-Q MI and 17.5% in patients with a transmural MI.
Stepwise logistic regression was performed to identify the independ­
ent predictors of operative mortality. The following variables were 
selected in order of decreasing importance: impaired left ventricular 
function (p < 0.001), coronary reoperation (p < 0.01), nonuse of the 
left internal mammary artery (p < 0.001), increasing age (p < 0.01), 
transmural MI (p = 0.02) and left main stenosis (p = 0.05). Predicted 
operative mortality varied between 0.4 ± 0.2% in patients with no risk 
to 90.5 ±  8.4% in patients with every variable present.
Patients with recent myocardial infarction without other risk factors 
can undergo coronary surgery with an anticipated operative mortality 
approaching that of elective surgery. Alternative treatment strategies 
are warranted for high-risk patients, particularly those with diminished 
ventricular function.
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TRAUMATIC RUPTURE OF THE THORACIC AORTA: A 20-YEAR 
REVIEW 1969-1989. S. Kodali, W.R.E. Jamieson, M. Leia-Stephens, 
R.T. Miyagishima, M.T. Janusz, G.F.O. Tyers. University of British 
Columbia, Vancouver, BC
Acute traumatic injury of the thoracic aorta is relatively common 
following deceleration accidents. Requirements for successful hospital 
managment are early diagnosis and prompt treatment. Between 1969 
and 1989, 120 patients (91 males and 29 females) were diagnosed by 
aortography, surgery or autopsy. This includes the total hospital 
experience with nonpenetrating or blunt injuries to the thoracic aorta. 
The mean age was 36.5, range 11 to 82 years. Ninety-two percent of 
the injuries resulted from motor vehicle accidents, and 8% from falls 
from heights. The site of injury was the aortic isthmus in 110 patients 
(92%), distal thoracic aorta in 7 patients (6.0%) and the aortic arch in 3 
patients. Associated injuries were present in 110 patients (92%), isolated 
aortic injuries in only 10 patients (8%). Initial chest roentgenograms 
were available on 68 patients and widening of the mediastinum was the 
predominant finding. Of this group, 32 patients had chest roentgeno­
grams with a radiopaque nasogastric tube. Deviation of the tube to the 
right contributed to the diagnosis in 80% of these cases. Only 47% (56 
patients) had the opportunity for definitive surgical management. The 
nonsurgical group (64 patients, 53%) died within 30 minutes of 
emergency department arrival unsuspected, suspected or diagnosed but 
without time for treatment. The group without definitive surgery 
included 13 patients with unsuccessful, primary emergency department 
thoractomies. There were 56 patients managed surgically for definitive 
aortic repair. The surgical methods included: simple aortic clamping 
(17), partial cardiopulmonary bypass (CPB) (34), full CPB (1) and 
techniques of nonheparinized bypass (4). There were 11 intraoperative 
deaths (19.6%) and 6 hospital deaths for a total early mortality of 26.7% 
(15). The operative mortality during the first decade was 40% (8 of 20 
patients) and for the second decade, 8.3% (3 of 36) (p < 0.05). 
Paraplegia occurred only in the simple aortic clamping group, 24% (four 
patients). Early diagnosis and prompt surgical management improved 
patient survival.
66
REDUCTION IN AUTOLOGOUS AND ARTIFICIAL VASCULAR 
GRAFT THROMBOGENICITY: IMPLICATIONS IN CARDIOVASCU­
LAR GRAFTING. T.A. Haas, M.C. Bertomeu, S.J. Brister, M.R. 
Buchanan. Department of Pathology and Department of Surgery, 
McMaster University, Hamilton, Ont.
Experimental studies, both in vitro and in vivo using human and rabbit
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vessel wall (VW) cells, indicate that there is an 1 /a  between VW 
13-hydroxyoctadecadienoic acid (13H0DE) synthesis and VW throm­
bogenicity. To determine the potential clinical relevance of this 
relationship, we examined (a) in intact VWs the correlation between VW 
13H0DE levels and VW thrombogenicity using internal mammary 
artery (IMA) segments obtained from 21 patients undergoing coronary 
artery bypass grafting (CABG); and (b) whether coating artificial 
vascular grafts (AVGs) with 13HODE also reduced their thrombogenici­
ty. To do this, we measured: (a) IMA 13HODE levels determined by 
HPLC, (b) IMA thrombogenicity, assessed as the number of 3H-platelets 
adherent/mm2 surface area and (c) AVG thrombogenicity, using AVGs 
(Hemashield vascular grafts) which were coated with increasing 
amounts of I4C-13HODE.
The levels of 13H0DE in the IMA segments ranged from 1 to 267 
pg/mm2, and were inversely related to IMA thrombogenicity, r = 
— 0.932, p < 0.001. Furthermore, there was concentration-dependent 
decrease in AVG thrombogenicity when the AVGs were coated with 
increasing amounts of 13HODE. For example, when the AVGs were 
coated with 21 ± 2 pg 13HODE/mm2, AVG thrombogenicity decreased 
29 ±  5%. p < 0.005.
We conclude that (a) the thrombogenicity of autologous grafts (i.e., 
IMAs) is influenced by their 13HODE level and (b) artificial vascular 
graft thrombogenicity can be reduced by coating the graft with 
13HODE.
67
FUNCTIONAL AND METABOLIC CHARACTERIZATION OF THE 
MARGINALLY PROTECTED VENTRICLE. T. Yau, R.D. Weisel, J. 
Ivanov, M. Komeda, G.T. Christakis, W. Martin, D.A.G. Mickel, 
Cardiovascular Surgery, The Toronto Hospital, University of Toronto, 
Toronto, Ont.
Myocardial revascularization for patients with progressive ischemia has 
a high perioperative morbidity and mortality. Improved methods of 
intraoperative myocardial protection may improve the results in these 
high-risk patients. We developed a canine model which simulates the 
myocardial metabolic depletion and the ventricular functional depression 
reported in patients after urgent revascularization for progessive 
ischemia.
Eighteeen dogs were exposed to variable durations of normothermic 
global ischemia (NTI) followed by 10 minutes of reperfusion, 1 hour of 
cold blood cardioplegic arrest (BCP) and 30 minutes of reperfusion 
(RP). Less than 50 minutes of NTI followed by BCP was well tolerated. 
However, 50 minutes of NTI produced a severe depression in both 
function and metabolism and only 50% of the dogs could be weaned 
from bypass. One hour of NIT resulted in a stone heart.
Ventricular function was assessed by measuring intraventricular 
pressures and cardiac output in response to volume loading at baseline 
(PRE) and following bypass (POST). Myocardial performance was 
severely depressed. Myocardial ATP content was only 35% of control 
values after BCP (6.3 ± 1.1 mmol/g protein). AMP levels were 
increased suggesting impaired mitochondrial function and inosine levels 
rose and then fell with reperfusion limiting the recovery of ATP.
This canine model simulated clinical studies and provides an opportu­
nity to evaluate new methods of protection.
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TUMOUR DORMANCY, INITIATION, MAINTENANCE AND TER­
MINATION IN ANIMALS AND HUMANS. T.H.M. Stewart,* A.C. 
Hollinshead, S.Raman.* ‘University of Ottawa, Ottawa, Ont. and 
George Washington University, Washington, DC
Tumour dormancy in man has long been noted by pathologists, 
surgeons and radiotherapists. In animal models immunization can 
induce tumour dormancy. Lymphocytes, macrophages and cytokine 
production are essential for maintenance of this state: regrowth of 
tumour follows immunosuppression. We describe five patients whose 
histories suggest that dormancy was induced in micrometastases 
present at the time of curative surgery, following specific immunothera­
py of lung cancer. In three patients extrathoracic metastases of 
adenocarcinoma appeared after 11, 12 and 14 years with no new 
primary tumour found. In two patients regional recurrence occurred 
after 8 and 9 years of clinical health: one adenocarcinoma, one 
squamous-cell carcinoma. In each patient an immunosuppressive event 
preceded the renewed tumour growth: three received steroids, one had 
severe endogenous depression and one had acute myocardial infarction. 
Each patient had shown a moderate to very strong delayed hypersensi­
tivity reaction to soluble tumour antigen maintained up to 14 years 
following surgery. The resurgence of growth of breast carcinoma 
metastases 7 years after mastectomy was seen 8 months after treatment 
with Cyclosporin A and steroids, following a renal transplant. This case 
prompted a review of the effect of transplantation-associated im­
munosuppression in patients with a previous history of curative surgery 
for cancer. We conclude that cellular immune mechanisms play a crucial 
role in maintenance of the tumour dormant state in man and that its 
induction in some patients with lung cancer will improve their 
prognosis.
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EMPYEMA FOLLOWING PNEUMONECTOMY FOR INFLAMMATO­
RY LUNG DISEASE. A.A. Conlan, M. Scoccianti, C. Hammond. 
Department of Surgery, University of Witwatersrand, Johannesburg, 
SA
One hundred and sixty-three patients underwent pneumonectomy for 
inflammatory lung disease and 30 developed post-pneumonectomy 
empyema (PPE). This study was done to determine the value of the 
treatment methods used. These were: (a) pleural drainage and irrigation 
to sterility, followed by neomycin 0.25% instillation and closure 
(Clagget) and (b) open thoracostoma drainage and later space closure. 
Post-pneumonectomy empyema followed elective surgery in 18 and 
emergency resection in 12. Eleven had preoperative empyema, 6 had 
preoperative bronchopleural fistula (BPF). Twenty-four had intraopera­
tive pleural spillage of infected material. Mixed aerobic and anaerobic 
infection was common. Dominant pathogens were Staphylococcus 
aureus 16. Klebsiella 9, Pseudomonas 7. Streptococcus faecalis 5. 
Seven patients had major BPF with PPE. Fourteen patients had pleural 
drainage and irrigation and 8 sterilized. Clagget closure was done, but 
six recurred. Twenty had formal thoracostoma drainage (two ribs) and 6 
patients had single rib resections. Four patients died (two early 
postoperatively from systemic sepsis). Two late deaths were due to 
pneumonia and aspiration. Five BPFs closed after thoracostoma drain­
age. Clearance of sepsis and marked clinical improvement occurred in 
all with space shrinkage. Space closure was completed by thoracoplasty 
16, muscle transposition 2 or chronic shrinkage. Post-pneumonectomy 
empyema was best managed by early open drainage and late space 
closure.
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RESULTS OF LUNG TRANSPLANTATION, 1983-1990, IN 
TORONTO LUNG TRANSPLANT PROGRAM. J.R. Maurer, 
G.A. Patterson, R.F. Grossman, Toronto Lung Transplant Group. 
University of Toronto, Toronto, Ont.
Between Nov. 7. 1983 and March 1990, 36 single (SLT) and 21 double 
lung transplants (DLT) were done by the Toronto Lung Transplant 
Team. Underlying diseases of patients receiving SLTs included 24 
pulmonary fibrosis. 4 pulmonary vascular disease, 6 emphysema. 1 
lymphangiomyomatosis, 1 fibrosing mediastinitis. Underlying diseases 
of DLTs included nine emphysema, five cystic fibrosis, four bronchiecta­
sis and one each of eosinophilic granuloma, bronchiolitis obliterans and 
primary pulmonary hypertension. Six SLTs (16.6%) died perioperatively 
and seven (19%) died from 4 months to 6 years following transplant. Of 
SLTs, 64.4% are alive, with survivals from 1 week to 5.5 years. Four 
DLTs (19%) died perioperatively and one (5%) died late. Seventy-six 
percent of DLTs are alive with survivals of 1 week to 3.5 years. Early 
deaths have generally been due to airway dehiscence or infection and 
late deaths to chronic rejection complicated by infection. One late death 
was due to renal failure. Of surviving SLTs 4 of 23 are functionally 
limited by chronic rejection/bronchiolitis obliterans. Two of 16 DLTs 
have mild to moderate bronchiolitis obliterans but are not significantly 
funtionally limited. Overall 39 patients (68.4%) have survived lung 
transplantation and 90% of those have near-normal lifestyles.
71
CARDIAC TRANSPLANTATION: THE TREATMENT FOR END- 
STAGE CARDIOGENIC SHOCK. S. Jackson, A.R.C. Dobell, A. 
Guerraty, J.F. Symes. Cardiovascular Research Unit, Royal Victoria 
Hospital, Montreal, PQ
Eighty-six patients received orthotopic cardiac transplants at the Royal 
Victoria Hospital from 1985 to 1989. Of these, 16 were considered to 
be mortally ill. being sustained in hospital by the use of intravenous 
inotropes (15 patients. 94%) and/or intra-aortic balloon counterpulsa­
tion (6. 38%). The average age of these 16 at the time of transplantation 
was 47 years (range from 19 to 58 years). Eleven were suffering from 
terminal coronary disease and 5 from cardiomyopathies. Nine (56%) 
were mechanically ventilated and nine had active pulmonary infection. 
Four patients (25%) had evidence of renal hypoperfusion (creatinine 
more than 120 ^mol/L). and four (25%) had evidence of hepatic failure 
(bilirubin more than 35 moioI/L). The average wait for a suitable donor 
for these patients was 11 days (range 1 to 27 days). In addition to the 
16 patients transplanted, there were 8 mortally ill patients who died 
before a donor became available. There was one operative death (at 7 
days) for a mortality of 6.3% (versus 8.6% for the 70 “elective” 
transplants). Two others died of delayed infection, one of viral hepatitis 
at 6 weeks and one of Pneumocystis pneumonia at 4 months 
postoperatively. The other 13 patients are alive and well at 3 to 57 
months postoperatively. Nine have resumed their preoperative work 
status, two have decreased activity levels but are functioning well, one is 
retired, and one is only 3 months postoperative and recuperating well.
As the salvage rate in this group of mortally-ill patients is so 
promising, we believe that transplantation is the treatment of choice in 
selected patients with end-stage cardiogenic shock.
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NEARING RETIREMENT?: -  I am looking 
for a rural general surgeon interested in work­
ing half time, eg: 4 months on and 4 months 
off, starting in 1 or 2 years. Located on the 
beautiful Sunshine Coast. Contact: Dr. Eric 
Paetkau. FRCS, Box 638, Sechelt, BC VON 
3A0 -S90-29
DOWNTOWN TORONTO -  Medical office 
available in Class "A "  professional building, 
600 sq. ft., recently decorated facility. Fully 
furnished. Current practitioner retiring after 17 
years at this location. Near hospitals. On 
subway. Ample parking. For further details, 
please contact, in confidence: ROI Corpora­
tion, Mississauga, tel: (416) 820-4145. 
Ref. 315. -S90-30
CARDIOVASCULAR AND THORACIC 
SURGERY, ACADEMIC APPOINTMENT:
SK -  The Department of Surgery, University 
of Saskatchewan, Saskatoon, Saskatchewan 
has a vacancy for a surgeon to  join the 
Division of Cardiovascular and Thoracic Sur­
gery with a full-time complement of three 
cardiovascular/thoracic surgeons. In addition 
to active clinical practice, the position in­
volves a strong commitment to undergradu­
ate and postgraduate teaching and surgical 
research. Applicants should have clinical ex­
perience in cardiovascular and thoracic sur­
gery with an interest in peripheral vascular 
surgery, and should have a demonstrable 
interest in surgical research. The successful 
candidate will join the full-time faculty of the 
College of Medicine with rank appropriate to 
training and experience. The Department of 
Surgery includes the divisions of cardiovascu­
lar and thoracic surgery, critical care medi­
cine, general surgery, neurosurgery, plastic 
surgery, orthopedic surgery, otorhinolaryn­
gology and urology. In accordance with Cana­
dian immigration requirements, this advertise­
ment is directed to Canadian citizens and 
permanent residents. Letters of enquiry and 
application including a curriculum vitae should 
be sent to: Dr. E. Wayne Chappell, Profes­
sor and Acting Head, Departm ent of Sur­
gery, University Hospital, Saskatoon, SK 
S7N 0X0. -S90-28
GENERAL SURGEON
PERM ANENT AN D /O R  LOCUM
A general surgeon is required, either as a 
summer locum and/or permanently, to 
join a busy community practice in PEI. The 
present medical centre has twenty doc­
tors, split evenly between GPs and spe­
cialists. The practice requires three gener­
al surgeons; as of July 1, 1990 it will have 
only two. Experience in orthopedics and 
urology would be an asset, but not a 
necessity. LMCC and FRCSC required for 
licensure.
Applications to:
W.L. W alker, MD, FRCSC 
Summerside Medical Center 
Summerside, PEI
C 1N 3N 9 _s
________ Tel: (902) 436 -9 2 8 3  bMU 14
CHIEF OF 
ANAESTHESIA
Central Hospital is an accredited, 176-bed community hospital, 
located in the core of downtown Toronto. The Hospital is 
currently expanding its community services to keep pace with 
the evolving needs of its exciting, culturally diverse, downtown 
community. To meet these needs, Central Hospital is expanding 
its program of day surgery as an addition to the in-patient 
services which utilize five O.R. theatres. To further the 
development of this program, we are presently searching for a 
new full-time Chief of Anaesthesia and an additional full-time 
anaesthesiologist.
As Chief of Anaesthesia, you will head a departm ent of 4  to 5 
anaesthesiologists and exert leadership in m aintaining 
anaesthesia QA and staff educational programs. Also, while in 
association with the Chief of Staff and Chief of Surgery, you wifi 
help ensure the effective utilization of in-patient and day surgical 
facilities.
Send Curriculum  Vitae to the 
M edical Director.
CENTRAL HOSPITALJ
333 Sherbourne Street, Toronto, Ontario M5A 2S5 
The Best Care in Any Language -S90-25 .
0SHAWA GENERAL HOSPITAL
A 650-bed regional general hospital approximately 
30 minutes east of metropolitan Toronto, requires 
an additional
GENERAL SURGEON
The individual selected will function within the 
framework of the Section of General Surgery in 
the Department of Surgery. Preference will be 
given to individuals with training in critical care 
and trauma. Candidates must have FRCSC or 
equivalent and be licensed to practise in 
Ontario. Interested physicians should direct 
enquiries to:
Dr. M. Pockey 
Oshawa General Hospital 
24 Alma Street 
Oshawa, Ontario 
L1G 2B9
Tel: (416) 576-8711
OSHAWA GENERAL HOSPITAL —  AN EQUAL OPPORTUNITY EMPLOYER 
—  A SMOKE-FREE ENVIRONMENT
— S90-26
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St. Clare’s Mercy Hospital, St. John’s, 
Newfoundland, a 323-bed university-affiliated 
(MUN) tertiary care facility, is looking for a 
surgeon (FRCSC) with VASCULAR training to 
join its Department of Surgery.
Applications and enquiries are invited and should 
be directed to:
Dr. Sean Conroy, Medical Director 
St. Clare’s Mercy Hospital 
LeMarchant Road 
St. John’s, Newfoundland 
A1C 5B8
Tel: (709) 778-3437 
Fax: (709) 738-0080
The successful applicant will be jointly appointed 
by St. Clare’s Mercy Hospital and Memorial 
University of Newfoundland. -sgo-27
ISCOTT&WHITE TEXAS A&M UNIVERSITY 
College of Medicine
TEMPLE CAMPUS
The Department o f Neurologic Surgery o f the Scott 
and White Institutions and Texas A&M University 
College o f Medicine is seeking applications for 
senior staff physician faculty in the Sections o f 
Pain/Stcrcotaxic Surgery or Neurosurgical Oncology. 
Residency or post residency experience and a 
defined interest in either subspecialty area together 
with a broad capability and interest in general 
neurosurgical disorders is desired. Basic and clinical 
research opportunities are available commensurate 
with previous experience. Medical student and 
resident teaching/daily responsibilities are required. 
The main campus is located in central Texas, north 
o f Austin in the approximate center o f the Dallas/ Ft. 
Worth, San Antonio, Houston triangle and benefits 
from easy access to other surrounding universities 
(Southwestern University, Georgetown; University o f 
Mary Ilardin-Baylor, Belton; Baylor University, 
Waco.)
For further information, please send curriculum 
vitae and references to:
Mitchell Smigicl, M.D.
Chairman, Neurologic Surgery 
Scott and White, Texas A&M University 
College o f  Medicine 
2401 South 31st Street 
Temple, TX 76508
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THE SURGEON’S CHOICE
SURGICAL SUTURES FROM SWITZERLAND 
ASSUT® BRAND AND SUPERB QUALITY
HSR-needles
1/2 circle, cutting-taper
HSR-18
V
i
HSRG-needles
1/2 circle, cutting-taper, heavy
HSRG-27
n ^
HSRG-38 
HSRG-45
TSR-needle ®
3/8 circle, cutting-taper
TSR-14
HSG-needle 1
1/2 circle, cutting, heavy
HSG-24
HS-needles P
1/2 circle, reverse cutting
HS-12 
IHS-171
V - A
HS-19
HS-2
h s -:
HS-38
HS-41
HS-45
HS-52
Introducing the finest quality of sterile double packed surgical 
-•sutures from Switzerland. Available in Blue Nylon, Black Silk, 
^Polypropylene. Also available in Linen, Surgical Steel, Astralen 
as well as Tendon Sutures, Double-Armed Needles, Round 
feodied and other type needles. A comprehensive catalogue 
* will be furnished upon request with first order. Free suture 
samples are available upon request.
TS-needles V
3/8 circle, reverse cutting
TS-12
TS-15
TS-17
TS-27
TS-30
TS-38
TS-45
I-60
TS-90
'-ISSsPEcwun SPECIAL $16.95/doz.REGULAR $23.95
nrv. v n n A n v i civic c D c n a i c iq  qc  / n n 7  N66dl6S 3T6 shown in 3ctu3l siz© forPOLYPROPYLENE - SPECIAL $18.95/D O Z. shape and |ength_ bu( nol for thickness.
ASTRALEN
* Green braided polyester with im­
proved tensile strength and knot 
“'security, siliconized. A modern 
braiding technique gives the 
strand a smooth and uniform sur­
face that minimizes the trauma.
V -
SUPRAMID
^  Black monofilament polyamide 
with supersoft core, resulting in 
r 'superior pliability and knot sec­
urity. The uniform and smooth 
surface permits effortless passage 
through tissue with minimum 
trauma. Supramid is extremely 
well tolerated.
LINEN
Natural white twisted strand very 
smooth and with high knot sec­
urity. This well-known material has 
been used in surgery for many 
years and it is still very 
appreciated.
POLYPROPYLENE
Blue monofilament polypropylene 
is flexible and ties securely. Ex­
tremely well tolerated, its smooth 
and uniform surface allows easy 
passage through tissue with min­
imum trauma.
SUPRAMID WHITE
White monofilament polyamide 
with supersoft core, with the same 
characteristics as Supramid.
SILK
Black braided surgical silk on 
twisted core for greater tensile 
strength. Silicone treatment and 
new braiding technique render 
the silk uniform and smooth and 
facilitate its handling.
SURGICAL STEEL
Twisted stainless steel with very 
high tensile strength and excellent 
knot security. This strand causes 
minimum tissue reaction.
MONOFIL NYLON
Blue monofilament polyamid with 
high tensile strength. The uniform 
and smooth surface permits effort­
less passage through tissue with 
minimum trauma. Extremely well 
tolerated.
THE ABOVE INFORMATION IS PROVIDED TO ASCERTAIN YOUR BEST AND CORRECT CHOICES.
MDICL INC.
175 TORYORK DRIVE, UNIT #6 
WESTON, ONTARIO 
M9L 2Y7
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All our products carry a one-year limited warranty  
Please call from anywhere in Canada
Toll Free - 1-800-387-7477
CALL 24 HRS A DAY 
TEL: (416) 747-1125
FAX: 1416) 783-5795 
VISA & MASTERCARD
The best tip 
for deep cavity surgery
VITAL VUE keeps control at your finger tips with superior 
illumination, irrigation and suction...all in one compact unit.
•Superior visibility in dark cavities •  Helps visualize elusive bleeders •  May reduce the risk 
of cross contamination •  Minimizes inconvenience and delay of overhead light adjustments 
•  Reduces surgeon fatigue • Compact -  easy to set up, easy to use, easy to store
VITAL'VUE
Irrigation, Suction and Illumination System
DAVIS+GECK
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